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Heparan sulfate in angiogenesis: a target for therapy
General introduction
Aims and outline of this thesis
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Introduction
Angiogenesis is the formation of new blood vessels out of pre-existing capillaries. This com-
plex process begins by detachment of pericytes, vessel dilatation of the existing vasculature 
and local degradation of the basement membrane and extracellular matrix (ECM), which 
allows endothelial cells to migrate into the perivascular space towards angiogenic stimuli. 
Proliferation and differentiation of endothelial cells result in new immature blood vessels, 
which are stabilized by attachment of pericytes and production of ECM. In physiology, angi-
ogenesis is important in processes as embryonic development, wound healing and the men-
strual cycle. Cancer is one example in which angiogenesis is considered to be pathological, 
as it supplies a growing tumor mass with oxygen and nutrients. In contrast to physiological 
angiogenesis, tumor angiogenesis is unresolved and persistent, resulting in a highly chaotic 
vasculature. This process is driven by pro-angiogenic factors as vascular endothelial growth 
factor (VEGF), fibroblast growth factor 2 (FGF2) and angiopoietin-1, required for proliferation 
and migration of endothelial cells, and platelet derived growth factor B (PDGF-B), which 
regulates vessel stabilization by perictyes. Gene expression of pro-angiogenic factors is often 
induced by hypoxia, a low concentration of oxygen. Ultimately, regulation of angiogenesis 
depends on the balance of pro-angiogenic factors and anti-angiogenic factors, examples of 
the latter being thrombospondin 1 (TSP1), platelet factor 4 (PF4) and endostatin (1-3). Of 
these angiogenic factors the majority, including VEGF, FGF2, PDGF-B, TSP1, PF4 and endosta-
tin, have been shown to bind to the sugar moieties of heparan sulfate proteoglycans (HSPGs).
Heparan sulfate proteoglycans (HSPGs)
Heparan sulfate (HS) is part of a larger family of glycosaminoglycans, which are long, lin-
ear and strongly negatively charged polysaccharides, characterized by a large quantity of 
repeating disaccharides. The basic structure of HS comprises disaccharide units of N-acetyl-
d-glucosamine (GlcNAc) and glucuronic acid (GlcA). This ‘precursor’ structure can be variably 
modified by epimerization of GlcA to iduronic acid (IdoA) and various N- and/or O-sulfations 
(Figure 1) (4). HS is present at the cell surface and in the ECM as HS proteoglycans (HSPGs), 
which are proteins that bear one or multiple covalently attached HS chains. Structural diver-
sity arises as HS can be coupled to a variety of core proteins, which include the transmem-
brane syndecans (family of 4 members), glycosylphosphatidylinositol (GPI) membrane-linked 
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glypicans (family of 6 members), and secreted basement membrane HSPGs including per-
lecan, agrin and collagen XVIII. Furthermore, large diversity arises out of the biosynthetic 
process of HS, as its modification is variable.
Biosynthesis of HS (schematically drawn in Figure 1) starts with  a linkage tetrasac-
charide that is shared with other glycosaminoglycans (chondroitin/dermatan sulfate). Xylose 
is the first monosaccharide added to the serine of the protein core, after which two galac-
tose units and one GlcA unit are added by three specific enzymes. At this point, addition of 
GlcNAc by exostosin-like 3 (EXTL3) determines the chain to be HS. HS synthesis starts with 
the alternating addition of GlcA and GlcNAc by the exostosin-1 /2 (EXT1/EXT2) copolymerase 
complex. While the chain is still growing, modification of this precursor HS chain starts with 
Figure 1. Biosynthesis of heparan sulfate (HS). Biosynthesis of HS starts with the assembly of a tetra-
saccharide linker region (xylose-galactose-galactose-GlcA) shared with other glycosaminoglycans, after 
which the addition of the first GlcNAc residue commits the chain to become HS. Copolymerase com-
plex EXT1/EXT2 adds GlcA-GlcNAc residues. The GlcA-GlcNAc precursor chain is variably modified by 
different enzymes. N-deactylation and N-sulfation of GlcNAc is done by NDSTs. The epimerase enzyme 
converts GlcA into IdoA. 2OST adds a 2O-sulfate to selected IdoA units. 6O-sulfation of glucosamine is 
carried out by 6OSTs. The final, and rare,  modification is 3O-sulfation of glucosamine by 3OSTs. Inter-
estingly, 3OSTs are the family with the most isozymes within HS biosynthesis. Consequences of gene 
deletion in mice of some of these different enzymes was recently reviewed in (167).
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N-deacetylation and N-sulfation of a glucosamine residues by N-deacetylase/N-sulfotrans-
ferases (NDSTs). This modification predominantly occurs in clusters and is largely a prereq-
uisite for following modification reactions. The GlcA C5-epimerase converts GlcA into IdoA, 
after which 2O-sulfotransferases (2OSTs) add 2O-sulfation to some generated IdoA units, 
although 2O-sulfation is known to occur on GlcA, be it to a low extent, as well. Modifi-
cation continues by 6O-sulfation of glucosamine by 6O-sulfotransferases (6OSTs) and ends 
with the rare modification of glucosamine 3O-sulfation by 3O-sulfotransferases (3OSTs). It 
is important to emphasize that these modifications do not go to completion, i.e. not every 
disaccharide is modified the same way, and HS chains with high (NS-domain), low (NA do-
main) and intermediate (NA/NS domain) regions of sulfation arise (5). Once displayed at the 
cell membrane or ECM, HS can be further modified by extracellular 6O-sulfatases (SULFs) (6), 
which can remove specific 6O-sulfation, by MMPs that can shed the complete ectodomain of 
syndecan-1 (7), or by a heparanase, the only mammalian enzyme that cleaves HS (8).
The domain structure of HS, together with its specific modification, is important 
for its ability to interact with a wide array of proteins. These proteins include enzymes and 
enzyme inhibitors, cell adhesion and ECM proteins, chemokines, growth factors and their re-
ceptors, morphogens, lipid-binding proteins, plaque proteins, nuclear proteins and pathogen 
surface proteins (9). In this way HSPGs fulfill various functions in physiology, for example in 
cell signaling and morphogenesis, organizing basement membrane barriers, lipolysis and 
inflammation (10). However, HSPGs often contribute to pathological processes as well, which 
include amyloidosis, inflammatory diseases, infection and cancer (11,12). The involvement of 
HSPGs in signaling of FGF2 and VEGF (often produced by tumor cells), and PDGF-B (primarily 
produced by endothelial cells), as well as their interaction with various anti-angiogenic fac-
tors, warrants their role as important modifiers of (tumor) angiogenesis.    
Interaction of HS with angiogenic factors
Vascular endothelial growth factor (VEGF)
VEGF, previously known as vascular permeability factor, is a highly specific endothelial mi-
togen and extremely important in developmental blood vessel formation. For example, even 
the lack of a single VEGF allele is embryonic lethal in mice (13,14). VEGF also majorly me-
diates pathological angiogenesis, e.g. tumor angiogenesis, and targeting with an antibody 
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against VEGF strongly reduces tumor growth (15). This led to the development of a human-
ized variant of this antibody, bevacizumab (Avastin; Genentech), which is FDA approved (16).
The human VEGF-A gene consists of eight exons and is alternatively spliced into 
several isoforms. Alternative splicing of exon 6 and 7 results in seven different splice variants 
of VEGF ranging from 121 to 206 amino acids (17,18). The most abundant and best character-
ized isoforms are VEGF
121
, VEGF
165
 and VEGF
189
 (19,20). VEGF
121
, the shortest isoform, does not 
bind to heparin (21) (a highly sulfated form of HS present in mast cells that is frequently used 
to substitute for HS in protein interaction studies) and is freely diffusible (22). VEGF
165
 binds 
to heparin and is associated with the cell-surface or ECM for about 50 -70% (22). VEGF
189
 
binds more strongly to heparin due to an additional heparin binding domain and is almost 
entirely bound to the cell surface or ECM (22). VEGF
165
 and VEGF
189
 can be released by action 
of plasmin generating a 110 amino acid long fragment (22,23).
The significance of heparin binding isoforms are underscored in mice engineered 
to selectively express only a single isoform (24,25): VEGF
120/120
 mice (analogous to VEGF
121
 in 
human) show severe defects in vascular outgrowth and patterning and die within 2 weeks, 
VEGF
164/164
 mice (analogous to VEGF
165
 in human) show normal development, and VEGF
188/188
 
(analogous to VEGF
189
 in human) mice show normal venular outgrowth but impaired arterial 
development. These developmental defects might reflect the importance of VEGF localiza-
tion and gradient formation, which is shaped by interaction with HS (26). 
VEGF
165
, the predominant isoform, is the best studied in relation to heparin/HS bind-
ing. Its binding to endothelial cells is virtually completely dependent on HS, as digestion 
with heparinase, a bacterial enzyme that cleaves HS, completely eliminates binding (27). 
Binding of VEGF
165
, normally present as a homodimer, depends on the domain organization 
of HS. It has been suggested that a VEGF
165
 dimer interacts simultaneously with two NS do-
mains of the HS chain, which can be separated by a NA/NS domain (28). In addition to domain 
organization, specific sulfation is also important for VEGF
165
 binding. VEGF
165
 binding to HS 
depends on all charged groups (carboxylate groups, N-, 2O- and 6O-sulfation), but N-sulfation 
and in particular 6O-sulfation are of most importance. 2O-sulfation is not required for high 
affinity interaction (28). 
Binding of VEGF
165
 to heparin/HS is mediated by a highly basic (estimated pI ~ 
11.6) 55 amino acid C-terminal heparin binding domain, which is largely comprised of exon 
7 and 8a and has no known protein homology (29). The heparin binding domain contains 
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four disulfide bridges (29), of which the C146-C160 disulfide bridge seems to be particularly 
important for the specific conformation of the heparin binding domain, as a C160S (located 
in exon 8a) mutant is unable to bind heparin (30). The lack of the C160 could also explain 
that a VEGF
165b
 isoform, which shows attenuated signaling, is not or only weakly able to bind 
heparin (30,31). This isoform is part of a second family of VEGF
xxxb
 proteins, generated by a 
distal splice site located in exon 8, which results in a different C-terminal end of 6 amino 
acids (exon 8b) (32). 
Although there are two VEGF receptors, VEGFR2 is the major effector of VEGF sig-
naling in angiogenesis (33). VEGFR2 is a tyrosine kinase receptor, which forms dimers upon 
activation. It consists of 7 extracellular Ig-like domains, of which Ig-like domain 2 and 3 are 
involved in VEGF binding (34). VEGFR2 is known to directly interact with heparin/HS (35,36), 
suggesting ternary complex formation between VEGF
165
, VEGFR2 and HS. Binding of heparin/
HS to VEGFR2 might be mediated by a ten amino acid sequence between Ig-like domains 6 
and 7 of VEGFR2 (37). 
By facilitating VEGF
165
-VEGFR2 interaction, HS plays a crucial role in VEGF
165
 sig-
naling. For example, low concentrations of heparin or HS (0.1-1 µg/ml) potentiate binding 
of VEGF
165 
to VEGFR2 (38), enhance VEGF
165
-induced phosphorylation of VEGFR2 (39), and 
increase mitogenic activity and endothelial tube formation of VEGF
165
 (39). Removal of HS 
by heparinase decreases VEGFR2 phopsphorylation and ERK1/2 phosphorylation induced by 
VEGF
165
 (39). Knockdown of Ndst1, resulting in undersulfated endothelial HS, reduced ERK1/2 
phosphorylation and rendered mutant cells insensitive to VEGF
165
 induced sprouting (40). 
Furthermore, HS present on adjacent cells, e.g. pericytes, can facilitate a VEGF
165
-VEGFR2 
complex in trans, which leads to prolonged and enhanced signal transduction by HS-depen-
dent entrapment of the complex (41).
It is noteworthy to mention that the VEGF
165
-VEGFR2-HS interaction, might involve 
one more component, as neuropilin-1 (NRP1), another VEGF coreceptor, is known to bind to 
VEGF
165 
and heparin (42), and forms a 4-component complex together with VEGFR2 (43,44). 
A schematic model of VEGF
165
 signaling is presented here (Figure 2), although the exact con-
figuration of complex is hypothetical and should ultimately be defined by techniques as 
crystallography.
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Fibroblast growth factor 2 (FGF2)
FGF2, also known as bFGF, is a member of a larger family of FGFs. FGF2 is a pleiotropic 
growth factor and not only implicated in angiogenesis, but for example also in development 
of the nervous system, lung, muscle, skeleton, and skin (45). Fgf2 deficient mice show cere-
bral cortex defects and are hypotensive due to neural blood pressure deregulation (46,47). 
However, these mice are viable, mature normally to adulthood and are fertile, which may 
be due to a redundancy in the FGF – tyrosine kinase FGF receptor (FGFR) system. However, 
injection of seven day old embryos with adenovirus encoding antisense FGF2 RNA did result 
in abnormal vasculature development (48). Until the discovery of VEGF, FGF2 was considered 
to be the most important factor in tumor angiogenesis. For example, FGF2 antisense cDNA 
in human melanoma cells regressed subcutaneous  tumor growth in mice and reduced blood 
vessel density (49). In addition, an anti-FGF2 immunoneutralizing monoclonal antibody was 
shown to inhibit tumor growth and angiogenesis in mice (50).
The human FGF2 gene encodes five different isoforms with apparent molecular 
weights of 18 to 34 kDa. The larger forms of FGF2 are N-terminal extensions of the 18 kDa 
form, are translated from alternate CUG codons and are localized predominantly to the nucle-
us (45,51). The precise biological role of these larger forms remains mainly elusive (52). The 
primary and best studied 18 kDa form is transcribed from the classic AUG codon and is found 
in the cytoplasm and extracellular (45,51). 
FGF2 binds to cell surface HS (53), as well as to HS in the basement membrane (54). 
HSPGs are relatively low affinity receptors (K
d
 = 2 nM) for FGF2 and are about 8 fold more 
abundant on the cell surface than FGF2 high affinity receptors (K
d
 = 20 pM) (53). This differ-
ence in K
d
 is the result of a more rapid dissociation of FGF2 from HS than from its cell surface 
receptor proteins, FGFRs (55,56). However, cell surface HS strongly enhances binding of FGF2 
to its high affinity receptor, FGFR1 (57), and is directly involved in FGF2 signaling (58). Addi-
tion of heparin to HS-deficient cells (59) or in a cell free system (60) increased the affinity of 
FGF2 for FGFR1 by 2-3, or 10 fold, respectively. HS catalyzes the FGF2-FGFR1 interaction, but 
in the presence of high concentrations of FGF2, dimerization and signaling can take place in 
the absence of heparin/HS (61). 
The heparin binding domain of FGF2 is discontinuous and located in the N-terminal, 
as well as in the C-terminal part (62-64). The C-terminal part was shown to contribute ~76% 
of the total binding free energy in heparin binding (63). FGF2 binding to HS depends on spe-
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cific HS sulfation: N-sulfation of glucosamine residues and 2O-sulfation of IdoA residues are 
of particular importance (65,66). The minimal binding sequence was defined as a pentasac-
charide: UA-GlcNS-UA-GlcNS-IdoA2S (67). Although 6O-sulfation is dispensable for binding of 
FGF2 to heparin (68), heparin, but not 6O-desulfated or 2O-desulfated heparin, was effective 
Figure 2. Heparan sulfate proteoglycans (HSPG) in angiogenesis. HSPGs interact with both pro- (e.g. 
FGF2, VEGF
165
, PDGF-B) and anti-angiogenic factors (e.g. endostatin).  HSPGs at the endothelial cell 
surface (GPI-anchored glypicans or transmembrane syndecans) potentiate binding of FGF2 and VEGF
165
 
to their receptors. This leads to receptor dimerization and signaling (e.g. phosphorylation of ERK). The 
drawn ternary structure of FGF2-FGFR1-HS is based on the crystal structure by Schlessinger et al.(79). 
Two non-reducing ends (NRE) of HS bind to two FGF2-FGFR1 complexes. These ends are highly sulfat-
ed and serve as high affinity FGF2 binding sites, whereas internal HS structures serve as low affinity 
binding sites. The low affinity binding site of FGF2 is based on the pentasaccharide reported in (67). A 
dimer of VEGF
165 
interacts with two NS domains, which are spaced by a NA/NS domain (28). The configu-
ration of the VEGF
165
-VEGFR2-HS-NRP1 complex is hypothetical. The binding site of endostatin is based 
on a reported hexasaccharide sequence (126). In the ECM, HSPGs as perlecan can act as growth factor 
reservoirs, and these growth factors can be released by action of proteases or heparanase. PDGF-B is 
produced by endothelial cells and signals to pericytes. PDGF-BB interaction with HS is based on a NS-
NA/NS-NS model (101), analogous to VEGF
165
.
15
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in potentiating the binding of FGF2 to FGFR1 (68). In agreement with this, 6O-sulfation, in 
addition to N-sulfation and 2O-sulfation, was required for FGF2 mitogenic activity (69,70). 
Reduced 6O-sulfation by downregulation of HS6ST-1 or HS6ST-2 reduced FGF2 dependent en-
dothelial cell sprouting and tube formation (71). 6O-desulfated, but not 2O-desulfated, hep-
arin was shown to inhibit FGF2 induced angiogenesis in vivo (72). Taken together, this sug-
gests that heparin/HS, FGF2 and FGFR1 are involved in a ternary complex, and 6O-sulfation 
is important for binding of FGFR1 to HS. The Ig-like module II of FGFR1 contains a heparin 
binding site, confirming a possible three way interaction (73). FGF2 is probably required for 
the HS/heparin-FGFR1 interaction, as the latter binary interaction is of micromolar affinity 
(60,74) and it is not certain whether this association occurs in the absence of FGF2 (75). Fur-
thermore, FGF2 strongly enhances the heparin-FGFR1 association (74).
Two crystallographic models of ternary heparin-FGF-FGFR complexes have been 
postulated. In the asymmetry model proposed by Pellegrini et al. (76), one heparin chain 
crosslinks two FGFs into a trans dimer bringing together two receptor chains. Interestingly, 
in this model there is a lack of protein-protein interactions between the two FGF-FGFR com-
plexes. Heparin interacts with both FGFs, but only with one of the two receptors, bridging 
the two complexes. However, there is more evidence now (77,78) for the symmetric two-end 
model proposed by Schlessinger et al. (79),  in which two heparin chains interact with two 
FGFs and two FGFRs. In this model, each FGF interacts with two receptors and the two recep-
tors interact directly with each other. The spatial interaction of FGF and FGFR brings their 
heparin binding domains together into one heparin binding cleft. Two heparin molecules 
are bound in this cleft, each occupying half, interacting with both FGFs and both receptors. 
The heparin non-reducing ends (NREs) are facing each other, which may indicate that on the 
cell surface the ends of two HS chains have to cooperate to form one complex with growth 
factors and receptors. 
In agreement with the two-end model, it was found that two classes of HS-binding 
sites for FGF2 exist. The major class was of relative low affinity (12 nM) and was 9 fold more 
abundant than the minor class, that had an affinity of 0.6 nM (80). Low and high affinity 
fractions of HS for FGF2 binding were also observed by mass spectrometry (81), and the high 
affinity fraction was specifically enriched in oligosaccharides from the NRE. Therefore, it is 
possible that the low affinity, abundant FGF2 binding sites function to sequester FGF2 and 
facilitate their access to the high affinity NRE binding sites (also see model in Figure 2). 
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In addition to signaling, HS might also play a protective role, as it has been shown 
that HS protects FGF2 from proteolytic digestion (65,82) and that heparin increases the ther-
mal stability of FGF2 (83). Furthermore, binding of FGF2 to the basement membrane can be 
released by action of proteolytic (84) and HS-degrading enzymes, (54,85,86), mobilizing the 
growth factor to act on endothelial cells. 
Platelet derived growth factor B (PDGF-B)
PDGF-B is part of a larger family of PDGFs (A-D), which in turn is part of the VEGF super-
family. PDGF-B is normally present as a homodimer (PDGF-BB), but can also heterodimerize 
with PDGF-A (PDGF-AB). PDGF-B signals to the tyrosine kinase PDGF-receptor β (PDGFR-β) 
present on mural cells, i.e. vascular smooth musle cells and pericytes, which results in re-
ceptor dimerization. PDGF-B is primarily produced by endothelial cells and is important in 
recruiting mural cells towards developing vessels, which is necessary for vessel stabilization 
(87). PDGF-B and PDGFR-β deficiency are homozygously lethal at birth due to hemorrhaging 
and edema formation (88,89). Anti-PDGF-B in combination with anti-VEGF therapy has syn-
ergistic effects in tumor angiogenesis (90-92), although this also depends on the strength 
of VEGF blockade (93). Targeting of PDGF-B alone might not be feasible as overexpression 
of PDGF-B inhibits cancer growth by increasing the amount of tumor pericytes (94). For ex-
ample, single-agent aptamer targeting of PDGF-B can increase tumor growth in an ovarian 
cancer model (91). 
PDGF-B is predominantly associated with the cell surface and the ECM (95,96). The 
determinant for this retention is a basic sequence of 11 amino acids found in the C-terminus 
of PDGF-B, which is highly homologous to a region present in the additional heparin binding 
domain in VEGF
189
 and PDGF-A
L
 (the long isoform of PDGF-A), but not present in PDGF-A
S
 (the 
short isoform of PDGF-A) (96,97). In line with PDGF-B, PDGF-A
L
 is predominantly associated 
with the cell surface and the ECM, whereas PDGF-A
S 
is not (95,96). A synthetic peptide repre-
senting the PDGF-B retention motif binds to the cell surface and potently releases PDGF (98). 
Interestingly, the released PDGF-B is slightly larger than the PDGF-B which was released by 
thrombin (99), indicating that direct or indirect proteolytic processing by thrombin releases 
PDGF-B from the cell surface and/or ECM. This retention motif in PDGF-B is important for 
pericyte recruitment and organization in vivo, as gene targeted deletion in mice results in 
defective pericyte investment and delayed glomerular mesangium formation (100). 
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PDGF-B binds directly to heparin and HS oligosaccharides and this interaction de-
pends on the overall degree of sulfation and not on a specific sulfation motif (101). Analogous 
to VEGF
165
, it has been suggested that a PDGF-B dimer interacts simultaneously with two NS 
domains of one HS chain, separated by a NA/NS domain (101). In line with PDGF-B, and cell 
surface retention of PDGF-A
L
, PDGF-A
L
 also binds to heparin and HS and this interaction is 
also dependent on the overall degree of sulfation (102,103). 
HS is important for PDGF-B signaling in vitro and reduced sulfation in Ndst1 defi-
cient mice resulted in pericyte detachment and delayed pericyte migration (101). Loss of HS 
by specific mural cell deletion of Ext1 results in embryonic lethality associated with edema, 
hemorrhages and defects in vascular pattering. These mice show impaired mural cell recruit-
ment and signaling through TGF-β and PDGFR-β (104). To our current knowledge, whether 
PDGFR-β binds to heparin or HS is not reported. However, given the fact that the PDGFRs 
share a common ancestral gene with FGFRs and VEGFRs (105), this is a plausible possibility. 
Interestingly, analogous to VEGF, NRP1 might be involved in PDGF-B signaling as well (106).
Endogenous angiogenesis inhibitors
Angiogenesis is a tightly controlled process. Hence, a number of endogeneous angiogenesis 
inhibitors exist (1). Two examples are TSP1 and PF4, both shown to bind HS (107,108). It has 
been suggested that these factors compete with pro-angiogenic factors for HS binding sites. 
For example, PF4 can bind to FGF2, and this interaction is stabilized by HS, suggesting ter-
nary complex formation that might prevent FGF2 from interacting with FGFR1 (109). TSP1 
binding to HS can displace VEGF
165
 and, in addition, TSP1 can bind directly to VEGF
165
 (110). 
However, TSP1 fragments without heparin binding domain retain most of their anti-angio-
genic activity (111) and TSP1 might function via CD36 and β1 integrins (112). 
Another example of endogenous angiogenesis inhibitors are proteolytic fragments 
of extracellular proteins and fragments of basement membrane proteins, e.g. fragments of 
plasminogen (113), prolactin (114), different types of collagen (115,116), fibronectin (117) 
and perlecan (118). Some of these fragments are reported to have heparin binding domains 
and/or bind to heparin (113,115,117,119), but whether heparin/HS is important in the an-
ti-angiogenic mechanism is not always clear. For example, a 26 kDa domain of type IV col-
lagen, arresten, inhibits endothelial cell proliferation, migration, tube formation and tumor 
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growth in mice (115). Arresten binds to HSPGs, but its anti-angiogenic activity is mediated 
by α1β1 integrin (115,120). 
The best example of HS interaction with an angiostatic protein fragment is prob-
ably endostatin, a C-terminal fragment of collagen XVIII (121). Treatment with endostatin 
in mice regressed several experimental tumor types (122). Endostatin binds to heparin and 
HS with a K
d
 of 0.3-2 µM (119,123). The heparin binding domain of endostatin  is composed 
of an extensive basic patch of 11 arginine residues (124), of which two arginine clusters are 
essential (119). Analogous to VEGF
165
 and PDGF-B, a domain structure of two NS domains 
separated by a (short) NA/NS domain is important for binding to HS (125), although an oc-
tasulfated hexasaccharide has some binding capacity as well (126). Similar to PDGF-B, the 
overall degree of HS sulfation is probably more important than one particular type of sulfa-
tion (119). Endostatin can bind to the cell surface glypican HSPGs (126) and has been shown 
to co-localize with perlecan in basement membranes (127). Analogous to TSP1 and PF4, en-
dostatin has been suggested to compete for binding sites on HS with pro-angiogenic factors 
as FGF2 (128). However, the angiostatic mechanism of endostatin is probably more complex, 
as endostatin has multiple binding partners in addition to HS (129), including integrins (130), 
transglutaminase 2 (131), and nucleolin (132), and in situ binding can occur independently 
of HS (133,134). 
Inhibiting angiogenesis by targeting of HS
Although HS interacts with both pro- and anti-angiogenic factors, genetic studies in mice 
and zebrafish have indicated that a reduction of endothelial HS sulfation (40), HS 6O-sulfa-
tion (135-137), knockdown of the HSPGs syndecan-2 (138), syndecan-4 (139) and perlecan 
(140), or deletion of the HS domain of perlecan (141), ultimately leads to impaired develop-
mental or pathological angiogenesis (reviewed in (142)). This could indicate that HS interact-
ing pro-angiogenic factors are more abundant/important than HS interacting endogenous 
anti-angiogenic factors, or that HS plays a more important role in its interaction with pro-an-
giogenic factors. In either case, HS proved to be a good target for inhibition of angiogenesis.
Therapeutic targeting of HS for angiogenesis has been achieved or can be achieved 
in two major ways (see schematic model in Figure 3). The first strategy is to disrupt the HS 
- growth factor interaction by soluble competitors. One competitor, PI-88, is now in clinical 
trials (for example see (143)). The second strategy is to reduce HS expression or specific HS 
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sulfation. This is still fairly hypothetical at this point, and one has to be careful reducing HS 
expression considering the role of HS in physiology.
Soluble competitors
The concept of binding to endogenous ligands to inhibit angiogenesis is based on soluble 
heparin mimetics that sequester HS/heparin binding angiogenic factors, as FGF2 and VEGF
165
, 
competing with endogenous cell surface HS, and preventing ternary complex formation on 
the cell surface and receptor signaling. The best example of such a competitor is probably 
PI-88 (144), and novel, more potent, compounds based on PI-88 have been reported recently 
(145) (146). PI-88 is a sulfated phosphomannopentaose that is prepared by exhaustive sulfa-
Figure 3. Strategies to prevent HS-growth factor binding and signaling. a) Heparin mimetics as PI-88 
can compete with cell surface HS for binding of growth factors as FGF2 and prevent ternary complex 
formation and signaling. In addition, heparin mimetics often have anti-heparanase activity (not depict-
ed). b) Small molecule competitors as surfen can bind to HS and prevent binding of growth factors to 
HS, resulting in signaling inhibition. c) Sugar analogs such as fluoro-xylosides or deoxy-sugars inhibit 
HS biosynthesis and reduce growth factor binding and signaling. d) Novel therapeutics may inhibit 
HS sulfotransferases, reducing HS sulfation and growth factor binding and signaling. e) Heparinases 
cleave HS and  reduce HS expression, but also potentially release bioactive HS fragments. Heparinase 
cleavage creates a double bond within the uronic acid (UA) residue, losing the distinction between the 
GlcA and IdoA configuration.
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tion of the phosphomannan produced by Pichia holstii (147,148). PI-88 inhibits angiogenic 
sprouting in vitro (144), angiogenesis in vivo in the chicken chorioallantoic membrane (CAM) 
assay (149), and tumor growth (by ~50%) and vascularity (by ~30%) in rat (144). PI-88 binds 
FGF2 and VEGF
165
 with higher affinity compared to HS (150), potently inhibits the interaction 
of FGF2 with HS (151) and reduces VEGF
165
-VEGFR2 complex formation (152). In addition, 
PI-88 inhibits heparanase activity (IC
50
 = 2 µg/ml) (144). As briefly mentioned above, hepara-
nase is the only mammalian enzyme that can cleave HS. It is commonly overexpressed in tu-
mors and facilitates tumor growth and angiogenesis by releasing HS bound (e.g. in the ECM) 
growth factors and making them more available for signaling (153). In addition, heparanase 
facitiliates ECM and basement membrane remodeling, facilitating tumor metastasis (153). 
As another example of the same principle, chemically modified heparins, so-called 
glycol-split heparins, have anti-angiogenic activity, can bind to FGF2 and prevent FGF2-FG-
FR1 complex formation, inhibit heparanase activity and reduce tumor growth in mice (154-
156). In contrast to heparin, these modified heparins do no bind to antithrombin and are 
non-anticoagulant (154-156).  
Binding to HS, instead of its ligands, is another way of preventing HS – growth fac-
tor interactions. Bis-2-methyl-4-amino-quinolyl-6-carbamide, also known as Surfen, is a small 
molecule antagonist of HS. It binds to HS, presumably electrostatically, blocks FGF2 binding 
and signaling, and prevents sprouting of endothelial cells induced by FGF2 or VEGF
165
 (157). 
Analogous, a HS binding peptide was shown to prevent VEGF
165
 binding to cells, inhibit 
VEGF
165
-VEGFR2 complex formation, endothelial cell migration and inhibit tumor growth in 
mice (158). This synthetic peptide corresponds to exon 6a of the VEGF gene, which encodes 
for the heparin binding domain that is present in the long, strongly cell surface and ECM 
associated VEGF
189
, and is not present in VEGF
165
. 
Reducing HS expression or HS sulfation
Another potential way of reducing HS dependent angiogenic signaling is by reducing HS 
expression, or by reducing HS sulfation that is necessary for its growth factor interaction. 
Reducing HS expression can be accomplished in two ways: by degrading HS or by inhibit-
ing HS biosynthesis. Degradation of HS is usually accomplished by treatment with bacterial 
enzymes (heparinases I-III) from Flavobacterium heparinum, a microorganism that is able to 
utilize heparin as a sole source of carbon, nitrogen, and sulfur (159). Although treatment 
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with heparinase I and III has been shown to reduce angiogenesis in the chicken CAM assay 
(160) and treatment with heparinase III reduced tumor growth in mice (161), the same treat-
ment with heparinase I increased tumor growth (161). This is probably due to the different 
specificity of heparinase I and III, and the release of different bioactive HS fragments (161). 
Therefore, and the notion that heparanase (the mammalian enzyme) promotes angiogenesis 
and tumorigenesis, care must be taken in this approach. 
Inhibition of HS biosynthesis is another strategy to reduce HS expression, which has 
the possible advantage of avoiding release of bioactive HS fragments. For example, fluoro-xy-
losides inhibit HS biosynthesis and endothelial tube formation in vitro (162,163). Monosac-
charide analogs have also been used to inhibit HS biosynthesis in vitro, and to inhibit amyloid 
deposition, a HS dependent process, in mice (164). No apparent toxic effect of this analog was 
noticed in mice treated intravenously for five days (164). Whether fluoro-xylosides or sugar 
analogs can reduce binding and signaling of HS binding angiogenic factors, and ultimately, 
angiogenesis in vivo, has not been reported and will be of therapeutic interest.
Finally, a more specific option of reducing the interaction of HS with pro-angiogenic 
factors, could be by reducing HS sulfation. In particular, 6O-sulfation could be a therapeutic 
target for inhibition of angiogenesis, due to its importance in FGF2 and VEGF signaling (71). 
To our knowledge, no inhibitor of HS 6O-sulfotransferases has been reported. Screening of 
small molecule libraries could be a feasible strategy to find possible inhibitors. For HS 2O-sul-
fotransferase activity, an inhibitor (a gem-diamine 1-N-iminosugar) has been reported (165), 
but this inhibitor was not tested for its activity in endothelial sprouting or angiogenesis 
assays. 
Concluding remarks
HS plays a central role in angiogenesis by interacting with pro-antiogenic factors, as well as 
anti-angiogenic factors. Overall, HS facilitates angiogenesis by potentiating receptor binding 
and signaling of VEGF
165, 
FGF2 and PDGF-B. The ability of HS to form ternary complexes with 
growth factor and receptor has been reported for FGF2 and VEGF
165
, but not (yet) for PDGF-B. 
In case of FGF2, a ternary complex crystal structure has been resolved. This is not (yet) the 
case for VEGF
165
 and its receptor, but it will be very interesting to see whether this complex 
resembles the FGF2-FGFR1-HS structure, and what the exact role for NRP1 is in this complex. 
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The observation that NRP1 can have covalently attached HS chains that modulate VEGFR2 
signaling (166) makes this even more interesting. 
In addition to facilitating signaling, HS can protect growth factors from proteolysis 
and can increase their thermal stability. Furthermore, HSPGs in the basement membrane 
and ECM can function as growth factor reservoirs and play important roles in growth factor 
localization and gradient formation. This is a tightly regulated process given the fact that 
different splice forms of growth factors exist that have or have not HS binding capacity and 
that HS binding growth factors can be released by action of proteases or heparanase. Further 
regulation is exemplified by the notion that C-terminal protein fragments of the ECM HSPGs 
perlecan and collagen XIII are anti-angiogenic.
Overall, HS is a good target for anti-angiogenic therapy, for example in tumor angi-
ogenesis. Several compounds that compete for binding either to HS or the growth factor can 
prevent ternary complex formation and angiogenesis. One of those compound, PI-88, is now 
in clinical trials. Future therapeutic strategies could involve modulating HS biosynthesis and 
6O-sulfation in particular.
Aims and outline of this thesis
HS plays a central role in angiogenesis, rendering it an excellent therapeutic target. Targeting 
HS in angiogenesis has primarily focused on the use of heparin mimetics. The aim of this 
thesis was to target HS in angiogenesis by developing and characterizing monosaccharide 
sugar analogs to inhibit and modulate HS biosynthesis. In chapter 1, an overview of the 
current literature concerning HS in angiogenesis and different strategies to target HS for an-
ti-angiogenic therapy is given. Chapter 2 describes the effect of a 4-deoxy analog of GlcNAc 
(4-deoxy-GlcNAc) on HS biosynthesis and growth factor binding in vitro. In chapter 3, this 
compound was peracetylated to facilitate its cell entry, its mechanism of action was studied, 
as was its effect on cellular processes using gene expression microarrays, and its effect on 
HS biosynthesis and angiogenesis in vivo. In chapter 4 a different sugar analog was studied: 
6F-GalNAc. This analog was chosen for its potential ability to inhibit 6O-sulfation of HS, 
which is an important modification for VEGF
165
 and FGF2 signaling. The mechanism of action 
of 6F-GalNAc turned out to be comparable to the mechanism of action of 4-deoxy-GlcNAc, 
indicating a general principle. In chapter 5, 4-deoxy-GlcNAc together with a set of anti-HS 
antibodies was used as a tool to study the structural organization of HS. Antibody NS4F5, 
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which recognizes highly sulfated HS, was found to recognize a structure towards the non-re-
ducing end of HS. This is of biological significance as the non-reducing end is implicated 
in FGF2 signaling. Chapter 6 describes the development of a procedure to extract glycos-
aminoglycans as HS from formalin-fixed, paraffin-embedded tissues. This enables the use of 
widely available paraffin-embedded material generated from human specimens for detailed 
(structural) analysis of HS in pathology. In chapter 7, a specific isoform of autotaxin, an en-
zyme generating the lipid mediator lysophosphatidic acid and implicated in a wide variety of 
physiological and pathological processes, including angiogenesis, was studied for its ability 
to bind to heparin and HS proteoglycans. Chapter 8 concludes this thesis with a summary 
and future perspectives.
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Abstract
Heparan sulphate (HS) is a long, linear polysaccharide, which has a basic backbone of - 
α1-4GlcA- β1-4GlcNAc- units. The involvement of HS in many steps of tumourigenesis, in-
cluding growth and angiogenesis, makes it an appealing target for cancer therapy. To tar-
get the biosynthesis of HS by interfering with its chain elongation, a 4-deoxy analogue of 
N-acetyl-d-glucosamine (4-deoxy-GlcNAc) was synthesized. Using immunocytochemistry and 
agarose gel electrophoresis it was shown that incubation with the 4-deoxysugar resulted in 
a dose dependent reduction of HS expression of MV3 melanoma cells,  1 mM resulting in an 
almost nullified HS expression. The parent sugar GlcNAc had no effect. 4-deoxysugar treated 
cells were viable and proliferated at the same rate as control cells. Other glycan structures 
appeared to be only mildly affected, as staining by various lectins was generally not or only 
modestly inhibited. At 1 mM of the 4-deoxysugar, the capacity of cells to bind the HS-depend-
ent pro-angiogenic growth factors FGF-2 and VEGF was greatly compromised. Using an in 
vitro angiogenesis assay, 4-deoxysugar treated endothelial cells showed a sharp reduction of 
FGF-2-induced sprout formation. Combined, these data indicate that an inexpensive, easily 
synthesized, water-soluble monosaccharide analogue can interfere with HS expression and 
pro-angiogenic growth factor binding.
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Introduction
Glycosaminoglycans (GAGs) are long, linear, and strongly negatively charged polysaccharides, 
generally bound to a core protein (forming proteoglycans) and present at the cell surface and 
in the extracellular matrix. Different GAG family members are distinguished on the basis of 
their structural backbone and include heparin/heparan sulphate (HS), chondroitin/dermatan 
sulphate (CS/DS), keratan sulphate and hyaluronan. HS consists of about a hundred repeating 
disaccharides and its backbone structure is composed of an uronic acid and N-acetyl-d-glu-
cosamine (GlcNAc). This backbone is extensively modified by a number of biosynthetic reac-
tions including N-deacetylation and N-sulphation, epimerization of glucuronic acid (GlcA) to 
iduronic acid (IdoA), and various O-sulphations (1). Extracellularly, HS can be further edited 
by removal of sulphate groups (2). Specific modifications, especially the degree and position 
of sulphation, are involved in the biological activity of HS. It is becoming increasingly clear 
that HS is a regulatory polysaccharide (3), interacting with a variety of proteins, including 
growth factors and their receptors (4). 
HS is involved in many aspects of tumourigenesis including growth, invasion, an-
giogenesis and metastasis (5). This involvement is in line with its capacity to bind, store 
and modulate many effector molecules including pro-angiogenic factors such as fibroblast 
growth factor-2 (FGF-2) (6) and vascular endothelial growth factor (VEGF) (7). Tumour cells 
and tissues are generally associated with altered levels of HS and changed degrees of sulpha-
tion. Metastatic melanoma cells, for example,  express high levels of the HS proteoglycan 
(HSPG) perlecan (8), and inhibition of perlecan reduces melanoma formation (9). Further-
more, the HSPGs syndecan-1 (10,11) and glypican-1 (12) are essential for tumourigenesis in 
mice. In addition to the quantitative aspect, qualitative aspects play an important role in 
tumourigenesis, especially the degree and position of sulphation. For example, extracellu-
lar sulphatases, which remove 6-O-sulphation from HS, have been reported to be negative 
(13,14) as well as positive (15) regulators of tumourigenesis. We previously showed upreg-
ulation of specific sulphated GAG domains in melanoma (16) and ovarian cancer (17). Also 
downregulation of specific domains was noted in metastatic melanoma (18). 
The involvement of HS at different steps in tumour formation makes HS an appeal-
ing target for cancer therapy (19). Generally, HS in tumours has been targeted by degradation 
using specific enzymes (e.g. bacterial heparinases (20)) or by using HS mimetics such as PI-88 
(21) and suramin (22). In this study, we do not focus on interference with existing HS chains, 
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but rather focus on the inhibition of the formation of new HS chains. For this, we used the 
principle of deoxysugars, as probed by us (23) and by others (24-28) before. A 4-deoxy ana-
logue of GlcNAc, 4-deoxy-GlcNAc (Figure 1A), was synthesized in order to target the biosyn-
thesis of HS. Incorporation of the monosaccharide analogue may result in HS chain trunca-
tion (acting as a chain stopper), since the 4-OH group is required for subsequent attachment 
of GlcA to continue chain elongation (Figure 1B). Here, we show that 4-deoxy-GlcNAc dose 
dependently inhibits HS expression in melanoma cells, prevents growth factor binding by 
melanoma cells, and inhibits sprouting of endothelial cells.
Figure 1. Structure and proposed working mechanism of 4-deoxy-GlcNAc. A) Structure of N-acetyl-d-
glucosamine (GlcNAc) and its analogue 4-deoxy-GlcNAc. Note that the 4-OH group of GlcNAc is replaced 
by a hydrogen group in case of 4-deoxy-GlcNAc (indicated by the arrow). B) Proposed working mech-
anism of 4-deoxy-GlcNAc. After UDP-activation, glucuronic acid (GlcA) and GlcNAc are incorporated in 
growing heparan sulphate (HS) chains (step I). If  cells are cultured in the presence of 4-deoxy-GlcNAc 
this analogue can also be incorporated into the growing HS chain (step II). This will result in chain 
termination, since the 4-deoxysugar lacks the 4-OH group (indicated by the arrow) needed for the sub-
sequent attachment of GlcA (step III).
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Materials and methods
Antibodies, lectins, enzymes and monosaccharides 
N-acetyl-d-glucosamine (A3286), chondroitinase ABC from Proteus vulgaris (C3667), papain 
from Papaya latex (P3125), the rabbit polyclonal anti-FGF-2 antibody (F3393; reactive with 
rat, human and bovine FGF-2) were purchased from Sigma-Aldrich (St Louis, MO, USA). The 
biotinylated lectins, AAL (Aleuria aurantia), ConA (Canavalia ensiformis), DSA (Datura stramo-
nium), GNA (Galanthus nivalis), LCA (Lens culinaris), PNA (Arachis hypogaea), RCA-I (Ricinus 
communis), SBA (Glycine max), VVA (Vicia villosa) and WGA (Triticum vulgaris) were from Vec-
tor Laboratories (Burlingame, CA, USA). Heparinase III from Flavobacterium heparinum was 
purchased from IBEX Pharmaceuticals Inc. (Montreal, Quebec, Canada), goat anti-rat VEGF
164
 
(AF564; IgG fraction) from R&D systems (Minneapolis, MN, USA) and mouse mAb anti-HS stub 
(3G10; IgG2b) from Seikagaku corporation (Tokyo, Japan).
Synthesis of 4-deoxy-GlcNAc
Synthesis of the 4-deoxy analogue of N-acetyl-d-glucosamine was achieved in a straightfor-
ward route from inexpensive N-acetyl-d-glucosamine by modification of a known procedure 
(24) (Scheme 1). For an overview of the reagents and conditions used, see legend of scheme 1. 
Scheme 1. Synthesis of 4-deoxy-GlcNAc (compound 5). Synthesis according to Berkin et al. (24) with 
minor changes. Reagents and conditions used: i: BnOH, AcCl, 4 h, 75 °C; ii: DCM/pyridine (4:3), 2.5 equiv. 
PivCl, 2 h, 0 °C; iii: a) DCE, 2 equiv. TCDI, 18 h, reflux, b) toluene, 2.5 equiv. Bu
3
SnH, 1.0 equiv. DMAP, cat. 
AIBN, 18 h, reflux; iv: MeOH, NaOt-Bu (0.5 M), 3 h, 60 °C; v: MeOH, cat. 10% Pd-C, 3 atm., 3 days, rt, (a/b 
= 1:1). For further information see text. Atm.: atmosphere, cat.: catalytic, equiv.: equivalent, rt: room 
temperature.
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First, Fischer glycosidation in benzyl alcohol gave, after crystallization from diethylether, the 
anomerically pure a-benzyl glycoside 1 (29) (42% yield). Dual esterification of both the 3-OH 
and 6-OH with a sterically bulky pivaloyl group led to compound 2 in excellent yield (91%), 
leaving the 4-OH selectively free for deoxygenation. The latter transformation was effected 
according to the two-step Barton-McCombie protocol (24,30), involving alcohol-to-thionocar-
bamate conversion, followed by radical treatment in the presence of Bu
3
SnH (86% yield for 
the 2 steps). Subsequent deprotection of esters under Zemplén conditions (3 → 4, 68% yield) 
and debenzylation by hydrogenolysis with 5% Pd-C (100% yield) gave the desired 4-deoxy 
derivative of GlcNAc 5 (2-acetamido-2,4-dideoxy-d-xylo-hexopyranose). A stock solution of 0.5 
M in milli-Q of compound 5, referred to as 4-deoxy-GlcNAc, was made and stored at -80 °C. 
Cell culture
The highly metastatic human MV3 melanoma cell line (31) was generously provided by dr. 
G. van Muijen (Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen, The Neth-
erlands). MV3 cells were cultured in DMEM medium containing glutamax (Invitrogen, Carls-
bad, CA, USA) supplemented with 10% foetal bovine serum (PAA, Pasching, Austria). Cultures 
were passaged twice a week and incubated at 37 °C in the presence of 5% CO
2.
 For immuno-
fluorescence analysis, MV3 cells were seeded on 10-well 7 mm microscope slides (1.5 • 103 
cells/well; Thermo Scientific, Waltham, MA, USA). For GAG isolation, approximately 0.5 • 106 
MV3 cells were seeded in a T175 tissue culture flask. After 24 hours (cell confluency around 
30%), medium was supplemented with GlcNAc or 4-deoxy-GlcNAc at various concentrations 
ranging from 0.13 to 10 mM. After three days, cells were fixed with cold methanol and air-
dried (immunofluorescence) or washed with PBS for GAG isolation.
Immunofluorescence assays  
For detection of HS, cells were incubated with the VSV-tag containing, single chain vari-
able fragment (ScFv) anti-HS antibodies AO4B08 (32), HS4C3 (33) and RB4EA12 (32). Next, 
cells were incubated with mouse anti-VSV IgG, followed by Alexa488 fluorochrome conjugat-
ed anti-mouse IgG antibody (1:200; Invitrogen). For staining of other glycans, biotinylated 
lectins were used. Cells were first incubated with avidin-biotin blocking solution (Vector 
Laboratories), followed by lectins (1:200 - 1:1000), and Alexa488 fluorochrome conjugated 
streptavidin (1:1000; Invitrogen). To establish FGF-2/VEGF binding capacity, cells were incu-
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bated with 5 µg recombinant rat (rr) FGF-2/ml or 10 µg rrVEGF
164
/ml (34). Bound FGF-2/VEGF 
was detected by anti-FGF-2 (1:250)/anti-VEGF
164 
(1:25) antibodies and Alexa488 fluorochrome 
conjugated anti-rabbit/anti-goat IgG antibodies (1:200; Invitrogen), respectively. Finally, cells 
were dehydrated with ethanol and mounted in mowiol. As a control, primary antibodies 
were omitted. Images were captured using a Leica-CTR6000 microscope.
Glycosaminoglycan isolation
After washing with PBS, cells were detached by 2.5 U papain/ml digestion buffer (50 mM so-
dium phosphate, 2 mM cysteine, 2 mM EDTA, pH 6.5) for 30 min at 37 °C and further digested 
for 16 hours at 65 °C. To precipitate proteins, trichloroacetic acid (TCA) was added to a final 
concentration of 15% (v/v) and samples were put on ice for 30 min. To remove the precip-
itated proteins, samples were centrifuged at 10,000 g for 30 min at 4 °C. The supernatant 
containing the GAGs was diluted five times to reduce the concentration of salt and subjected 
to diethylaminoethyl (DEAE) sepharose (GE Healthcare, Chalfont St. Giles) columns. GAGs 
were eluted with 2 M NaCl in 10 mM Tris (pH 6.8) and precipitated by addition of five volumes 
methanol (incubation overnight -20 °C). GAGs were pelleted by centrifugation at 10,000 g for 
30 min at 4 °C, air-dried, dissolved in milli-Q and stored at 4 °C.
Agarose gel electrophoresis 
Agarose gel electrophoresis was basically performed as described earlier (35). In short, iso-
lated GAGs were separated using 1% agarose (w/v) in 50 mM Ba(Ac)
2
 buffer (pH 5.0). After 
electrophoresis (30 mA/gel, 50 min), gels were fixed and stained with 0.1% (w/v) cationic 
dye azure A, destained with 10 mM NaAc buffer (pH 5.5) and washed in milli-Q. GAGs were 
visualized by silver staining. 
Enzymatic glycosaminoglycan digestion
Cells or isolated HS, were digested with 0.04 or 0.02 IU heparinase III/ml 50 mM NaAc/50 mM 
Ca(Ac)
2
 buffer (pH 7.5), respectively, overnight at 37 °C. Heparinase III digestion on fixed cells 
was evaluated with antibody 3G10, which recognizes HS stubs resulting after heparinase di-
gestion, and anti-HS antibodies. Chondroitin sulphate and dermatan sulphate were digested 
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overnight at 37 °C with 1 IU chondroitinase ABC/ml 25 mM Tris/2 mM Mg(Ac)
2
 (pH 8.0). As 
control, cells or isolated GAGs were incubated with digestion buffer only.
WST-1 cell proliferation assay
To assess cell proliferation 1.5 • 103  cells/well were seeded into 96-wells plates. After 24 
hours, GlcNAc or 4-deoxy-GlcNAc was added to the medium at a final concentration of 1 mM. 
WST-1, a tetrazolium salt, was added according to the protocol provided by the manufacturer 
(Roche Diagnostics, Mannheim, Germany). The absorbance at 450 nm, corresponding to the 
number of metabolically active cells, was measured 30 minutes after WST-1 addition by a 
microtiter plate reader at 1, 2, 3, 4 or 5 days after the addition of GlcNAc or 4-deoxy-GlcNAc.
Endothelial cell sprouting assay
Sprouting of endothelial cells was studied with the use of cytodex-3 beads overgrown with 
endothelial cells in a three-dimensional gel and performed as described earlier (36). After 
gel-formation, medium containing 20 ng FGF-2/ml with or without 1 mM GlcNAc or 1 mM 
4-deoxy-GlcNAc was applied on top of the gel. After 24 hours, photographs were made.
Statistics
Data are presented as mean with standard deviation. Sprouting assay data were analyzed 
using a two-tailed Student’s t-test, with P < 0.05 considered as significant. All statistical 
analyses were performed in GraphPad Prism 5.0 (GraphPad, San Diego, CA, USA).
Results
4-deoxy-GlcNAc inhibits HS expression
The melanoma cell line MV3 was used to determine the effect of 4-deoxy-GlcNAc on HS 
expression. MV3 cells were cultured in the presence of various concentrations of the 4-deox-
ysugar and HS expression was analysed by agarose gel electrophoresis (Figure 2A). Without 
addition of the 4-deoxysugar, HS and CS were the main glycosaminoglycans produced by 
MV3 melanoma cells. The HS band was sensitive to heparinase III treatment, whereas the 
CS band was abolished by chondroitinase ABC treatment, indicating the HS and CS nature of 
the respective bands (Figure 2B). Addition of the 4-deoxysugar resulted in a dose dependent 
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reduction of HS expression (Figure 2A). At a concentration of 1 mM, the HS band was not 
detectable anymore. Therefore, this concentration was used for further studies. In addition 
to HS, CS band intensity was affected by the 4-deoxysugar, possibly by interference with 
4-O-sulphation of CS (see discussion). Addition of 1 mM of the parent sugar GlcNAc had no 
effect on the amount or type of glycosaminoglycans produced by MV3 melanoma cells. 
The reduction of HS by 4-deoxy-GlcNAc was further substantiated by immunocyto-
chemistry using anti-HS antibodies (Figure 2C). At a concentration of 1 mM 4-deoxy-GlcNAc 
no staining was observed in cultures of MV3 melanoma cells, in contrast to clear HS staining 
in cultures without 4-deoxy-GlcNAc or with 1 mM GlcNAc.  No major changes in cellular mor-
phology were observed. Similar results were obtained with Mel57 melanoma cells, SKOV-3 
ovarian carcinoma cells and HFL-1 lung fibroblasts (data not shown).
Figure 2. 4-deoxy-GlcNAc strongly reduces HS expression. MV3 melanoma cells were cultured for three 
days with or without 0.13 – 1 mM (A)/1 mM (B and C) 4-deoxy-GlcNAc or with 1 mM GlcNAc. Hereafter, 
cells were A and B) analyzed for GAGs using agarose gel electrophoresis and a combined azure A-silver 
staining procedure; C) stained for HS using antibody AO4B08 (original magnification 100x; scale bar = 
100 µm); same results were observed for the antibodies HS4C3 and RB4EA12, which recognize different 
HS epitopes (data not shown).  HepIII: heparinase III, Ch.ABC: Chondroitinase ABC, HS: heparan sul-
phate, CS: chondroitin sulphate, DS: dermatan sulphate.
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Effect of 4-deoxy-GlcNAc on cell proliferation 
To determine the effect on cell proliferation and viability, cells were cultured for up to five 
days in the presence of the 4-deoxysugar. On each day, the amount of metabolically active 
cells was established by the WST-1 assay (Figure 3). Cells incubated with the 4-deoxysugar 
remained viable and proliferated at the same rate as untreated or GlcNAc treated cells. Com-
parable results were found with Mel57 melanoma cells, SKOV-3 ovarian carcinoma cells and 
HFL-1 lung fibroblasts (data not shown). 
 
Effect of 4-deoxy-GlcNAc on lectin-positive glycans
To assess the effect of 4-deoxy-GlcNAc on other glycan structures, cells were stained with 
various lectins (Figure 4 and Table 1). For most of the lectins (6 out of 10), staining remained 
largely unaffected. Four lectins showed a moderate reduction of staining, and they included 
the polyLacNAc recognizing lectin DSA and the O-glycan associated lectins PNA, SBA and 
VVA. Out of these four, staining by DSA seemed most affected. Staining for the latter three 
was quite similar and was found predominantly intracellular, presumably in the Golgi appa-
ratus. Staining of WGA and the N-glycan associated lectins ConA, GNA and RCA-I appeared 
not affected by 4-deoxysugar treatment, or seemed slightly elevated in case of LCA and AAL.
Figure 3. The effect of 4-deoxy-GlcNAc on cell proliferation. MV3 melanoma cells were cultured for 
several days with or without 1 mM GlcNAc or 1 mM 4-deoxy-GlcNAc, and the amount of metabolically 
active cells was measured on each day by the WST-1 cell proliferation assay. The absorbance of for-
mazan (the cleavage-product of WST-1), which increases proportionally to the number of viable cells, 
was measured 30 minutes after addition of WST-1 at 450 nm. Data are expressed as mean ± SD (n = 5).
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4-deoxy-GlcNAc inhibits growth factor binding
HS is able to bind several growth factors, including FGF-2 (6) and VEGF (7). Therefore, it was 
tested whether the binding of FGF-2 and VEGF to HS was impaired in 4-deoxysugar treated 
cells. As endogenously bound FGF-2 and VEGF could not be detected, cells were incubated 
with FGF-2 or VEGF and subsequently stained for bound growth factors using anti-FGF-2 or 
anti-VEGF antibodies (Figure 5). 4-deoxysugar treated cells showed a pronounced decrease 
in bound FGF-2 and VEGF, compared to control and GlcNAc treated cells. Furthermore, the 
importance of HS for growth factor binding was confirmed as binding of FGF-2 and VEGF to 
heparinase III digested control cells was strongly reduced (Figure 5). 
Table 1. The effect of 4-deoxy-GlcNAc on staining by lectins of MV3 melanoma cells. 
Lectin Binding specifictya Control GlcNAc 4-deoxy-GlcNAc
AAL α1-2/3/6 linked Fuc to Gal/GlcNAc ++ 
i s
++ ++b
ConA αMan (oligomannose, hybrid and biant-
ennary complex N-glycans)
+++ 
i s
+++ +++
DSA (-β1-3Galβ1-4GlcNAc-)
n
 (PolyLacNac; N- 
and O-glycans)
++ 
i s
 ++ ↓
GNA Terminal α1-3Man (oligomannose N-gly-
cans)
+++ 
i
 +++ +++
LCA Fucosylated core region of bi- and triant-
ennary complex N-glycans
++ 
i s
 ++ ++b
PNA Galβ1-3GalNAcα-R (O-glycans) + 
i
+ ↓
RCA-I Terminal βGal (N-glycans) +++ 
s
+++ +++
SBA GalNAcα/β-R (O-glycans) + 
i
+ ↓
VVA GalNAcα-R (O-glycans) ++ 
i
++ ↓
WGA GlcNAcβ-R, Neu5Acα-R (O- and N-gly-
cans)
++ 
s
++ ++
MV3 melanoma cells were cultured for three days with or without 1 mM 4-deoxy-GlcNAc, or with 1 mM 
GlcNAc, and stained with various lectins. aBinding specificities are from (50) and (51). Where possible, 
it is indicated whether these structures are found on N- and/or O-linked glycans. +++ strong; ++ 
moderate; + weak staining. bslight increase;  ↓ modest decrease compared to staining of control and 
GlcNAc treated cells. Staining found i: intracellular (presumably Golgi); s: at the cell surface.
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4-deoxy-GlcNAc inhibits endothelial cell sprouting
FGF-2 is an important player in the cascade of angiogenesis (37). Since HS can bind this 
growth factor and can regulate its signalling, it was tested whether the 4-deoxysugar has the 
ability to inhibit FGF-2 dependent sprouting of endothelial cells in an in vitro angiogenesis 
assay (Figure 6). Endothelial cells were cultured on the surface of beads and embedded in a 
three-dimensional collagen gel and sprouting was induced by FGF-2. In the presence of  4-de-
oxy-GlcNAc sprouting of endothelial cells was strongly inhibited as compared to control and 
GlcNAc treated cells (Figure 6A). Quantification of these results showed that the 4-deoxysug-
ar significantly inhibited sprouting by 75% as compared to the control (Figure 6B). Sprouting 
of GlcNAc treated cells did not significantly differ from control.
Figure 4. The effect of 4-deoxy-GlcNAc on staining of the lectins DSA and RCA-I (also see Table 1). 
MV3 melanoma cells were cultured for three days with or without 1 mM GlcNAc or 1 mM 4-deoxy-Gl-
cNAc, fixed and stained with various lectins. Shown here is the staining by the lectins RCA-I (from 
Ricinus communis) and DSA (from Datura stramonium). Staining by RCA-I is predominantly found at the 
cell surface, whereas staining by DSA is also found intracellular (probably in the Golgi-apparatus). For 
further information see table 1. Original magnification 100x; scale bar = 100 µm.
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Figure 5. 4-deoxy-GlcNAc strongly reduces binding of FGF-2 and VEGF. MV3 cells treated with or 
without 1 mM GlcNAc or 1 mM 4-deoxy-GlcNAc were fixed, incubated with and stained for FGF-2 or 
VEGF
164
. In the case of 4-deoxy-GlcNAc treated cells, a strongly reduced staining for both growth factors 
was observed. Removal of HS by heparinase III (HepIII) also results in strong reduction of growth factor 
staining. Original magnification 100x; scale bar = 100 µm.
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Discussion
It is becoming increasingly clear that the amount and the fine structure of glycosaminogly-
cans are important determinants in tumourigenesis. Especially HS is a key player by regulat-
ing tumour cell proliferation, angiogenesis, invasion and metastasis (5). A central aspect is 
the function of HS chains as co-receptors for growth factors, including FGF-2 and VEGF (6,7). 
By this involvement, HS serves as a good target for cancer therapy. Most strategies to reduce/
eliminate HS in tumours are based on either digestion of the HS by enzymatic treatment, or 
by interference of the activity of HS by administration of HS mimetics. Some agents interfer-
ing with HS function have already entered clinical trials, e.g. PI-88 (38).
An alternative route to decrease HS is by targeting its biosynthesis. There are a 
number of strategies which can be applied including  interference with biosynthetic en-
zymes such as EXT1/EXT2 polymerizing enzymes (39,40), and modifying enzymes, such as 
Figure 6. 4-deoxy-GlcNAc inhibits the sprouting of endothelial cells. A) Sprouting of bovine microvas-
cular endothelial cells cultured on gelatin-coated beads in a collagen gel was induced by FGF-2. Sprout-
ing was strongly affected by addition of 1 mM 4-deoxy-GlcNAc. Scale bar = 100 µm. B) Quantification 
of sprouting was performed by NIH image software. Data are expressed as arbitrary units (a.u.) and are 
shown as mean with SD (n = 3 or 4). Representative data of one of two separate experiments is shown. 
*: P < 0.005 compared to control or GlcNAc, using the Student’s t-test.
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N-deacetylase/N-sulphotransferase-1 (NDST-1) (41), 6-O-sulphotransferase-1 (42) and 6-O-en-
dosulphatase hSulf-1 (13). As an alternative to such approaches, we probed a monosaccha-
ride analogue (4-deoxy-GlcNAc) for its capacity to inhibit HS expression. The rationale of 
this strategy is that when cells incorporate the 4-deoxysugar into HS chains, the formation 
of a glycosidic bond between the 1-OH group of GlcA and the 4-OH group of GlcNAc will be 
prevented, thereby stopping chain elongation. A similar approach has been used by Berkin 
et al. before; deoxysugars have been synthesized and evaluated for their effect on HS (26). 
The 4-deoxysugar has been reported to inhibit HS biosynthesis of hepatocytes (24-26), islets 
of Langerhans and ß-TC3 cells (28), and cells of the central nervous system (27). We previ-
ously showed this is also true for RFL-6 rat fibroblasts (23). Kisilevsky et al. have found that 
incorporation of the 4-deoxysugar resulted in truncated HS chains in vitro and inhibition 
of amyloidogenesis in vivo, with no apparent toxicity (25). In the present study, we found a 
strongly diminished HS expression as a result of 4-deoxy-GlcNAc treatment, as shown by HS 
immunocytochemistry and agarose gel electrophoresis. In addition, binding of pro-angio-
genic growth factors was inhibited, as was FGF-2 dependent endothelial sprouting. 
As GlcNAc is not only incorporated into HS, it is likely that the 4-deoxysugar may also 
affect other glycosaminoglycans (e.g. hyaluronan, keratan sulphate), and/or N- and O-linked 
glycan containing glycoproteins. We did observe a reduction in staining for chondroitin sul-
phate. Since 4-deoxy-GlcNAc lacks the hydroxyl group which distinguishes between GlcNAc 
and N-acetyl-d-galactosamine (GalNAc), it is not unlikely that the 4-deoxysugar also affects 
the GalNAc containing CS/DS chains. If the 4-deoxysugar is incorporated into CS/DS it may 
result in an inhibition of 4-O sulphation. Alternatively, it may inhibit epimerase activity re-
quired for the formation of UDP-GalNAc out of UDP-GlcNAc, as previously suggested for a 
peracetylated 4-fluoro analogue of GlcNAc (43). Unexpectedly, staining with lectins were not 
or only mildly affected, in sharp contrast to the strong effect on HS. Out of the ten lectins 
tested, staining by DSA appeared to be affected the most, which might be explained by the 
fact that N-acetyllactosamine (LacNAc) units (-β1-3Galβ1-4GlcNAc-), as recognized by DSA, 
contain multiple 4-GlcNAc linkages. 
Reduction of HS by the 4-deoxysugar was associated with a reduced capability of 
cells to bind the HS-dependent growth factors FGF-2 and VEGF. Sprouting of endothelial cells 
in response to FGF-2 was strongly reduced. For efficient signalling, FGF-2 as well as its cog-
nate receptor  have to bind to HS (44,45), and  FGF-2 induced sprouting of endothelial cells 
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has been reported to be strongly decreased by heparinase III treatment (41). Furthermore, an-
giogenic sprouting in response to VEGF is dependent on HS, as treatment with a combination 
of heparinase I, II and III markedly decreased the number of angiogenic sprouts induced by 
VEGF (46). It was observed that heparinase I and III inhibited neovascularisation in an in vivo 
chicken chorio-allantoic membrane angiogenesis assay (47). Combined, these data indicate 
that reduction of HS results in an inhibition of angiogenic events. 
Next to the effect of quantitative reduction of HS, changes in HS fine structures 
may also result in altered growth factor binding. Although not tested here, the deoxysugar 
approach allows such a strategy e.g. by application of deoxysugars lacking a specific hy-
droxyl group involved in O-sulphations. Binding of FGF-2 to HS is dependent on N-sulphated 
glucosamine units and one IdoA2S unit (48). For interaction with its cognate receptor and 
downstream signalling additional 6-O-sulphation is required (45). Binding of dimeric VEGF 
to HS depends on two highly sulphated domains, in which 6-O-sulphation appears particu-
larly important, both domains  linked by a less sulphated domain (49). An example of fine 
structure alteration resulting in reduced growth factor binding, is the endothelium specific 
knock out of NDST-1 in mice (41). Endothelial cells showed a reduced binding capacity for 
FGF-2 and VEGF, whereas endothelial cell sprouting in response to these growth factors was 
markedly reduced (41). The dependency on sulphation motifs provides options for a more 
specific inhibition of growth factor binding. Current research focuses on novel deoxysugars 
aimed at blocking specific sulphation sites.
In conclusion, we have shown that an inexpensive, easily synthesized, water-solu-
ble monosaccharide analogue can interfere with HS expression and pro-angiogenic growth 
factor binding. Further research will focus on the effect of the 4-deoxysugar on tumour for-
mation in vivo.
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Abstract 
Heparan sulfate (HS), a long linear polysaccharide, is implicated in various steps of tumor-
igenesis, including angiogenesis. We successfully interfered with HS biosynthesis using a 
4-deoxy analog of the HS constituent GlcNAc and studied the compound’s metabolic fate and 
its effect on angiogenesis. The 4-deoxy analog was activated intracellularly into UDP-4-de-
oxy-GlcNAc and HS expression was inhibited up to ~96%. HS chain size was reduced, with-
out detectable incorporation of the 4-deoxy analog, likely due to reduced levels of UDP-Gl-
cNAc. Inhibition of some other types of glycosylation was observed, although generally not 
as extensive as for HS. Cellular binding and signaling of the angiogenic factors FGF-2 and 
VEGF were inhibited. Comprehensive gene expression analysis revealed reduced expression 
of genes regulated by these HS binding growth factors. Micro-injection in zebrafish embryos 
strongly reduced HS biosynthesis, and angiogenesis was inhibited in both zebrafish and 
chicken model systems. All these data identify 4-deoxy-GlcNAc as a potent inhibitor of HS 
synthesis which hampers neo-vessel formation via inhibition of pro-angiogenic signaling.
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Introduction
Glycosaminoglycans (GAGs) are long, linear, negatively charged polysaccharides generally at-
tached to a core protein, forming proteoglycans. They are present on the surface of virtually 
every mammalian cell and in the extracellular matrix. By interacting with a wide variety of 
effector molecules, GAGs are involved in many physiological and pathological processes (1). 
Based on their backbone structure, the GAG family of molecules can be subdivided into differ-
ent family members, such as hyaluronan, chondroitin/dermatan sulfate (CS/DS) and heparan 
sulfate (HS). HS is essential in angiogenesis due to its capacity to interact with pro-angiogenic 
growth factors like fibroblast growth factor 2 (FGF-2) and vascular endothelial growth factor 
(VEGF), and to present them to their receptor (2,3). HS is also an important player in tumor 
biology through its role in cell growth and invasion, as well as in metastasis formation (4). 
The HS precursor polysaccharide consists of up to a hundred repeated disaccharide 
units composed of glucuronic acid (GlcA) and N-acetyl-d-glucosamine (GlcNAc). The [-4Gl-
cA-β1-4GlcNAc-α1-]
n
 backbone is variably modified by epimerization of GlcA to iduronic acid 
(IdoA) and by various sulfation reactions (5). 6O-sulfation of HS has been shown to be of 
particular importance for angiogenesis (6), which is likely due to 6O-sulfation dependency of 
FGF-2 and VEGF signaling (7). 
The role of HS in angiogenesis and other stages of tumor progression makes it a 
promising target for cancer therapy. Different strategies have been employed to target HS, 
including specific enzymes such as bacterial heparinases (8) and HS mimetics like suramin (9) 
and PI-88. For example, PI-88 was shown to reduce tumor vascularity and growth of rat mam-
mary adenocarcinoma by ~50% (10). We and others have previously used GlcNAc analogs 
lacking the C4-OH (11-15), hypothesizing that incorporation of such sugars will function as a 
HS chain terminator. A 4-deoxy analog of GlcNAc has been shown to inhibit HS biosynthesis 
(13,15). The molecular mechanism of inhibition, however, is unclear, and it remains to be 
evaluated whether 4-deoxy-GlcNAc, or monosaccharide analogs in general, can inhibit in vivo 
HS biosynthesis and HS dependent processes as angiogenesis. 
In this study, we describe the effects of peracetylated 4-deoxy-GlcNAc (4-deoxy-Gl-
cNAc (Ac
3
)) on UDP-sugar biosynthesis, expression of GAGs and other glycoconjugates. We 
show that 4-deoxy-GlcNAc is not incorporated into HS, but decreases synthesis of natural 
UDP-GlcNAc causing considerable HS size reduction. This readily affects biological process-
es, i.e. FGF-2 and VEGF signaling, as evidenced by high density gene expression microarray 
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analysis. The 4-deoxy analog reduced HS synthesis in vivo, and its biological relevance was 
illustrated by impaired in vivo angiogenesis in both zebrafish and chicken model systems. 
Materials and methods
Peracetylated 4-deoxy-GlcNAc was prepared by a single transformation from 4-deoxy-Glc-
NAc, of which the synthesis has been described (15). Purity was >95% and 1H and 13C-NMR 
data was in accordance with literature data. For detection of HS/CS, cells were incubated with 
single chain variable fragment (ScFv) anti-HS antibodies LKIV69 and HS4C3 or anti-CS an-
tibody IO3H10. For staining of HS ‘stubs’, obtained after digestion with heparinase III, cells 
were incubated with anti-stub ‘3G10’. For staining of other glycans, cells were incubated 
with biotinylated lectins. To establish FGF-2/VEGF binding capacity, cells were incubated 
with 5 µg/ml recombinant rat (rr) FGF-2 or 10 µg/ml rrVEGF-164, and bound FGF-2/VEGF 
was detected by anti-FGF-2/anti-VEGF164. To establish FGF2-FGFR1 complex formation, 
cells were subsequently incubated with 1 µg/ml recombinant human (rh) FGF-2 and 1 µg/
ml rhFGFR1α (IIIc) Fc chimera. Bound FGFR1 was detected by Alexa488 fluorochrome 
conjugated anti-human IgG. GAG isolation and agarose gel electrophoresis was performed 
as described (15). Size exclusion was performed using a Superdex 200 (10/300 GL) column 
and fractions were analyzed by agarose gel electrophoresis. Sugar nucleotides were extract-
ed by addition of ethanol (to 80% v/v) to lysed SKOV3 cells, and after centrifugation, the 
supernatant was dried under nitrogen and dissolved in water. Separation was carried out by 
Dx600 HPAEC-UV using a Dionex Analytical Carbo Pac PA 1 column (4 x 250 mm). For 
glycan reductive isotope labeling-LC/MS analysis of heparan sulfate NRE disaccharides and 
UDP-hexosamines, enzymatically depolymerized GAG preparations of SKOV3 cells were 
differentially mass labeled by reductive amination with [12C6]aniline as previously described 
(16). Gene expression of SKOV3 cells was analyzed by Affymetrix® GeneChip®  human 
exon 1.0 ST arrays as described (17). Phospho-ERK of 6h serum starved, and subsequently 
10 ng/ml rhFGF-2 and 10 ng/ml rhVEGF stimulated HUVECs was detected by western blot 
using anti-phospho-Erk1/2. HUVEC proliferation was analyzed using the CellTiter-Glo® 
Luminescent Cell Viability Assay according to the suppliers protocol. For zebrafish embryo 
micro-injection, GlcNAc and 4-deoxy-GlcNAc (peracetylated and non-peracetylated) were 
diluted to a final concentration of 450, 250 and 125 mM in PBS containing 0.5% phenol red, 
and 1 nl was injected into the yolk of one- to two-cell-stage embryos. For flow cytometry, 
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embryos were dechorionated using pronase, deyolked by passing through a 200 µl pipette 
tip and dissociated by pipetting up and down in 5 mM EDTA. For immunohistochemistry, 
embryos were placed in Tissue Tek and were snap frozen in precooled isopropyl alcohol. 
For zebrafish embryo bathing, strain Fli-1:eGFP/GATA-1:DsRed (in house bred) was used 
for all experiments. When the embryos reached the 19-somite stage, 4-deoxy-GlcNAc (Ac3) 
was, or was not (control), added to the water at a final concentration of 10 mM. For whole 
vasculature imaging, the fish embryos were visualized at 48 hpf under a fluorescence micro-
scope. For alkaline phosphatase staining, the fish embryos were fixed at 72 hpf and the blood 
vessels within the subintestinal basket were visualized by staining with nitrotetrazolium blue 
chloride. Images of subintestinal baskets on both sides of the fish were captured under a 
stereomicroscope and the whole embryo, subintestinal veins (SIVs), branch and extension 
lengths were measured using AxioVision. The chorioallantoic membrane (CAM) assay was 
performed by daily application of the appropriate concentration of GlcNAc (Ac4) or 4-de-
oxy-GlcNAc (Ac3) in a volume of 50 µl within a ring placed on the CAM for 4 days. Vessel 
density was quantified as the total number of cross-sections of the blood vessels with 5 con-
centric circles which were projected onto a picture of the CAM.  More detailed information 
is provided in Supplementary methods.
Results
4-deoxy-GlcNAc (Ac
3
) inhibits HS and CS expression
To study the effects of 4-deoxy-GlcNAc on HS expression the sugar analog was peracetylat-
ed (Scheme S1) as peracetylation of sugars increases lipophilicity allowing passive diffusion 
over the cell membrane (18). Once inside the cell the acetyl groups are removed by aspecific 
esterases (19). First, human ovarian carcinoma cells (SKOV3) were cultured for three days 
in the presence of different concentrations of 4-deoxy-GlcNAc (Ac3). Subsequent analysis 
of HS levels revealed a dose-dependent reduction in HS expression (Fig. 1a) with an IC50 of 
16 µM (Fig. 1b). At 50 µM, HS expression was inhibited by ~93%; at 100 µM this was ~96%. 
There was no effect on cellular proliferation at these concentrations (Supplementary results 
and Fig. S1). In addition, incubation with 100 µM parent sugar, GlcNAc (Ac4), did not affect 
HS expression (Fig. 1c). Agarose gel electrophoresis confirmed the strong reduction of HS at 
50 and 100 µM 4-deoxy-GlcNAc (Ac3) (Fig. 1d). We also noted a decreased CS expression 
using this technique, albeit less effective compared to HS, which was confirmed by flow cy-
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tometry (Fig. 1e). Since 4-deoxy-GlcNAc (Ac3) did not affect syndecan-1 protein levels (Fig. 
1f) it is unlikely that the reduction of GAG levels resulted from a reduction of proteoglycan 
core protein expression. To exclude that the observed effects were restricted to SKOV3 cells, 
CHO-K1 Chinese hamster ovary cells, MV3 melanoma cells, HeLa cervical cancer cells and 
IGROV1 ovarian carcinoma cells were also treated. In all cell lines, we found a strong reduc-
tion in HS and moderate reduction in CS expression (in case CS was produced in non-treated 
Figure 1. 4-deoxy-GlcNAc (Ac
3
) inhibits expression of HS and CS, but not of the core protein of the 
HS-proteoglycan syndecan-1. (a) 4-deoxy-GlcNAc (Ac
3
) reduces HS expression of SKOV3 cells dose-de-
pendently, as determined by flow cytometry using anti-HS antibody LKIV69. The number of counted 
cells is indicated by the number of events. b) IC
50
-value for reduction of HS expression, as determined 
by the percentage of inhibition of mean fluorescence intensity of the control (see a). Data is presented 
as mean±sd from three separate experiments. (c) 100 µM GlcNAc (Ac
4
), the parent sugar, has no effect 
on HS expression. (d) 4-deoxy-GlcNAc (Ac
3
) reduces CS expression in addition to strongly reducing HS 
expression, as determined by separation and staining of isolated GAGs on agarose gel. (e) 4-deoxy-Glc-
NAc (Ac
3
) reduces CS expression using anti-CS antibody IO3H10. For clarity, the y-axis was cut off at 300 
events. (f) 4-deoxy-GlcNAc (Ac
3
) does not inhibit expression of syndecan-1 core protein.
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controls), although the required dosage differed per cell line (50 – 500 µM; Fig. S2). Alto-
gether, these data show that 4-deoxy-GlcNAc (Ac3) is a potent inhibitor of HS expression. 
4-deoxy-GlcNAc (Ac
3
) reduces HS and CS chain size without detectable incorporation
Subsequent GAG chain size analysis revealed that HS of control cells (Kav 0.03) eluted nota-
bly earlier than HS of 25 µM 4-deoxy-GlcNAc (Ac3) treated cells (Kav 0.33), indicating that 
treatment reduces HS chain size (Fig. 2a). CS of 25 µM treated cells eluted slightly later than 
Figure 2. 4-deoxy-GlcNAc (Ac
3
) reduces HS and CS chain size without detectable incorporation. (a) 
4-deoxy-GlcNAc (Ac
3
) strongly reduces HS chain size. GAGs from SKOV3 cells treated with or without 
25 µM 4-deoxy-GlcNAc (Ac
3
) were subjected to Superdex 200 size exclusion chromatography, fractions 
were analyzed on agarose gel and band intensity of HS was quantified. (b) 4-deoxy-GlcNAc (Ac
3
) reduces 
CS chain size. (c) 50 µM 4-deoxy-GlcNAc (Ac
3
) reduces CS chain size more prominently. (d) 4-deoxy-Glc-
NAc (Ac
3
) reduces staining for HS-‘stubs’ generated by heparinase III digestion, and analyzed by flow 
cytometry using antibody 3G10. For clarity, the y-axis was cut off at 300 events. e, f) 4-deoxy-GlcNAc 
(Ac
3
) is not detectably incorporated into HS chains, as shown by analysis of internal and non-reducing 
end disaccharides (generated by heparinase digestion) of 50 µM 4-deoxy-GlcNAc (Ac
3
) treated (e) and 
untreated (f) cells. For explanation see text.
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CS of control cells (Fig. 2b), but  this effect was more apparent at 50 µM (Kav shift from 0.05 
to 0.15; Fig. 2c). Staining for HS ‘stubs’ decreased by ~50% at 100 µM 4-deoxy-GlcNAc (Ac3) 
compared to the control or to the parent sugar (Fig. 2d), indicating a reduction in the number 
of HS chains. As ‘general’ HS staining was reduced almost completely at this concentration 
(Fig. 1a), this also indicates that HS chains were considerably smaller. HS and CS/DS disac-
charide composition, however, had not changed to a major extent (Supplementary results and 
Fig. S3).
To investigate whether the effect on HS chain size was due to 4-deoxy-GlcNAc in-
corporation, we analyzed the disaccharides present at the non-reducing end (NRE). If incor-
porated, depolymerization of HS by heparinases would generate terminal mono- or trisac-
charides with a specific mass. However, no evidence was found for the presence of these 
structures after 4-deoxy-GlcNAc (Ac
3
) treatment. Instead, NRE disaccharides having no ace-
tate and a single sulfate, likely GlcA-GlcNS, were detected (Fig. 2e), indicating that HS chains 
of treated cells terminate with GlcA or IdoA, rendering it unlikely for incorporation to be the 
main mechanism for HS truncation. In addition, the amount of NRE disaccharides relative to 
internal disaccharides UA-GlcNAc was increased by 4-deoxy-GlcNAc (Ac
3
) treatment (Fig. 2f), 
again indicating reduced HS chain size. Thus, 4-deoxy-GlcNAc reduces HS chain size without 
detectable incorporation into HS.
4-deoxy-GlcNAc (Ac
3
) is metabolized into UDP-4-deoxy-GlcNAc and reduces UDP-HexNAc 
Next, we determined whether a reduced amount of the sugar nucleotide UDP-GlcNAc could 
account for the observed HS size reduction. Culturing cells with 100 µM 4-deoxy-GlcNAc (Ac
3
) 
markedly reduced the amount of UDP-GlcNAc (Fig. 3a). In addition, a large additional peak 
was found overlapping  UDP-GalNAc. Since UDP-GlcNAc and UDP-GalNAc are normally in 
equilibrium, it is unlikely this peak represents UDP-GalNAc. Furthermore, the retention time 
of the additional peak was similar to that of standard UDP-4-deoxy-GlcNAc, indicating activa-
tion of the sugar analog. In addition, we noticed a reduction in ATP level and a concomitant 
increase in ADP, consistent with activation of a large amount of 4-deoxy-GlcNAc. To confirm 
the presence of UDP-4-deoxy-GlcNAc, LC/MS was performed (Fig. 3b). UDP-4-deoxy-GlcNAc, 
which has a mass reduction of 16 amu compared to UDP-GlcNAc (upper panel), was abun-
dantly present in 4-deoxy-GlcNAc (Ac
3
) treated cells, but not in untreated cells (middle pan-
el). A strong reduction of UDP-HexNAc (UDP-GlcNAc and UDP-GalNAc) was confirmed (lower 
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panel). Collision induced dissociation further proved the identity of UDP-HexNAc and UDP-4-
deoxy-GlcNAc, as UDP and specific monosaccharide fragments were found (Fig. S4a, c). The 
profile for the cellular UDP-4-deoxy-GlcNAc was identical to fractions obtained from a UDP-4-
deoxy-GlcNAc standard (Fig. S4b). These data indicate that 4-deoxy-GlcNAc is formed into its 
activated sugar nucleotide UDP-4-deoxy-GlcNAc, and this abundant formation decreases the 
formation of natural UDP-GlcNAc and UDP-GalNAc. This not only results in decreased HS syn-
thesis but also explains the CS size reduction, as the [-4GlcA-β1-3GalNAc-β1-]
n
 CS backbone 
requires UDP-GalNAc for biosynthesis.
Figure 3. 4-deoxy-GlcNAc (Ac
3
) is metabolized into UDP-4-deoxy-GlcNAc and reduces levels of UDP-Glc-
NAc. (a) HPAEC-UV analysis of sugar nucleotides. UDP-4-deoxy-GlcNAc is abundantly present in SKOV3 
cells treated with 100 µM 4-deoxy-GlcNAc (Ac
3
). Treatment with 4-deoxy-GlcNAc (Ac
3
) reduces levels 
of UDP-GlcNAc and ATP. (b) LC/MS analysis of sugar nucleotides. The mass of UDP-4-deoxy-GlcNAc is 
reduced by 16 amu compared to UDP-HexNAc (upper panel). Extracted ion current shows that UDP-
4-deoxy-GlcNAc is abundantly present after 4-deoxy-GlcNAc (Ac
3
) treatment (middle panel), whereas 
UDP-HexNAc (lower panel) is strongly reduced. 
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Effect of 4-deoxy-GlcNAc (Ac
3
) on expression of other glycans
Considering the effect on UDP-sugar biosynthesis, we evaluated other glycan structures by 
studying O-GlcNAc protein modification (Fig. S5a), hyaluronan expression (Fig. S5b) and lec-
tin binding (Fig. S5c). 4-deoxy-GlcNAc (Ac
3
), but not GlcNAc (Ac
4
), treatment reduced O-GlcNAc 
modification, consistent with the notion that the O-GlcNAc transferase strongly depends 
on the level of UDP-GlcNAc (20). Expression of the non-sulfated GAG hyaluronan which has 
a basic backbone of [-4GlcA-β1-3GlcNAc-β1-]
n
, was reduced by 37-50%, whereas addition of 
GlcNAc (Ac
4
) more than doubled its expression. Of the 12 lectins used for glycan staining, 5 
showed reduced reactivity after treatment with 4-deoxy-GlcNAc (Ac
3
), and these include MAA 
and DSA (recognizing the GlcNAc containing N-acetyl-lactosamine residues) and the lectins 
PNA, VVA and SBA (recognizing O-linked GalNAc glycans). Except for DSA, which was reduced 
by  ~80% at 100 µM, reduction of lectin stainings was ~50%. Taken together, these data 
are consistent with reduced levels of UDP-GlcNAc and UDP-GalNAc by treatment with 4-de-
oxy-GlcNAc (Ac
3
). The expression of HS is generally more affected than other GlcNAc/GalNAc 
glycosylation types. 
Effect of 4-deoxy-GlcNAc (Ac
3
)
 
on gene expression using microarray analysis
To investigate the effect of on cellular processes, we performed a comprehensive gene ex-
pression analysis using DNA exon microarrays. To identify affected pathways we employed 
expression target analysis using Pathway studio software, and analyzed a set of 327 over-
lapping genes that displayed a >1.2 fold decrease in expression after treatment with 50 
µM 4-deoxy-GlcNAc (Ac
3
) compared to untreated and 50 µM GlcNAc (Ac
4
) treated cells (Fig. 
S6a). In this set, we found an over-representation of genes regulated by HS binding growth 
factors as FGF-2, VEGF and CTGF (connective tissue growth factor), as well as targets of their 
downstream signaling molecules as Ras, MAPKs, PI3K and SMADs (Table 1, Fig. S6b and Table 
S1). Downregulation of selected FGF-2, VEGF and CTGF regulated genes was confirmed by 
real-time Q-PCR (Fig. S6c). Using Pathway studio, we also analyzed a set of 173 overlapping 
genes of which the expression increased by >1.2 fold after treatment with 4-deoxy-GlcNAc 
(Ac
3
) (Fig. S5a) and found an over-representation of genes involved in cholesterol biosynthesis 
(Table S2). 
69
A GlcNAc analog interferes with UDP-GlcNAc metabolism, 
inhibits heparan sulfate expression, and influences angiogenesis in vivo
4-deoxy-GlcNAc (Ac
3
) reduces FGF-2 and VEGF binding and signaling
To assess cellular binding of FGF-2 and VEGF, both molecules were added to SKOV3 cells and 
the amount of bound proteins was analyzed by flow cytometry. Binding capacity for FGF-2 
(Fig. 4a) and VEGF (Fig. 4b) was effectively reduced after 4-deoxy-GlcNAc (Ac
3
) treatment. In 
addition, the amount of (soluble) FGF-receptor 1 (FGFR1) that could bind to FGF-2 incubated 
cells incubated was reduced as well (Fig. 4c), further indicating an effect on ligand/receptor 
binding. Since FGF-2 and VEGF mainly affect signaling during neovessel formation, i.e. angi-
ogenesis, we subsequently focused on endothelial cells. For endothelial cells (HUVEC, RF24) 
we found a strong reduction of HS at 50 µM 4-deoxy-GlcNAc (Ac
3
) (Fig. S2) and this treatment 
abolished the FGF-2/VEGF induced increase in phospho-ERK1/2 (Fig. 4d). Furthermore, FGF-2 
Table 1. 4-deoxy-GlcNAc (Ac
3
) downregulates expression of genes regulated by HS binding growth 
factors and their downstream signaling proteins (partial list). Analysis of a list of 327 genes downreg-
ulated by treatment with 50 µM 4-deoxy-GlcNAc (Ac
3
), as determined by microarray analysis, in Path-
way studio indicates that most genes are regulated by HS binding growth factors (e.g. VEGF-A) or by 
downstream signaling proteins (e.g. SMADs). P-values are calculated by Pathway studio using Fisher’s 
Exact Test based on the overlap with the total number of regulated genes. P-values < 0.001 indicate 
high confidence. Individual genes are shown in Fig. S6b and Table S1.
Genes regulated 
by
Total no. of regulated 
genes 
Number of downregulated genes after 
treatment with 4-deoxy-GlcNAc (Ac
3
)
P-value
PI3K 424 21 (4%) 7.82x10-7
VEGFA 234 15 (6%) 1.53x10-6
NF-kB 706 27 (3%) 2.82x10-6
SMAD7 66 8 (11%) 5.25x10-6
SMAD4 117 10 (8%) 7.96x10-6
FGF2 402 18 (4%) 2.08x10-5
CTGF 61 7 (11%) 3.02x10-5
SRC 170 11 (6%) 3.82x10-5
MAP2K6 47 6 (12%) 6.38x10-5
SMAD 150 10 (6%) 6.81x10-5
Jun/Fos 533 20 (3%) 8.67x10-5
RF-X 16 4 (23%) 8.88x10-5
PRRX1 6 3 (42%) 1.02x10-4
SYNPO 1 2 (100%) 2.11x10-4
MAPK 528 19 (3%) 2.28x10-4
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induced proliferation of HUVECs was inhibited dose-dependently by 4-deoxy-GlcNAc (Ac
3
) 
(Fig. 4e). 
4-deoxy-GlcNAc (Ac
3
) affects HS biosynthesis and angiogenesis in vivo
To determine the effect on HS biosynthesis and angiogenesis in vivo we used a zebrafish 
developmental model. In line with the results above, surface expression of HS was reduced 
following injection of both 4-deoxy-GlcNAc (Ac
3
) and its non-peracetylated counterpart, 4-de-
oxy-GlcNAc, the latter being slightly more effective in this system (Fig. 5a, see also Baskin et 
al. (21)). Subsequent experiments were thus performed with 4-deoxy-GlcNAc. Injection with 
Figure 4. 4-deoxy-GlcNAc (Ac
3
) inhibits binding and signaling of FGF-2 and VEGF. (a, b) 4-deoxy-GlcNAc 
(Ac
3
) strongly inhibits binding of rrFGF-2 (a) and rrVEGF
164
 (b) to SKOV3 cells, as determined by addition 
of the growth factor and flow cytometry using an antibody against FGF-2 or VEGF. (c) 4-deoxy-GlcNAc 
(Ac
3
) strongly inhibits binding of (soluble) rhFGFR1 (Fc chimera) to SKOV3 cells, previously incubated 
with rhFGF2, using an anti-IgG antibody. (d) 4-deoxy-GlcNAc (Ac
3
) inhibits formation of intracellular 
p-ERK1/2 (a components essential in the downstream signaling by FGF-2 and VEGF) in HUVECs, as de-
termined by western blot using an antibody against p-ERK 1/2 or GAPDH (control). (e) 4-deoxy-GlcNAc 
(Ac
3
) inhibits FGF-2 (10 ng/ml)-induced proliferation of HUVECs, as determined by the CellTiter-Glo 
assay. Data is presented as mean±sd from three separate experiments. *P < 0.05 compared to control, 
using Student’s t-test. 
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125 and 250 pmol of 4-deoxy-GlcNAc resulted in a dose dependent reduction of HS expres-
sion and, to a lesser extent, staining of DSA and PNA (Fig. 5b). As seen in vitro, binding of the 
lectin ConA was not affected. Injection with 250 pmol of GlcNAc did not alter HS expression, 
nor expression of glycans recognized by the lectins ConA, DSA and PNA (Fig. 5b). Interest-
ingly, while HS expression was reduced by ~87% in case of 250 pmol 4-deoxy-GlcNAc, only 
~10% of injected embryos displayed abnormal morphology (Fig. 5c: ‘strongly affected’). This 
percentage increased to ~40% when we increased the amount of injected 4-deoxy-GlcNAc 
Figure 5. 4-deoxy-GlcNAc inhibits heparan sulfate/glycosylation and angiogenesis in vivo. (a) Mi-
cro-injection with 250 pmol 4-deoxy-GlcNAc (peracetylated or not) strongly reduces cell surface HS, 
as assessed by flow cytometry of embryo derived cells (2 dpf) using anti-HS antibody HS4C3. (b) 
4-deoxy-GlcNAc, but not GlcNAc, reduces staining by the lectins PNA and DSA. Data is presented as 
mean±sd from two separate experiments (at least 10 embryos were pooled for one measurement). *P 
< 0.05 compared to control, using Student’s t-test. (c) The majority of 4-deoxy-GlcNAc injected embry-
os appears macroscopically normal, whereas ~10% lost their normal phenotype (‘strongly affected’). 
(d,e) Flow cytometry (d) and immunohistochemistry (e) of ‘strongly affected’ embryos (enriched for by 
injecting 450 pmol 4-deoxy-GlcNAc) reveal that HS expression is almost nullified. Scale bar = 200 µm. 
(f) Bathing of Fli-eGFP embryos in 4-deoxy-GlcNAc (Ac
3
) reveals pericardial oedema in 12 out of 23 em-
bryos (middle panel) and major vasculature defects in 2 embryos (lower panel). Scale bar = 200 µm. (g) 
Left panels: example of alkaline phosphatase vessel staining with indicated parameters. Right panel: 
bathing with 4-deoxy-GlcNAc (Ac
3
) reduces number and length of SIVs, mean basket length, and basket 
area. Data is presented as mean±SEM. P-values are determined by the Mann-Whitney U test. *P < 0.05, 
**P < 0.01, ***P < 0.001. (g) 4-deoxy-GlcNAc (Ac
3
) inhibits in vivo angiogenesis (vessel density) in the 
chicken chorioallantoic membrane assay. Data is presented as mean±SEM. P-values are indicated, and 
determined by the Mann-Whitney U test.
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to 450 pmol. The HS expression of these embryos was almost nullified as revealed by flow 
cytometry (~4% compared to control, Fig. 5d) and immunohistochemistry (Fig. 5e). 
Next, we assessed the formation of the subintestinal vessels (SIVs), which are 
formed by angiogenesis (22). Embryos were bathed in 10 mM 4-deoxy-GlcNAc (Ac
3
) after they 
reached the 19-somite stage. This concentration was based on a previous study in which em-
bryos were bathed with peracetylated azido-GalNAc for glycan labeling (23). First, the whole 
vasculature was imaged in transgenic zebrafish that have harboured eGFP (enhanced green 
fluorescent protein) under the control of Fli-1, an endothelial cell marker. Although the vas-
culature of most treated animals appeared grossly normal, pericardial oedema was observed 
in 12 out of 23 fish, indicating vascular abnormalities (Fig. 5f, middle panel, arrowhead). In 
two animals, major vasculature defects were observed, i.e. a total loss of dorsal longitudinal 
anastomic vessels (DLAV) and intersegmental vessels (IV) (Fig. 5f, lower panel, arrows). As a 
measure of angiogenesis, the formation of the subintestinal basket was assessed by alkaline 
phosphatase staining. The number of SIVs, their mean length as well as their total length 
was significantly decreased by bathing in 4-deoxy-GlcNAc (Ac
3
) (Fig. 5g). Basket area, mean 
length of the basket and the total length of the subintestinal vasculature were significantly 
decreased as well. This was not caused by an overall reduction of fish length, as this was only 
decreased by 4%. Interestingly, we found a significant increase in the number, total and mean 
length of the extensions out of the basket. 
In addition to the zebrafish model, in vivo angiogenesis was evaluated in the chick-
en chorioallantoic membrane (CAM) model. 4-deoxy-GlcNAc (Ac
3
) was added topically on day 
6 of embryo development. Treatment of the CAM for 4 days with 5 and 10 mM 4-deoxy-Gl-
cNAc (Ac
3
) significantly reduced vessel-density by 34% and 30%, respectively, whereas 10 mM 
of the peracetylated parent sugar had no significant effect (Fig. 5h). Altogether, 4-deoxy-Gl-
cNAc (Ac
3
) is able to reduce HS synthesis in vivo leading to vascular defects and impaired 
angiogenesis. 
Discussion
In this study, it was found that 4-deoxy-GlcNAc (Ac
3
) dose-dependently inhibited HS synthesis 
in several cell types, and resulted in strongly truncated HS chains. Surprisingly, even though 
4-deoxy-GlcNAc was formed into UDP-4-deoxy-GlcNAc and this nucleotide sugar was abun-
dantly present in the cell, we did not find 4-deoxy-GlcNAc at the NRE of HS. While Kisilevsky 
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et al. (13) showed incorporation of a radiolabeled 4-deoxy-GlcNAc, our results indicate that 
incorporation is not a prime event. Instead, our data suggest that 4-deoxy-GlcNAc reduces 
the level of UDP-GlcNAc available for HS biosynthesis. This mechanism, i.e. inhibition of 
UDP-GlcNAc formation and glycan synthesis by activation of a GlcNAc analog without incor-
poration, is supported by data for 4F-GlcNAc. Nigro et al. (14) have shown that peracetylated 
4F-GlcNAc inhibits quantity and size of HS/CS GAGs by 64 - 77%. While that study did not 
address sugar analog incorporation into GAGs, it was described that 4F-GlcNAc (Ac
3
) reduced 
the content of N- and O-linked glycans without incorporation (24). Similar to our findings, 
a reduction in cellular UDP-GlcNAc levels was found (24) and another group reported that 
4F-GlcNAc was activated into UDP-4F-GlcNAc (25). Together with our current data a mecha-
nism emerges in which the machinery that is necessary for the formation of natural UDP-Gl-
cNAc is hijacked by activation of 4-deoxy-GlcNAc into UDP-4-deoxy-GlcNAc. As an additional 
mechanism, UDP-4-deoxy-GlcNAc might inhibit one or several glycosyltransferases. For ex-
ample, a 5S-GlcNAc analog was recently shown to be formed into UDP-5S-GlcNAc, was not 
transferred onto proteins, and inhibited O-GlcNAc protein modification by inhibition of the 
O-GlcNAc transferase (26). 
In the present study we studied the biological effects of 4-deoxy-GlcNAc (Ac
3
) both in 
vitro and in vivo. We found an inhibition of FGF-2 and VEGF binding and signaling. Compre-
hensive gene expression analysis confirmed that expression of genes regulated by these HS 
binding growth factors was inhibited. In addition, a number of genes involved in cholesterol 
synthesis were found upregulated by 4-deoxy-GlcNAc (Ac
3
). Increased cholesterol synthesis 
has been reported after desulfation of GAGs by chlorate treatment (27). As HS plays an im-
portant role in lipolysis and uptake of (cholesterol containing) lipoproteins, one explanation 
could be that because of the lack of HS, cells are not fully capacitated for cholesterol uptake, 
resulting in an increased intracellular synthesis. Other effects, such as altered LDL recep-
tor-glycanation cannot be excluded, however. 
Another aspect of this study was the evaluation of HS biosynthesis in vivo, injecting 
zebrafish embryos at the one-cell stage. Surprisingly, even though it is known that HS plays 
important roles in zebrafish development, e.g.  in axon sorting (28), muscle development 
(29) and vascular development (6), injected embryos still appeared grossly macroscopically 
normal, while cell surface HS was reduced by  ~87%. Only when HS expression was almost 
nullified, which was the case in a small proportion of the injected embryos, did they lose 
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their normal morphology. It should be noted here that even with a ~87% reduction of cellu-
lar HS, immunohistochemistry still showed major HS staining. This may be due to a relative 
insensitivity of this method, but may also indicate that HS in the extracellular matrix has a 
slower turn over in comparison with cell surface HS. Furthermore, vascular defects indicated 
by oedema and a reduction of angiogenesis were found by bathing zebrafish embryos in 
the 4-deoxy analog. Interestingly, although most characteristics of the SIVs were negatively 
compromised, the total number and length of extensions out of the basket were increased by 
the presence of the 4-deoxy analog. This could reflect ectopic angiogenesis, as HS is critical 
for the formation of the VEGF gradient (30). 
In conclusion, we propose a model (Fig. S7) in which 4-deoxy-GlcNAc is transformed 
into UDP-4-deoxy-GlcNAc intracellularly (via the salvage pathway), resulting in a depletion 
of UDP-GlcNAc, leading to shortened HS chains on the cell surface, resulting in a diminished 
formation of complexes of FGF-2/VEGF and their receptors, diminished FGF-2 and VEGF sig-
naling and a decrease in gene expression of genes regulated by FGF-2 and VEGF, cumulating 
in a reduction of the process of angiogenesis. 
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Supplementary data
Supplementary Methods
Synthesis of GlcNAc (Ac
4
) and 4-deoxy-GlcNAc (Ac
3
)
2-acetamido-1,3,6-tri-O-acetyl-2,4-dideoxy-d-xylo-hexopyranose (2). Peracetylated 4-deoxy-GlcNAc 
(2) was prepared by a single transformation from 4-deoxy-GlcNAc (1) (Scheme S1a), of which 
the synthesis has been described (1). Purity of 2 was >95% and 1H and 13C-NMR data was in 
accordance with literature data. A stock solution of 100 (or 500 mM for zebrafish injections) 
in milli-Q was made and stored at -80 °C. Experimental details were as follows: 1 (510 mg, 
2.49 mmole) was dissolved in CH
2
Cl
2
 (25 mL). Pyridine (12.5 mL) and acetic anhydride (12.5 
mL) were added and the reaction was stirred for 16 hours. After 16 hours, the reaction was 
slowly quenched with sat. Na
2
CO
3
 (aq) (10 mL) and stirred for another 30 min. The organic 
layer was extracted with Na
2
CO
3
 (aq) (50 mL). The organic layer was then washed with H
2
O 
(50 mL), sat. NaCl (aq) (50 mL), dried with MgSO
4
 and concentrated in vacuo. The residue was 
purified by flash column chromatography (EtOAc/heptane 1:2 → 1:1) and lyophilised afford-
ing compound 2 (732 mg, 89%) as a white solid. R
f
 0.31 (EtOAc/heptane 1:2). FTIR (ATR) 1740, 
1660, 1370, 1226 cm-1. 1H NMR (CDCl
3
, 400 MHz): α-anomer: δ 6.21 (d, J = 1.7 Hz, 1H), 5.52 (d, 
J = 4.9 Hz, 1H), 5.21 (m, 1H), 4.28 (m, 1H), 4.07 (m, 2H), 2.11 (s, 3H), 2.09 (s, 3H), 2.06 (m, 4H), 
1.95 (s, 3H), 1.95 (m, 1H). ß-anomer: δ 5.60 (d, J = 3.5 Hz, 1H), 5.47 (m, 1H), 5.01 (m, 1H), 4.28 
(m, 1H), 4.07 (m, 2H), 2.11 (s, 3H), 2.09 (s, 3H), 2.06 (m, 4H), 1.95 (s, 3H), 1.9 (m, 1H). 13C NMR 
(CDCl
3
, 75 MHz): δ 171.2, 170.5, 170.1, 169.6, 91.4, 67.2, 64.8, 51.2, 32.1, 24.1, 21.6, 21.3, 19.8. 
HRMS (ESI) m/z calcd for C
14
H
21
N
1
O
8
Na (M+Na)+: 354.11649, found: 354.11719.
2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-α-d-glucopyranose (4). Peracetylated GlcNAc 
(4) was prepared by a single step from GlcNAc (3) (Scheme S1b). Both α and ß stereoisomers 
were formed and subsequently separated by flash column chromatography. As the solubil-
ity of the ß stereoisomer in water was very low, the α stereoisomer was used, which had 
a better solubility. Purity of 4 was >95% and 1H and 13C-NMR data was in accordance with 
literature data. A stock solution of 100 mM in milli-Q was made and stored at -80 °C. Exper-
imental details were as follows: 3 (1000 mg, 4.52 mmole) was dissolved in CH
2
Cl
2
 (45 mL). 
Pyridine (22.5 mL) and acetic anhydride (22.5 mL) were added and the reaction was stirred 
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for 16 hours. After 16 hours, the reaction was slowly quenched with sat. Na
2
CO
3
 (aq) (15 mL) 
band stirred for another 30 min. The organic layer was extracted with Na
2
CO
3
 (aq) (100 mL). 
The organic layer was then washed with H
2
O (100 mL), sat. NaCl (aq) (100 mL), dried with 
MgSO
4
 and concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/heptane 1:2) and lyophilised affording the α-anomer of compound 4 (1003 mg, 57%) 
as a viscous white solid. R
f
 0.43 (EtOAc/heptane 1:2 → 1:1). FTIR (ATR) 1745, 1368, 1217, 1040 
cm-1. 1H NMR (CDCl
3
, 400 MHz): α-anomer: δ 6.21 (d, J = 1.7 Hz, 1H), 5.48 (d, J = 4.9 Hz, 1H), 
5.21 (m, 2H), 4.57 (m, 1H), 4.23 (m, 1H), 4.07 (m, 1H), 4.02 (m, 1H), 2.11 (s, 3H), 2.09 (s, 3H), 
2.06 (m, 3H), 1.95 (s, 3H). 13C NMR (CDCl
3
, 75 MHz): δ 171.3, 170.6, 170.4, 169.6, 168.9, 90.9, 
70.2, 69.2, 67.0, 61.0, 50.6, 23.6, 21.5, 21.3, 20.6, 19.8. HRMS (ESI) m/z calcd for C
16
H
23
N
1
O
10
Na 
(M+Na)+: 412.12196 found: 412.12369.
Antibodies, lectins, enzymes and saccharides
HS- and CS/DS-unsaturated disaccharides were obtained from Iduron (Manchester, UK). 
Mouse mAb against O-GlcNAc (ß-O-linked N-acetylglucosamine; clone CTD110.6) was from 
Covance (Princeton, NJ). Rabbit mAb anti human phospho-Erk1/2 (p44/42 MAPK) (D13.14.4E; 
IgG), and rabbit mAb anti human GAPDH (14C10; IgG) were from Cell Signaling Technology 
(Danvers, MA). Goat anti-rat VEGF (AF564; IgG fraction) was from R&D systems (Minneap-
olis, MN). Mouse mAb anti-HS stub (3G10; IgG2b) was from Seikagaku corporation (Tokyo, 
Japan). Mouse mAb anti-human-syndecan-1 (MCA681H, IgG1) was from Serotec (Kidling-
ton, UK). Heparinase I, II and III from Flavobacterium heparinum were purchased from IBEX 
Pharmaceuticals Inc. (Montreal, Quebec, Canada). Chondroitinase ABC from Proteus vulgaris 
(C3667), papain from Papaya latex (P3125) and the rabbit polyclonal anti bovine FGF-2 anti-
body (F3393; reactive with rat, human and bovine FGF-2) were purchased from Sigma-Aldrich 
(St Louis, MO). The biotinylated lectins, AAL (Aleuria aurantia), ConA (Canavalia ensiformis), 
DSA (Datura stramonium), GNA (Galanthus nivalis), LCA (Lens culinaris), PNA (Arachis hypo-
gaea), RCA-I (Ricinus communis), SBA (Glycine max), VVA (Vicia villosa), WGA (Triticum vulgaris) 
and FITC-conjugated SNA (Sambucus nigra) were from Vector Laboratories (Burlingame, CA). 
FITC-conjugated MAA (Maackia amurensis) was from EY Laboratories (San Mateo, CA).  
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Cell culture
The human ovarian carcinoma cell line SKOV3 was purchased from the American Type Cul-
ture Collection (ATCC, Manassas, VA) and was cultured in McCoy’s 5A medium containing 
GlutaMax (Invitrogen, Carlsbad, CA), supplemented with 10% (v/v) fetal bovine serum (FBS)
(PAA, Pasching, Austria) and 1 mM sodium pyruvate (Invitrogen). RF24 human endothelial 
cells were cultured upon 1% (w/v) gelatin in F-12 Kaighn’s modification medium (Invitro-
gen) supplemented with penicillin/streptomycin (Invitrogen), 5% (v/v) newborn calf serum 
(Invitrogen) and 5% (v/v) human serum (Lonza, Basel, Switzerland). HeLa human cervical 
cancer cells and IGROV1 human ovarian carcinoma cells were cultured in RPMI-1640 medium 
(Invitrogen) supplemented with 10% FBS. CHO-K1 chinese hamster ovary cells were grown 
in F-12 Ham’s modification medium (Invitrogen) supplemented with 10% FBS. MV3 human 
melanoma cells were cultured as described (1). Primary human umbilical vein endothelial 
cells (HUVECs) used in proliferation experiments were isolated and cultured as described 
(2). HUVECs used in growth factor stimulation experiments were harvested from umbilical 
vein according to Jaffe et al. (3). HUVECs were cultured upon 1% (w/v) gelatin coating in 
F-12 Kaighn’s modification medium (Invitrogen) supplemented with penicillin/streptomycin 
(Invitrogen), 10% (v/v) newborn calf serum (Invitrogen), 10% (v/v) human serum (Lonza), 
0.03% (w/v) heparin and 0.15% (w/v) rat brain extract (as a source for endothelial cell growth 
factor). Cultures were passaged twice a week and incubated at 37 °C in the presence of 5% 
CO
2. 
In all cases, cells were seeded one day before addition of GlcNAc (Ac
4
) or 4-deoxy-GlcNAc 
(Ac
3
). After three days of culturing in the presence of either of these sugars, cells were used 
for further analyses. To isolate a sufficient amount of GAGs needed for size exclusion exper-
iments and disaccharide analysis, the double amount of cells were used for analysis of 4-de-
oxy-GlcNAc (Ac
3
) treatment in these experiments.
Flow cytometry
For flow cytometry, cells were detached by enzyme free cell dissociation solution (Millipore; 
Billerica, MA) and kept on ice for the remaining of the procedure. For detection of HS/CS, cells 
were incubated with the VSV-tag containing, single chain variable fragment (ScFv) anti-HS 
antibodies LKIV69 (4) and HS4C3 (5) or anti-CS antibody IO3H10 (6). Next, cells were incubat-
ed with mouse anti-VSV IgG, followed by Alexa488 fluorochrome conjugated anti-mouse IgG 
antibody (1:100; Invitrogen). For staining of HS ‘stubs’, obtained after digestion with 0.02 
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IU heparinase III / ml culture medium containing 1% FCS for 3-6 h at 4°C, incubation with 
anti-stub ‘3G10’ (1:100) and Alexa488 fluorochrome conjugated anti-mouse IgG antibody 
was performed. For staining of other glycans, cells were incubated with biotinylated lectins 
(1:200), followed by Alexa488 fluorochrome conjugated streptavidin (1:500; Invitrogen), or 
with FITC-conjugated lectins (MAA 1:15, SNA 1:100). To establish FGF-2/VEGF binding capac-
ity, cells were incubated with 5 µg recombinant rat (rr) FGF-2/ml or 10 µg rrVEGF-164/ml 
(7). Bound FGF-2/VEGF was detected by anti-FGF-2 (1:250)/anti-VEGF
164 
(1:25) antibodies and 
Alexa488 fluorochrome conjugated anti-rabbit/anti-goat IgG antibodies (1:200; Invitrogen), 
respectively. To establish FGF2-FGFR1 complex formation, cells were incubated with 1 µg 
recombinant human (rh) FGF-2 (R&D systems)/ml and 1 µg recombinant human (rh) FGFR1α 
(IIIc) Fc chimera (R&D systems, 658-FR)/ml, subsequently. Bound FGFR1 was detected by Al-
exa488 fluorochrome conjugated anti-human IgG (1:100; Invitrogen). For staining of syn-
decan-1, cells were incubated with mouse mAb anti-human-syndecan-1 (1:50) followed by 
Alexa488 fluorochrome conjugated anti-mouse IgG antibody. Omission of the first antibody 
was used as a negative control. Flow cytometry analyses were performed using a Beckton 
Dickinson FACSscan or FACScalibur. Viable cells were gated using forward and side scatter, 
and the fluorescence, including mean fluorescence intensity (MFI), of this population was 
measured. 
Immunocytochemistry
Immunocytochemistry was performed as described (1).
GAG isolation and agarose gel electrophoresis
GAG isolation and agarose gel electrophoresis was performed as described (1). 
Size exclusion chromatography
GAGs from SKOV3 cells treated for three days with or without 25/50 µM 4-deoxy-GlcNAc 
(Ac
3
) were dissolved in milli-Q and (NH
4
)
2
CO
3 
was added to a final concentration of 0.2 M, 
after which the solution was applied to a Superdex 200 (10/300 GL) column (GE Healthcare, 
Chalfont St. Giles, UK) coupled to an ÄKTA purifier system. Fractions of 0.5 ml (69 fractions in 
total) were automatically collected at a constant flow rate of 0.5 ml/min in 0.2M (NH
4
)
2
CO
3
. 
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Fractions were lyophilized, dissolved in 10 µl milli-Q and analyzed by agarose gel electro-
phoresis. Band intensity was quantified by Gene Tools (Syngene, Cambridge, UK) and relative 
intensity was calculated according to the standard present on each gel. To calculate K
av
, void 
volume and total volume were determined by dextran-blue and phenol red, respectively. 
Hyaluronan ELISA
SKOV3 cells were seeded one day before media was replaced by media with or without 50 µM 
GlcNAc (Ac
4
) or 50/100 µM  4-deoxy-GlcNAc (Ac
3
), cells were counted and media was collected 
after three days. A sandwich type ELISA assay for hyaluronan content of cultured media was 
performed as described (8,9).
Disaccharide analysis
Disaccharides were generated enzymatically from GAGs isolated from SKOV3 cells treated for 
three days with or without 50 µM GlcNAc (Ac
4
) or 4-deoxy-GlcNAc (Ac
3
). GAGs were digested 
either with 0.1U chondroitinase ABC /100 µl GAGs (derived from 4 or 8 T175 culture flasks) 
in 25 mM Tris/2 mM Mg(Ac)
2
 buffer (pH 8.0), or with a mixture of 10 mU each of heparinases 
I,II and III/ 100 µl GAGs (derived from 8 or 16 T175 culture flasks) in 100 mM NaAc/0.2 mM 
Ca(Ac)
2
 buffer (pH 7.0), overnight at 37°C. Enzymes were inactivated by boiling for three 
min and digestion was confirmed by agarose gel electrophoresis. Separation of disaccharides 
was carried out by ion-pair reversed-phase chromatography with a gradient elution on a 
Shimadzu Prominence system, using a Supelcosil LC-18-T column (150x4.6mm; 3 µm). Sol-
vent A consisted of 5% and solvent B of 50% aqueous acetonitrile both supplemented with 5 
mM tetrabutylammonium phosphate and 10 mM ammonium phosphate monobasic (pH 7.0). 
Reagents (analytical grade) were from Sigma-Aldrich. Elution was carried out using isocratic 
elution with 100% A for 2 min, linear gradient elution for 33 min to 100% B, followed by a 
5 min wash with 100% B and equilibration by 100% A for 10 min. The flow-rate was 1.2 ml/
min, column temperature was 25°C and detection took place at 232 nm. Identity of disac-
charides was determined by comparison to HS or CS/DS disaccharide standards (Iduron) and 
amount of specific disaccharides was calculated by peak surface area analysis.
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Detection of phosphorylated ERK1/2 and O-GlcNAc modified proteins
For analysis of phospho-Erk1/2 levels, HUVECs were cultured for three days with or with-
out 50 µM 4-deoxy-GlcNAc (Ac
3
) in above mentioned medium without heparin, after which 
medium was replaced by medium containing 0.25% newborn calf serum and 0.25% human 
serum with or without 50 µM 4-deoxy-GlcNAc (Ac
3
). After approximately 6h, HUVECs were 
incubated with 10 ng/ml rhFGF-2 (R&D systems) and 10 ng/ml rhVEGF (R&D systems) for 10 
min at 37ºC, and harvested in sample buffer. For analysis of O-GlcNAc modified proteins, 
SKOV3 cells were cultured for three days with or without 50 µM GlcNAc (Ac
4
) or 50/100 µM 
4-deoxy-GlcNAc (Ac
3
) and harvested in sample buffer. Proteins were run on 12% SDS-PAGE, 
blotted onto nitrocellulose and incubated with rabbit-anti-phospho-Erk1/2 (1:2,000), mouse 
mAb against O-GlcNAc (ß-O-linked N-acetylglucosamine; clone CTD110.6, 1:500) or rabbit-an-
ti-GAPDH (1:1,000), followed by IRDye800-conjugated goat anti-mouse IgG or IRDye680-con-
jugated goat anti-rabbit IgG (1:10,000) (LI-COR Biosciences, Lincoln, NE). Blots were scanned 
using a LI-COR Odyssey scanner.
HUVEC proliferation assay
For the proliferation assay, primary HUVEC were seeded in a 0.2% gelatin-coated 96-wells 
plate at a density of 5.0 • 103 cells / well. Cells were incubated overnight at 37°C/5% CO
2
 in 
HUVEC starvation medium, which contains 1% human serum and 1% FBS. Subsequently, the 
culture medium was replaced with starvation medium containing the appropriate concen-
tration of GlcNAc (Ac
4
) or 4-deoxy-GlcNAc (Ac
3
) supplemented with 10 ng/ml FGF-2. Following 
3 days of incubation at 37°C/5% CO
2
, the CellTiter-Glo® Luminescent Cell Viability Assay was 
performed according to the suppliers protocol. Luminescence was recorded on a Tecan In-
finite F200 multimode microplate reader (Tecan Group Ltd.). All assays were run in triplicate 
using 3 independent HUVEC isolations.
WST-1 cell proliferation/viability assay
To assess cell proliferation/viability 3.0 • 103  SKOV3 cells/well were seeded into 96-wells 
plates. After 24 hours, GlcNAc (Ac
4
) or 4-deoxy-GlcNAc (Ac
3
) was added to the medium at a 
final concentration of 100 to 400 µM and cells were cultured for an additional 3 days. WST-1, 
a tetrazolium salt, was added according to the protocol provided by the manufacturer (Roche 
84
Chapter 3
Diagnostics, Mannheim, Germany). The absorbance at 450 nm, corresponding to the number 
of metabolically active cells, was measured 30 minutes after WST-1 addition by a microtiter 
plate reader.
Real-Time QPCR
RNA was isolated from SKOV3 cells using a Qiagen RNeasy Mini kit (Qiagen GmbH, Hilden, 
Germany), as described under gene expression exon array analysis. cDNA synthesis was per-
formed using a Bio-Rad iScript cDNA Synthesis kit using (Bio-Rad Laboratories, Inc., Hercules, 
CA) according to manufacturer’s instructions. 2 ng of total RNA was used to determine mRNA 
expression levels of SKOV3 cells, using Bio-Rad CFX manager software version 1.6 and CFX 
Real Time PCR detection system (Bio-Rad Laboratories, Inc., Hercules, CA). Amplifications 
were performed starting with a 10 min template denaturation step at 95°C, followed by 40 
cycles of denaturation at 95°C for 15 s and combined primer annealing/extension at 60°C for 
60 s. All samples were amplified in triplicate and the mean was obtained for further calcula-
tions. CT values > 35 were excluded from further mathematical calculations. To control for 
variability of RNA input, all PCR reactions were normalized to the amount of GAPDH, HPRT, 
RPII and TBP mRNA. Primer sets for GAPDH, HPRT, RPII and TBP (according to Radonic et al. 
(10)) were ordered from Ocimum Biosolutions Ltd. (Banjara Hills, Hyderabad, India). Primer 
sets for IGFBP, MAP2, ID3, CDK5, HES1, MMP2, VASH1, and ENPP2 (out of the Rtprimer DB 
(11)) were purchased from Biolegio (Nijmegen, The Netherlands). 
Oligonucleotides used for QPCR are as follows: TBP-F: 5’ TTCGGAGAGTTCTGG-
GATTGTA 3’, TBP-R: 5’ TGGACTGTTCTTCACTCTTGGC 3’, RPII-F: 5’ GCACCACGTCCAATGACAT 
3’, RPII-R: 5’ GTGCGGCTGCTTCCATAA 3’, HPRT-F: 5’ CTCAACTTTAACTGGAAAGAATGTC 3’, 
HPRT-R: 5’ TCCTTTTCACCAGCAAGCT 3’, GAPDH-F: 5’ GAAGGTGAAGGTCGGAGTC 3’, GAPDH-R: 
5’ GAAGATGGTGATGGGATTTC 3’, IGFBP3-F: 5’ GCTAGTGAGTCGGAGGAAGA 3’, IGFBP3-R: 
5’ CTGTCTTTAGCATGCCCTTT 3’, MAP2-F: 5’ GGGCCTTTTCTTTGAAATCTAGTTT 3’, MAP2-R: 
5’CAAATGTGGCTCTCTGAAGAACA 3’, ID3-F: 5’ TCAGCTTAGCCAGGTGGAAATC 3’, ID3-R: 5’ 
TGGCTCGGCCAGGACTAC 3’, CDK5-F: 5’ ACCAGGACCTGAAGAAGTAT 3’, CDK5-R: 5’ TAGCTGGAA-
GAGGAATGACT 3’, HES1-F: 5’ ACGTGCGAGGGCGTTAATAC 3’, HES1-R: 5’ ATTGATCTGGGTCATG-
CAGTTG 3’, MMP2-F: 5’ TGATCTTGACCAGAATACCATCGA 3’, MMP2-R: 5’ GGCTTGCGAGGGAA-
GAAGTT 3’, VASH1-F: 5’ TTCAGGCTGTTCTCATCTCA 3’, VASH1-R: 5’ GGAGCTGGGGAGACTTTATT 
3’, ENPP2-F: 5’ TGAAACAGCACCTTCCCAAA 3’, ENPP2-R: 5’ CCAAAGGTTTCCTTGCAACA 3’.
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Gene expression exon array analysis
RNA was isolated from SKOV3 cells of three separate culture flasks per experimental condition 
(control, 50 µM GlcNAc (Ac
4
) or 50 µM 4-deoxy-GlcNAc (Ac
3
)) using the Qiagen RNeasy Mini 
Kit (Qiagen GmbH, Hilden, Germany), including a  DNase digestion step. RNA concentration 
and purity were measured with a Nanodrop spectrophotometer (Thermo Scientific, Waltham, 
MA) and  RNA integrity was confirmed on an Agilent Bioanalyzer (Santa Clara, CA). Further 
processing and gene expression exon array analysis by Affymetrix® GeneChip®  human exon 
1.0 ST arrays was performed as described (12). A list of 173 or 327 overlapping genes >1.2 
fold up - or downregulated, respectively, after 4-deoxy-GlcNAc (Ac
3
) treatment compared to 
control, as well as GlcNAc (Ac
4
), and step up P < 0.2 (corrected for multiple testing according 
to Benjamini-Hochberg), was analyzed using Pathway studio 6 (Ariadne). P values (non step 
up) were all smaller then 0.05, except for one gene, for which the P value was 0.0505.  Step 
up P value cut off was chosen as a Step up P < 0.05 or <0.1 was too stringent to generate a 
sufficient number of genes for analysis (up: 2 and 69, down: 11 and 119, respectively). 
HPAEC-UV analysis of (sugar) nucleotides
SKOV3 cells treated with or without 100 µM 4-deoxy-GlcNAc (Ac
3
) were harvested by trypsini-
zation, pelleted and resuspended in ice-cold PBS. The cell suspension was subsequently lysed 
by sonication and centrifuged at 16,000 g for 5 min. Ethanol was added to the supernatant 
to 80% (v/v), and the sample was subsequently sonicated, incubated at -80°C for an hour and 
centrifuged at 20,8000 g for 10 minutes at 4°C. The supernatant was dried under nitrogen, 
dissolved in 200 µl of water and 20 µl was injected for analysis. Separation of different (sug-
ar) nucleotides was carried out by Dx600 HPAEC-UV using a Dionex Analytical Carbo Pac PA 1 
column (4 x 250 mm), with a Carbo Pac PA 1 guard (4 x 50 mm), by a linear gradient elution 
from 20 minutes (100% A) to 70 minutes (100% B). Solvent A consisted of 70 mM NaOH with 
100 mM NaOAc and solvent B consisted of 40 mM NaOH with 1 M NaOAc. Detection was 
at 262 nm. Identity of eluted peaks was determined by comparison to (sugar) nucleotide 
standards.
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Glycan reductive isotope labeling (GRIL)-LC/MS analysis of heparan sulfate NRE (non 
reducing end)  disaccharides and UDP-hexosamines 
Enzymatically depolymerized GAG preparations of SKOV3 cells treated with or without 100 
µM 4-deoxy-GlcNAc (Ac
3
) were differentially mass labeled by reductive amination with [12C
6
]
aniline as previously described (13). Each sample was mixed with commercially available 
standard unsaturated disaccharides that were tagged with [13C
6
]aniline. Samples were ana-
lyzed by liquid chromatography-mass spectrometry (LC/MS) using an LTQ Orbitrap Discovery 
electrospray ionization mass spectrometer (Thermo Scientific) equipped with an Ultimate 
3000 quaternary high-performance liquid chromatography micro pump (Dionex) and a C-18 
reverse-phase micro-bore column (1mm by 150mm, 5um, Higgins Analytical) as previously 
described (13,14). UDP-sugars present in cell extracts were subjected to tandem mass spec-
trometry to verify their identity. The production of daughter ions with m/z values consistent 
with UDP and UMP were indicative of UDP-sugars.       
Chorioallantoic membrane assay
The chorioallantoic membrane (CAM) assay was performed using fertilized white leghorn 
eggs. Eggs were incubated for 3 days at 38°C in humidified egg incubator (rolling). Next, the 
eggs were placed in an upright position, the top of the egg was carefully punctured using 
tweezers and the eggs were incubated for an additional 3 days at 38°C in a humidified incu-
bator. Subsequently, a window of approximately 1x1 cm was created at the top of the egg 
and a non-silicone ring (intraoral elastic band, Ø 9 mm) was carefully applied on the CAM. 
The window was sealed and the eggs were placed at 37°C in a humidified incubator for at 
least 4 hours. Treatment consisted of daily application of the appropriate concentration of Gl-
cNAc (Ac
4
) or 4-deoxy-GlcNAc (Ac
3
) in a volume of 50 µl within the ring for 4 days. At the end 
of the experiment, images were acquired using an Optech LFZ stereo microscope (Optech) 
after injection of approximately 1 ml contrast agent (zinc oxide in pure vegetable oil) under 
the CAM and the ring. Vessel density was quantified as the total number of cross-sections of 
the blood vessels with 5 concentric circles which were projected onto the picture of the CAM. 
Data were obtained from a total of at least 8 eggs per treatment from three independent 
experiments.
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Zebrafish embryo micro-injections and analyses
Wild type adult Tupfel Long fin (TL) zebrafish were used. Experimental procedures were con-
ducted in accordance with international and institutional guidelines. Zebrafish eggs were 
obtained from natural spawning of wild-type breeding fish. Larvae were maintained and 
raised by standard methods, according to Nüsslein-Volhard (15). GlcNAc and 4-deoxy-GlcNAc 
(peracetylated and non-peracetylated) were diluted to a final concentration of 450, 250 and 
125 mM in PBS containing 0.5% phenol red, and 1 nl of was injected into the yolk of one- to 
two-cell-stage embryos using a Pneumatic Picopump pv280. A minimum sample size of 50 
was used in each case. After injection, embryos were cultured at 28 ˚C in E3 embryo medium 
(5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl
2
, 0.33 mM MgSO
4
, supplemented with 0.1% meth-
ylene blue) and subsequently phenotyped at 2 dpf (days post fertilization). Injected embryos 
were classified into two classes of phenotypes on the basis of the relative severity as com-
pared to control-sugar injected, age-matched embryos of the same clutch. Images were taken 
using an Axio Cam Icc-3 camera. At 2 dpf embryos (at least 10 embryos were taken for one 
analysis) were dechorionated using 200 µg pronase (Sigma-Aldrich) / ml embryo medium for 
about 10 min, after which they were washed in ice-cold PBS and deyolked by passing through 
a 200 µl pipette tip. Embryos were dissociated by pipetting up and down in 5 mM EDTA for 
10 min at room temperature, after which PBS containing 5% FCS and 1 mM CaCl
2
 was added. 
The cell suspension was passed through a 70 µm cell strainer, pelleted and resuspended 
in PBS for further analysis as described under flow cytometry. For immunohistochemistry, 
embryos were placed in Tissue Tek, snap frozen in precooled isopropyl alcohol, and sections 
were made and stained as described previously (1). 
Zebrafish embryo bathing in 4-deoxy-GlcNAc (Ac
3
) and analyses
Zebrafish strain Fli-1:eGFP/GATA-1:DsRed (in house bred) was used for all experiments. After 
fertilisation, fish embryos were collected and incubated in embryo water (60 µg/ml Instant 
Ocean sea salts (Aquarium Systems) supplemented with 0.05% methylene blue) at 28 °C for 
approximately 7h. The embryos were then transferred to room temperature (22.5 °C) and in-
cubated overnight. The lower incubation temperature slows down the embryo development 
so that the embryos can reach the correct stage for compound addition the following day. 
The embryos were dechorionated by incubating the embryos in 200 µg/ml pronase for ap-
proximately 6 min at 28 °C, followed by gentle titration to separate chorion from the embry-
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os. Enzyme activity was terminated by transferring the embryos to fresh embryo water. The 
number of somites on the fish were constantly counted under the stereomicroscope (Leica 
MZ95, Leica Microsystems Ltd). When the fish reached the 19-somite stage, 4-deoxy-GlcNAc 
(Ac
3
) was, or was not (control), added to the embryo water at a final concentration of 10 mM. 
For whole vasculature imaging, the fish embryos were visualized at 48 hpf, un-
der a fluorescence microscope (Leica MZ95, Leica Microsystems Ltd) for vasculature defects. 
The blood vessels were showing as green fluorescent images and were captured under GFP 
illumination. The images were capture using Leica Application Suit 2.8.1 software (Leica Mi-
crosystems, Ltd).
For alkaline phosphatase staining, the fish embryos were fixed at 72 hpf and the 
blood vessels within the subintestinal basket were visualized by staining with nitrotetrazoli-
um blue chloride. The embryos were fixed by incubation in 4% (w/v) paraformaldehyde in 
PBS for 1 h at room temperature or overnight at 4 °C. For staining, the embryos were washed 
with PBS and incubated in acetone at -20 °C for 20 min followed by two PBS washes (10 min 
each). The embryos were dehydrated and rehydrated in increasing proportion of ethanol 
(50%, 66%, 75% and 100%) and Tris-Tween (50%, 66%, 75% and 100%), respectively, for 10 
min for each step. The embryos were then incubated in 1 ml NTMT buffer (100 mM TrisHCl 
pH 9.5; 50 mM MgCl
2
; 100 mM NaCl; 0.1% (v/v) Tween-20) for 10 min; this step was repeated 
3 times. To the final solution, 0.34 mg/ml nitrotetrazolium blue chloride (Sigma-Aldrich) and 
0.175 mg/ml X-phosphate (Sigma-Aldrich) were added. The mixture was wrapped in tin foil 
and incubated for 10 min to allow staining which was followed by 10 min in PBST. Finally, 
bleaching solution (PBS containing 5% (v/v) formamide and 10% (v/v) H
2
O
2
) was added to 
the embryos for 15 min to remove background staining as well as the fish pigments. Em-
bryos were washed and stored in PBS until further analysis. Images of subintestinal baskets 
on both sides of the fish were captured under a stereomicroscope (Leica DFC240C, Leica 
Microsystems, Ltd) via the Leica Application Suit 2.8.1 software (Leica Microsystems, Ltd). 
AxioVision 4.8.1 (Carl Zeiss Imaging Solutions GmbH) was then used to measure the whole 
embryo, subintestinal veins (SIVs), branch and extension lengths. The area of the basket was 
defined as the area enclosed by the white and gray dotted lines as shown in Fig. 5g (left pan-
el); basket length was the length of the white dotted line. Total vasculature was the sum of 
SIV, branch, extension and basket lengths.
89
A GlcNAc analog interferes with UDP-GlcNAc metabolism, 
inhibits heparan sulfate expression, and influences angiogenesis in vivo
Statistics
Data are presented as mean with standard deviation, unless indicated otherwise. IC
50
 curves 
were plotted by GraphPad Prism (GraphPad, San Diego, CA, USA). Data of disaccharide analy-
sis, hyaluronan analysis, lectin flow cytometry, HUVEC and SKOV3 proliferation, and zebraf-
ish flow cytometry was analyzed using a two-tailed Student’s t-test, with P < 0.05 consid-
ered as significant. CAM assay and zebrafish subintestinal basket data was analyzed using 
the Mann-Whitney U test.
Supplementary Results
Effect of 4-deoxy-GlcNAc (Ac
3
) on cellular proliferation
To determine the effect on cellular proliferation, SKOV3 cells were cultured for three days 
with or without 50 to 400 µM GlcNAc (Ac
4
) or 4-deoxy-GlcNAc (Ac
3
), and analyzed for meta-
bolic activity (as a measure for cell numbers) by the WST-1 assay (Fig. S1). For up to 200 µM 
4-deoxy-GlcNAc (Ac
3
) cell numbers were comparable to the control; at 400 µM a small reduc-
tion (approximately 10%) was noted. For GlcNAc (Ac
4
) a significant increase in cell numbers 
compared to control was noted up to 200 µM, whereas a significant reduction was seen at 
400 µM. This latter effect was previously reported by Bernacki et al.(16), and is also seen with 
perbutanoylated GlcNAc (17), although the mechanism is unclear. 
Effect of 4-deoxy-GlcNAc (Ac
3
) on GAG disaccharide composition
To assess the effect of 50 µM 4-deoxy-GlcNAc (Ac
3
) on the structural composition of HS and CS/
DS, disaccharide analysis was performed. Disaccharide composition of HS was not changed 
to a major extent, although we did find a significant increase of UA2S-GlcNAc, UA-GlcNS6S 
and UA2S-GlcNS6S (Fig. S3a). A tendency for an increase in 6O-sulfation was observed (Fig. 
S3b; not significant, p = 0.11) and this trend was confirmed in independent experiments 
using LC/MS (Fig. S3c). For CS/DS, no major differences in disaccharide composition were 
noticed (Fig. S3d).
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Table S1. Fold changes of gene expression of targets  of VEGFA, FGF-2 and CTGF (also see Table 1), 
as observed by gene expression exon array analysis. SKOV3 cells were treated for three days with or 
without 50 µM GlcNAc (Ac
4
) or 4-deoxy-GlcNAc (Ac
3
) and gene expression was analyzed by human exon 
arrays. X denotes if a gene is regulated by VEGFA, FGF-2, CTGF or combinations of these growth factors. 
Indicated p-values and step up p-values are as in exon array data.
Gene Expression target of Control (medium only) vs. 
4-deoxy-GlcNAc (Ac
3
)
GlcNAc (Ac
4
) vs. 
4-deoxy-GlcNAc (Ac
3
)
VEGFA FGF2 CTGF Fold 
change
p-value Step up 
p-value
Fold 
change
p-value Step up 
p-value
ENPP2 X X -1.92 2.23x10-6 0.00549 -4.65 7.04x10-7 0.00515
SERPINE1 X X X -1.43 0.00319 0.06944 -1.65 0.00055 0.08111
GUCY1A3 X -1.44 0.00016 0.02631 -1.21 0.00479 0.16302
IGFBP3 X X -1.53 0.00012 0.02584 -1.33 0.00101 0.08895
MMP2 X X X -1.33 0.00352 0.07079 -1.37 0.00205 0.12047
CTGF X X X -1.28 0.00384 0.07288 -1.32 0.00192 0.11678
MARCKS X -1.26 7.88x10-6 0.01180 -1.21 2.33x10-5 0.03357
SLC2A1 X X -1.27 0.00227 0.06231 -1.22 0.00546 0.17216
TFPI2 X X -1.26 0.00510 0.07988 -1.38 0.00096 0.08754
NR4A2 X -1.26 0.00240 0.06414 -1.21 0.00565 0.17464
VASH1 X X -1.27 0.00138 0.05335 -1.26 0.00143 0.10161
STC1 X X -1.50 0.00143 0.05335 -1.45 0.00212 0.12194
COL1A1 X X* X -1.89 8.48x10-6 0.01180 -1.47 0.00015 0.05601
MAP2 X -1.43 0.00127 0.05240 -1.53 0.00048 0.08098
ID3 X -1.39 0.01608 0.12462 -1.75 0.00143 0.10161
SERPINE2 X* -1.21 0.01665 0.12634 -1.26 0.00763 0.19474
ACTA2 X* -1.55 6.07x10-5 0.01935 -1.53 6.77x10-5 0.05592
SPARC X* -1.74 1.54x10-5 0.01371 -1.44 0.00016 0.05601
JAG1 X -1.42 0.00028 0.03105 -1.47 0.00016 0.05601
COL1A2 X* X -1.80 8.98x10-5 0.02383 -1.34 0.00380 0.14840
CDK5 X -1.48 0.00544 0.08196 -1.53 0.00358 0.14475
PPP1R1B X -1.28 0.01246 0.11410 -1.34 0.00604 0.18026
SDC-1 X -1.26 0.00929 0.10225 -1.27 0.00776 0.19593
SMAD-7 X* -1.45 0.00352 0.07079 -1.39 0.00660 0.18447
HES-1 X -2.57 9.42x10-5 0.02415 -2.05 0.00043 0.07928
*indicates that the effect of the growth factor on gene expression is inhibitory
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Table S2. Upregulated genes, clustered according to pathway or ontology, after treatment with 4-de-
oxy-GlcNAc (Ac3). SKOV3 cells were treated for three days with or without 50 µM GlcNAc (Ac4) or 4-de-
oxy-GlcNAc (Ac
3
) and gene expression was analyzed by gene expression human exon arrays. A list of 
173 overlapping genes that were >1.2 fold upregulated (step up P < 0.2) after treatment with 50 µM 
4-deoxy-GlcNAc (Ac
3
) compared to both untreated and 50 µM GlcNAc (Ac
4
) treated cells, was analyzed 
in Ariadne Pathway studio 6 for over-representation of a certain cluster, according to ontology, or met-
abolic or signaling pathways.
Name Total # 
of genes 
involved
Overlap  
(number of 
upregulated 
genes)
Upregulated genes after 
4-deoxy-GlcNAc (Ac
3
) 
treatment
p-value Data 
Source
Cholesterol/ 
isoprenoid  
metabolism
28 9 (32%) FDFT1,LSS,SC4MOL,MVK, 
DHCR7,SQLE,HMGCS1, 
MVD,IDI1
3.71x10-12 Ontology
Adipocytokine 
signaling
780 26 (3%) IL6,SCD,FASN,FDFT1, 
ACACB,ACAT2,LIPG,LSS, 
SREBF2,CUBN,ACACA, 
PCK2,PLCB1,SC4MOL, 
HSD17B12,OGT,MVK, 
DHCR7,PNPLA3,ACSS2, 
SQLE,SLC27A2,HMGCS1, 
MVD,IDI1,EP400
6.44x10-7 Signaling 
Pathways
Biosynthesis of 
cholesterol
97 9 (9%) FDFT1,LSS,SC4MOL,MVK, 
DHCR7,SQLE,HMGCS1, 
MVD,IDI1
8.84x10-7 Metabolic 
Pathways
Trithorax 5 3 (60%) MLL,MLL2,MLL3 9.24x10-6 Ontology
Fatty acid  
biosynthesis
15 4 (26%) SCD,FASN,ACACB,ACACA 1.13x10-5 Ontology
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Scheme S1. Synthesis of peracetylated 4-deoxy-GlcNAc (compound 2) and its peracetylated parent 
sugar GlcNAc (compound 4). Note that peracetylated 4-deoxy-GlcNAc lacks the C4-OAc group, as com-
pared to peracetylated GlcNAc (indicated by the arrow). (a) Peracetylated 4-deoxy-GlcNAc (compound 
2) was prepared in a single step from 4-deoxy-GlcNAc, which was synthesized previously(1). (b) Per-
acetylated GlcNAc (compound 4) was prepared by a single step from GlcNAc (compound 3). Both α and 
ß stereoisomers were formed and subsequently separated by flash column chromatography. As the 
solubility of the ß stereoisomer in water was very low, the α stereoisomer was used. For experimental 
details, see methods.
Figure S1. Effect of 4-deoxy-GlcNAc (Ac) on cell viability. SKOV3 cells were cultured for three days with 
or without GlcNAc (Ac
4
) or 4-deoxy-GlcNAc (Ac
3
) at indicated concentrations, after which the number 
of cells was determined by the WST-1 assay. Data is presented as mean with SD (n=6). * P < 0.05 com-
pared to control, using Student’s t-test. One representative experiment of two separate experiments 
is shown.
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Figure S2. 4-deoxy-GlcNAc (Ac
3
) inhibits expression of HS and CS in multiple cell lines and primary 
endothelial cells (HUVEC). (a-b) 4-deoxy-GlcNAc (Ac
3
) reduces HS and CS expression of IGROV1 ovarian 
carcinoma cells and HeLa cervical cancer cells dose-dependently, as determined by flow cytometry 
using anti-HS antibody AO4B08 (a) or HS4C3 (b) and anti-CS antibody IO3H10. The number of counted 
cells is indicated by the number of events. For clarity, the y-axis was cut off at 200 events in (b). (c-d) 
50 µM 4-deoxy-GlcNAc (Ac
3
) strongly reduces HS expression in RF24 endothelial cells and CHO-K1 cells, 
and reduces CS expression in RF24 cells to a lesser extent, as determined by flow cytometry using an-
ti-HS antibody HS4C3 and anti-CS antibody IO3H10. (e-f) 250/50 µM 4-deoxy-GlcNAc (Ac
3
), respectively, 
strongly reduces HS expression in MV3 melanoma cells and primary human umbilical vein endothelial 
cells (HUVECs), as determined by immunocytochemistry using anti-HS antibody AO4B08. Scale bar = 
(e) 100 µm, (f) 50 µm. In case of MV3 and CHO-K1 cells, no cell surface CS was detected in untreated 
controls.
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Figure S3. Disaccharide composition of HS and CS after 4-deoxy-GlcNAc (Ac
3
) treatment. (a-c) HS 
disaccharide composition of SKOV3 cells, as generated by digestion with heparinase I, II and III and 
HPLC analysis, reveals three significantly changed disaccharide structures after treatment with 4-de-
oxy-GlcNAc (Ac
3
) (a) and a trend towards increased 6O-sulfation (b, c). Data presented in b is calculated 
from the analysis shown in a, and is presented as mean+sd from three separate experiments. * P < 
0.05 compared to control or GlcNAc (Ac
4
), using Student’s t-test. Data presented in c is an independent 
duplicate experiment using LC/MS analysis. (d) CS/DS disaccharides composition of SKOV3 cells, as 
determined by digestion with chondroitinase ABC and HPLC analysis, was not significantly changed by 
treatment with 4-deoxy-GlcNAc (Ac
3
). UA2S-GalNAc4S and UA2S-GalNAc6S are eluted as one peak and is 
therefore calculated together. Data is presented as mean+sd from three separate experiments.
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Figure S4. Tandem mass spectrometry with constellation of daughter ions of sugar nucleotides. 
UDP-HexNAc from control cells (a), UDP-4-deoxy-GlcNAc standard (b), and UDP-4-deoxy-GlcNAc recov-
ered from 4-deoxy-GlcNAc (Ac
3
) treated cells (c) were analyzed. Assignments are indicated by the mo-
lecular diagram to the right. Ions marked with a black dot above represent non-reducing end fragment 
ions that include carbon-4 which differs by 16 amu depending on whether the parent molecule is 
HexNAc or 4-deoxy-GlcNAc. 
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Figure S5. Effect of 4-deoxy-GlcNAc (Ac
3
) on glycans other than heparan/chondroitin sulfate. (a) 4-de-
oxy-GlcNAc (Ac
3
) reduces O-GlcNAc protein modification, as shown by western blot of SKOV3 cell lysates 
using an antibody against O-GlcNAc protein modification. GAPDH was used as control. (b) 4-deoxy-Glc-
NAc (Ac
3
) reduces the amount of hyaluronan present in the media of SKOV3 cells, whereas treatment 
with GlcNAc (Ac
4
) increased these levels. Data is presented as mean±sd (% of control) from six separate 
experiments. *P < 0.05 compared to control, using Student’s t-test. NS: not significant (c) 4-deoxy-Glc-
NAc (Ac
3
) reduces lectin staining of SKOV3 cells of 5 out of 12 lectins, as determined by flow cytometry. 
Data is presented as mean±sd (% of control) from at least three separate experiments. *P < 0.05 
compared to control, using Student’s t-test. aBinding specificities are from (18). Where possible, it is 
indicated whether these structures are found on N- and/or O-linked glycans.
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Figure S6. 4-deoxy-GlcNAc (Ac
3
) differentially regulates gene expression. (a) Venn diagram of the 
number of differentially regulated genes by 4-deoxy-GlcNAc (Ac
3
) compared to untreated or parent 
sugar treated controls. Treatment with 50 µM 4-deoxy-GlcNAc (Ac
3
) results in the downregulation of an 
overlapping set of 327, and upregulation of 173, genes in SKOV3 cells when compared to untreated and 
50 µM GlcNAc (Ac
4
) treated cells, as determined by gene expression exon array analysis. These gene sets 
were analyzed in Pathway studio software for expression regulators or clustering according to ontolo-
gy/pathways. (b) Downregulation of genes associated with FGF2, VEGF and CTGF signaling. Treatment 
of SKOV3 cells with 50 µM 4-deoxy-GlcNAc (Ac
3
) inhibits expression of 327 genes when compared to 
untreated and 50 µM GlcNAc (Ac
4
) treated cells, as determined by gene expression exon array analysis. 
Analysis for expression regulators in Pathway studio software revealed that several of these genes are 
regulated by HS binding growth factors FGF-2, VEGF and CTGF. *indicates that the effect of the growth 
factor on the gene expression is inhibitory. (c) Downregulation of expression targets of the growth fac-
tors FGF-2, VEGFA and CTGF analyzed by real-time QPCR. Analysis was performed on 8 selected targets 
using cDNA also used in gene expression exon array analysis. Data is presented as mean with SEM 
(n=3). * P < 0.05 compared to control, using Student’s t-test.
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Figure S7. Proposed mechanistic route for inhibition of angiogenesis by 4-deoxy-GlcNAc. In the ab-
sence of 4-deoxy-GlcNAc (left panel) UDP-GlcNAc is de novo synthesized from Fruc-6P (1). UDP-GlcNAc 
subsequently enters the ER/Golgi compartment (2), where it is incorporated into growing HS chains (3). 
The HS-proteoglycan (HSPG) translocates to the cell membrane (4), where it can form active ternary sig-
naling complexes with (pro-angiogenic) growth factors, such as FGF-2 and VEGF, and their receptors (5). 
FGF-2 and VEGF signaling cascade results in phosphorylation of ERK (6), which locates to the nucleus 
(7) to ultimately induce gene expression (8) resulting in angiogenesis (9). In the presence of 4-deoxy-Gl-
cNAc (right panel) angiogenesis is inhibited. 4-deoxy-GlcNAc (Ac
3
) first passes the cell membrane and is 
de-O-acetylated by cytosolic esterases (1). Free 4-deoxy-GlcNAc is transformed into UDP-4-deoxy-GlcNAc 
by enzymes of the GlcNAc salvage pathway (2), resulting in decreased levels of UDP-GlcNAc (3). A re-
duced amount of UDP-GlcNAc enters the ER/Golgi (4) and as a consequence HS chains are considerably 
truncated (5). After translocation to the cell surface (6), the shortened HS chains are unable to form 
active signaling complexes (7), signaling cascades are inhibited (8), ERK is not phosphorylated and will 
not enter the nucleus (9) and gene expression associated with angiogenesis is inhibited (10). 
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Abstract
Chondroitin/dermatan sulfate (CS/DS) and heparan sulfate (HS) are glycosaminoglycans 
(GAGs), which are long, linear polysaccharide chains that play a role in cellular processes 
such as proliferation and migration, and have been implicated in a number of pathologies 
including cancer. A number of sugar analogs directly involved in the glycosidic linkages of 
GAGs (e.g. 4-deoxy and 4F analogs) have been probed for their effect on GAG biosynthesis. 
In this study we applied a differently modified analog, aimed to interfere with a GAG modi-
fying process, 6O-sulfation, and not with chain elongation. For this, a peracetylated 6-fluoro 
analog of the CS/DS constituent GalNAc, 6F-GalNAc, was applied in vitro and in vivo. The 
analog was transformed in cells into its UDP-activated form, but although abundantly pres-
ent, it was not incorporated into GAGs. Rather, a strong reduction of cellular UDP-GalNAc 
and UDP-GlcNAc pools  was found, and a reduced expression of CS/DS and HS expression 
was observed in addition to reduced staining of other glycans by 3 out of 11 lectins, and 
reduced O-GlcNAc substitution of proteins. Signaling by the HS dependent growth factors 
VEGF and FGF-2 was inhibited, as was angiogenesis in vivo in a chicken chorioallantoic mem-
brane assay. Together, these data indicate that an analog not directly involved in glycosidic 
bonds inhibits biosynthesis of  GAGs without incorporation, the depletion of UDP-GalNAc 
and UDP-GlcNAc being a prime event. This may indicate a common mechanism for inhibition 
of glycan biosynthesis by sugar analogs.
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Introduction
Glycosaminoglycans (GAGs) as chondroitin/dermatan sulfate (CS/DS) and heparan sulfate 
(HS) are long, linear, strongly negatively charged polysaccharide chains, bound to a protein 
core. They are present at the cell surface of virtually every mammalian cell and in the ex-
tracellular matrix. GAGs are important in a wide variety of physiological processes, mainly 
by interacting with numerous effector molecules, e.g. growth factors and their receptors 
(1). GAGs are composed of repeating disaccharides of d-glucuronic acid (GlcA) and either 
N-acetyl-d-galactosamine (GalNAc) for CS/DS or N-acetyl-d-glucosamine (GlcNAc) for HS. This 
‘precursor’ structure is variably modified by epimerization of GlcA to l-iduronic acid (IdoA) 
and various sulfation reactions (2). Quantity and fine-structure of GAGs are often changed 
under pathological conditions, including amyloidosis, inflammatory diseases and cancer (3). 
This provides a need for compounds that can interfere with GAG function, synthesis or spe-
cific sulfation. In cancer, 6O-sulfation targeting is of therapeutic importance. For example, 
in gastrointestinal carcinoma, an increase up to 50 fold in 6O-sulfated CS disaccharides was 
shown (4). Furthermore, specific 6O-sulfated and 4O-, 6O-disulfated CS structures are elevat-
ed in ovarian cancer (5,6). 6O-sulfation of HS has been shown to be of particular importance 
for signaling of the HS dependent pro-angiogenic factors vascular endothelial growth factor 
(VEGF) and fibroblast growth factor 2 (FGF-2) (7). Expression of HSulf-1, a modifying enzyme 
which removes specific HS 6O-sulfation extracellularly and is downregulated in several tu-
mor types (8), and silencing of HS 6O-sulfotransferase-2 (HS6ST2), a biosynthetic enzyme 
adding 6O-sulfation, inhibited angiogenesis and tumorigenesis in mice (9,10). In this study, 
we used peracetylated 6-fluoro GalNAc, 6F-GalNAc (Ac
3
), hypothesizing that cellular acti-
vation into UDP-6F-GalNAc and subsequent incorporation of this analog specifically blocks 
6O-sulfation of CS/DS (Fig. 1a). In addition, epimerization into UDP-6F-GlcNAc by cellular 
enzymes potentially blocks HS 6O-sulfation. 
Materials and methods
Monosaccharides
Peracetylated 6F-GalNAc (2-acetamido-1,3,4-tri-O-acetyl-2,6-dideoxy-6-fluoro-d-galac-
topyranose) was from Sussex Research (Ottawa, Canada). Structure was confirmed by 1H and 
19F NMR, and mass spectrometry. Purity was > 95%, as determined by HPLC. Peracetylat-
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ed GalNAc (2-acetamido-1,3,4,6-tetra-O-acetyl-2- d-galactopyranose) was from Carbosynth 
(Berkshire, UK). Purity was 98.1%, and structure was confirmed by NMR. A stock solution of 
peracetylated 6F-GalNAc and GalNAc of 100 and 25 mM in milli-Q respectively was prepared..
Cell culture
SKOV3 ovarian carcinoma cells, human umbilical vein endothelial cells (HUVECs), RF24 en-
dothelial cells and HeLa cervical cancer cells were cultured as described (11). Cells were seed-
ed one day before the addition of GalNAc (Ac
4
) or 6F-GalNAc (Ac
3
). After three days of cultur-
ing in the presence of either of these sugars, cells were used for further analyses. 
GAG isolation and agarose gel electrophoresis
GAG isolation and agarose gel electrophoresis was performed as described (12). In short, 
GAGs were isolated by papain digestion, TCA precipitation, DEAE ion exchange and metha-
nol precipitation. GAGs were separated using 1% agarose in Ba(Ac)
2
 buffer and stained by a 
combined azure A-silver staining.
Figure 1. Hypothesized and proposed working mechanism of 6F-GalNAc (Ac
3
). (a) Hypothesized 
mechanism: 6F-GalNAc (Ac
3
) enters the cell by passive diffusion, is de-acetylated by aspecific cytosolic 
esterases,  is activated into UDP-6F-GalNAc by the salvage pathway, and inhibits 6O-sulfation after 
incorporation into GAGs. (b) Proposed mechanism: 6F-GalNAc (Ac
3
) is transformed into UDP-6F-GalNAc 
as in (a), is not incorporated into GAGs, but reduces natural UDP-GalNAc and UDP-GlcNAc pools by hi-
jacking the machinery needed for activation of these natural hexosamines. As a result, the biosynthesis 
of GAGs and other glycans is reduced.
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Flow cytometry
Flow cytometry was performed as described (11). Single chain variable fragment (ScFv) anti-
body GD3A12 was used to analyze DS (13). To determine FGF-2 binding capacity, SKOV3 cells 
were incubated with 1µg/ml rhFGF-2 (R&D systems, Minneapolis, MN) and this was detected 
as described (11).
Proliferation assays 
SKOV3 and HUVEC proliferation was assessed as reported earlier (11). Briefly, SKOV3 cells 
were incubated for three days with various concentrations of GalNAc (Ac
4
) or 6F-GalNAc (Ac
3
) 
and the amount of metabolic active cells was assessed by the WST-1 assay. Primary HUVECs 
were incubated for three days with medium containing 1% human serum and 1% FBS, Gal-
NAc (Ac
4
) or 6F-GalNAc (Ac
3
) in various concentrations, and 10 ng/ml FGF-2, and assayed by 
the CellTiter-Glo® Luminescent Cell Viability Assay.
Disaccharide analysis
Disaccharide analysis was performed as described (11). In short, CS/DS or HS disaccharides 
were obtained  by digestion with chondroitinase ABC or by a combination of heparinase I, II 
and III, respectively, and separation was performed by ion-pair reversed-phase chromatogra-
phy with a gradient elution using a Supelcosil LC-18-T column. Identity of disaccharides was 
determined by disaccharide standards and amount of specific disaccharides was calculated 
by peak surface area analysis.
Glycan reductive isotope labeling (GRIL)-LC/MS analysis of GAG disaccharides and UDP-
hexosamines
Analysis of CS/DS and HS disaccharides, and UDP-hexosamines was assessed as reported 
(11,14). Samples were analyzed by liquid chromatography-mass spectrometry (LC/MS) using 
an LTQ Orbitrap Discovery electrospray ionization mass spectrometer (Thermo Scientific) 
equipped with an Ultimate 3000 quaternary high-performance liquid chromatography micro 
pump (Dionex) and a C-18 reverse-phase micro-bore column (1mm by 150mm, 5um, Higgins 
Analytical).
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nanoLC-Chip-QTOF monosaccharide analysis
Isolated GAGs from SKOV3 cells, cultured with or without 50 µM 6F-GalNAc (Ac
3
), were dis-
solved in 100 µl Milli-Q. To isolate a comparable amount of GAGs, GAGs from untreated cells 
and treated cells were derived from 3 and 6 confluent culture flasks (175 cm2), respectively. 
GAGs were hydrolyzed by addition of 400 µl 6M HCl and incubation at 105°C for 6 h under 
nitrogen gas in sealed glass tubes. 10 µl of a 100 mM 6F-GalNAc (Ac
3
) solution in water 
was hydrolyzed as a control. HCl and water were removed by drying the samples in a vac-
uum-desiccator in the presence of NaOH pellets. Samples were dissolved in 1 ml Milli-Q, 
lyophilized and dissolved in 50 µl milli-Q. To improve ionization, 10 µl of a 50% MeOH, 0.1% 
formic acid solution (v/v/v) in MilliQ, was added to 20 µl of each sample before analysis. Anal-
ysis was performed in positive mode using a microfluidic 6540 HPLC-chip-QTOF instrument 
(Agilent Technologies) by direct infusion via a syringe pump and a direct infusion chip with a 
nanoelectrospray tip. Drying gas was set at a flow rate of 3.0 L/min and a temperature of 300 
C˚, capillary voltage was set at 1900 V and fragmentor voltage at 175 V.  Data analysis was 
performed using Agilent Mass Hunter Qualitative Analysis Software B.04.00. 
HPAEC-UV analysis of (sugar) nucleotides
Analysis of sugar nucleotides was performed as described (11). Briefly, cells were pelleted, 
lysed by sonication, and ethanol was added to the supernatant to 80% (v/v). After centrif-
ugation, the supernatant was dried under nitrogen and dissolved in water. Separation of 
different (sugar) nucleotides was carried out by Dx600 HPAEC-UV using a Dionex Analytical 
Carbo Pac PA 1 column.
Detection of phosphorylated ERK1/2 and O-GlcNAc modified proteins
Detection of phosphorylated ERK1/2 and O-GlcNAc modified proteins was performed as de-
scribed (11). Briefly, HUVECs, treated with or without 50 µM GalNAc (Ac
4
) or 6F-GalNAc (Ac
3
) 
for three days, were incubated with medium containing 0.25% newborn calf serum and 
0.25% human serum for 6 h, after which 10 ng/ml rhFGF-2 (R&D systems) or 10 ng/ml rhVEGF 
(R&D systems) was added and HUVECs were harvested 10 min later. For analysis of O-GlcNAc 
modified proteins, SKOV3 cells were cultured for three days with or without 50 µM GalNAc 
(Ac
4
) or 6F-GalNAc (Ac
3
) and harvested in sample buffer.
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Chorioallantoic membrane assay
The chicken chorioallantoic membrane (CAM) assay was performed as described (11). Brief-
ly, treatment consisted of daily application of GalNAc (Ac
4
) or 6F-GalNAc (Ac
3
) at indicated 
concentrations in a volume of 50 µl within a non-silicone ring (intraoral elastic band, Ø 9 
mm) applied on the CAM for 4 days. Vessel density was quantified as the total number of 
cross-sections of the blood vessels with 5 concentric circles which were projected onto a 
picture of the CAM. 
Statistics
Data are presented as mean with standard deviation, unless indicated otherwise. Data of 
disaccharide analysis, lectin flow cytometry, HUVEC and SKOV3 proliferation was analyzed 
using a two-tailed Student’s t-test, with P < 0.05 considered as significant. CAM assay data 
was analyzed using the Mann-Whitney U test.
Results and discussion
We first determined whether 6F-GalNAc (Ac
3
) entered cells and was activated into UDP-6F-
GalNAc. Therefore, human ovarian carcinoma cells (SKOV3) were cultured for three days with 
or without 50 µM 6F-GalNAc (Ac
3
) and sugar nucleotides were analyzed. There was no effect 
on cellular proliferation at this concentration (Supplementary results and Supplementary 
Fig. 1). HPAEC-UV analysis of sugar nucleotides indicated that an additional sugar nucleotide 
was abundantly present in 6F-GalNAc (Ac
3
) treated cells, but not in untreated cells (Fig. 2a). 
This peak likely corresponds to an UDP-activated product of 6F-GalNAc, UDP-6F-GalNAc and/
or UDP-6F-GlcNAc (UDP-6F-HexNAc). Mass spectrometry showed that UDP-6F-HexNAc, with 
a mass increased by 2 amu compared to natural UDP-HexNAc (UDP-GlcNAc and UDP-GalNAc) 
(Fig. 2b, upper panel), was abundantly present in treated cells, but not in untreated cells (Fig. 
2b, middle panel). Collision induced dissociation confirmed sugar nucleotide identity, as m/z 
values corresponding to UDP and monosaccharide fragments were found (Supplementary Fig. 
2). The presence of the fluorine was further established as all monosaccharide fragments, but 
not UDP fragments, of UDP-6F-HexNAc were increased by 2 amu compared to UDP-HexNAc. 
These data indicated that 6F-GalNAc (Ac
3
) entered the cells, was de-acetylated (by aspecific 
esterases (15)), and was transformed into UDP-6F-GalNAc by enzymes of the salvage pathway 
108
Chapter 4
(GalNAc kinase and UDP-GalNAc pyrophosphorylase). The phosphorylation of 6F-GalNAc may 
be somewhat surprising given the notion that human recombinant GalNAc kinase, involved 
in phosphorylation of GalNAc, does not readily tolerate modifications at C6 (16). We also 
noted a decreased ATP level (Fig. 2a), possibly due to extensive UDP activation of the sugar 
analog. Parallel to sugar analog activation, we noticed a strong reduction in the amount of 
UDP-GlcNAc and UDP-GalNAc in treated cells, both by HPAEC-UV and LC/MS (Fig. 2a and Fig 
2b, bottom panel). To determine whether 6F-GalNAc was incorporated into GAG chains, GAGs 
were isolated,  hydrolyzed to monosaccharides and analyzed by mass spectrometry. Natu-
Figure 2. 6F-GalNAc (Ac
3
) is UDP-activated and reduces cellular UDP-GlcNAc and UDP-GalNAc levels. 
(a) HPAEC-UV analysis of sugar nucleotides. A large additional (sugar) nucleotide, likely representing 
UDP-6F-HexNAc (see b), is present in 50 µM 6F-GalNAc (Ac
3
) treated SKOV3 cells, as indicated by the 
*-sign. Incubation with 6F-GalNAc (Ac
3
)
 
reduces UDP-GlcNAc and UDP-GalNAc, and ATP. The amount of 
6F-GalNAc (Ac
3
) treated cells used for sugar nucleotides extraction was 86% of the control. (b) LC/MS 
analysis of sugar nucleotides. The mass of UDP-6F-HexNAc is 2 amu more compared to UDP-HexNAc 
(upper panel). Extracted ion current shows that UDP-6F-HexNAc is abundantly present after 50 µM 
6F-GalNAc (Ac
3
) treatment (middle panel), whereas UDP-HexNAc (lower panel) is strongly reduced. The 
experiments shown in (a) and (b) were conducted together with untreated cells of which the data was 
also shown before(11).
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ral hexosamines (GlcN and GalN) were readily found in both untreated and 6F-GalNAc (Ac
3
) 
treated samples (Supplementary Fig. 3a). Presence of 6F-hexosamine (amu + 2 compared to 
natural hexosamine) was not observed in cellular samples (Supplementary Fig. 3a), but was 
detected by hydrolyzing 6F-GalNAc (Ac
3
) itself (Supplementary Fig. 3b). 6F-GalNAc was also 
not found in GAG disaccharides, as determined by LC/MS analysis (Supplementary Table 1). 
These data indicate that although UDP-6F-HexNAc is abundantly present, incorporation of 
6F-HexNAc into GAG chains is not a major event. Rather, it indicates that the UDP activation 
of 6F-GalNAc largely decreases the amount of the natural UDP-GalNAc and UDP-GlcNAc. This 
is in line with data for peracetylated 4F-GlcNAc (17,18), 4-deoxy-GlcNAc (11), 5T-Fuc (19), 
2F-Fuc (20) and 3F
ax
-NeuAc (20), indicating a general mechanism. Similar to the present study, 
abundant transformation of the analog into its nucleotide sugar was observed, natural nu-
cleotide sugar pools were reduced, and the analog was not incorporated. 
Figure 3. 6F-GalNAc (Ac
3
) reduces expression of GAGs and other glycans. (a-c) Treatment of SKOV3 
cells with 50 µM 6F-GalNAc (Ac
3
), but not GalNAc (Ac
4
), reduces expression of CS (a, antibody IO3H10), 
DS (b, antibody GD3A12) and HS (c, antibody HS4C3), as analyzed by flow cytometry. (d) Treatment of 
SKOV3 cells with 6F-GalNAc (Ac
3
) reduces O-GlcNAc protein modification, as determined by western 
blotting using an antibody against this modification. GAPDH was used as a (control). (e) Treatment of 
SKOV3 cells with 50 µM 6F-GalNAc (Ac
3
), but not GalNAc (Ac
4
) reduces binding of 3 out of 11 lectins, 
which recognize different structures found on N- and/or O-linked glycans(27). Data is presented as 
mean±sd. * P < 0.05 compared to untreated, using Student’s t-test (n = 3 or more). For comparison, 
quantification of CS and HS expression is also given. 
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Next, we determined the effect of 6F-GalNAc (Ac
3
) treatment (and the resulting 
UDP-HexNAc depletion) on expression of GAGs and other glycans. Analysis of cell surface 
GAG levels by flow cytometry using specific antibodies revealed a reduction of CS, DS and 
HS staining by ~50%, ~50% and ~35%, respectively (Fig. 3a-c). In addition, 3G10 staining 
for HS ‘stubs’, created by heparinase treatment, was decreased by ~45% (mean fluorescence 
intensity (MFI) ± sd for untreated cells was 1380 ± 80; MFI ± sd for 6F-GalNAc (Ac
3
) treated 
cells was 754 ± 82; n = 3; P < 0.001 by Student’s t-test). Reduced GAG expression by incu-
bation with 6F-GalNAc (Ac
3
) was also shown by agarose gel electrophoresis (Supplementary 
Fig. 4). In this case, staining for HS was more affected, possibly due to the presence of ma-
trix-derived GAGs in this assay. Culturing in the presence of the parent peracetylated sugar, 
GalNAc (Ac
4
), had no effect on the type or amount of GAGs produced (Fig 3a-c and Supplemen-
tary Fig 4). We also assessed GAG disaccharide composition after 6F-GalNAc (Ac
3
) treatment 
(Supplementary results and Supplementary Fig. 5). We found an increase in HS 6O-sulfation, 
possibly indicating reduced HS chain size(21), and a reduction in the major CS/DS 6O-sulfated 
disaccharide, UA-GalNAc6S.
The effect of 6F-GalNAc (Ac
3
) on glycan structures, other than GAGs, was determined 
by western blotting for O-GlcNAc protein modification (Fig. 3d), and by lectin flow cytometry 
for other glycans (Fig. 3e). O-GlcNAc protein modification, in line with the UDP-GlcNAc con-
centration dependency of the O-GlcNAc transferase (22), was strongly reduced. Binding of 3 
out of 11 lectins was significantly reduced. Binding of DSA, recognizing the repetitive GlcNAc 
containing poly-N-acetyl-lactosamine, and PNA, recognizing O-GalNAc linked glycans, was 
most strongly inhibited. Interestingly, there was no reduction in staining by mannose-bind-
ing lectins (GNA, ConA), a fucose binding lectin (AAL), and a sialic acid binding lectin (SNA). 
This indicates that predominantly the GlcNAc/GalNAc family of glycans had been affected 
and indicates family specificity of sugar analogs. This is in line with a recent report showing 
that staining by AAL and SNA is strongly reduced by incubation of cells with  2F-Fuc and 3F
ax
-
NeuAc, respectively (20). To exclude that observed effects were restricted to SKOV3 cells, RF24 
endothelial and HeLa cervical cancer cells were also treated with 6F-GalNAc (Ac
3
) and assayed 
for GAG levels. In RF24 cells, 50 µM 6F-GalNAc (Ac
3
) reduced CS and HS expression to a similar 
extent as in SKOV3 cells (Supplementary Fig. 6a, b). In HeLa cells, 300 µM was required for 
a comparable effect (Supplementary Fig. 6c, d), indicating cell specific sensitivity for sugar 
analogs. Altogether, these data indicate that a reduction of natural UDP-GalNAc and UDP-Glc-
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NAc by UDP-activation of 6F-GalNAc reduces biosynthesis of GAGs and other GlcNAc/GalNAc 
containing glycans (also see model in Fig. 1b). Activation of 6F-GalNAc might reduce the 
formation of the natural nucleotide sugar by hijacking its machinery. In addition, accumula-
tion of activated analog inside the cell may inhibit the de novo synthesis of UDP-GalNAc and/
or UDP-GlcNAc as a result of a feedback mechanism, as proposed for fluorinated fucose and 
Figure 4. 6F-GalNAc (Ac
3
) inhibits FGF-2 and VEGF signaling and reduces in vivo angiogenesis. Treat-
ment of SKOV3 cells with 6F-GalNAc (Ac
3
), but not GalNAc (Ac
4
), reduces binding of rrVEGF
164
 (a), but 
not rhFGF-2 (b), as determined by addition of the growth factor and flow cytometry using an antibody 
against VEGF or FGF-2. (c) 6F-GalNAc (Ac
3
) reduces binding of (soluble) rhFGFR1 (Fc chimera) to SKOV3 
cells, previously incubated with rhFGF2, and assayed using an anti-IgG antibody. (d) 6F-GalNAc (Ac
3
), 
but not GalNAc (Ac
4
), inhibits formation of intracellular p-ERK1/2 (a components essential in the down-
stream signaling by FGF-2 and VEGF) in HUVECs, as determined by western blot using an antibody 
against p-ERK 1/2 or GAPDH (control). (e) 6F-GalNAc (Ac
3
), but not GalNAc (Ac
4
), inhibits FGF-2 (10 ng/
ml)-induced proliferation of HUVECs, as determined by the CellTiter-Glo assay. Data is presented as 
mean±sd from three separate experiments. *P < 0.05 compared to untreated, using Student’s t-test. (f) 
6F-GalNAc (Ac
3
), but not GalNAc (Ac
4
), inhibits in vivo angiogenesis (vessel density) in the chicken cho-
rioallantoic membrane assay. Data is presented as mean±SEM. P-values are indicated, and determined 
by the Mann-Whitney U test.
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sialic acid analogs (20). The activated analog may also inhibit glycosyltransferases, as shown 
for peracetylated 2F-Fuc (20) and 3F
ax
-NeuAc (20), although this was not evaluated here.
Considering the role of GAGs in growth factor signaling and angiogenesis (23-26), 
biological effects of 6F-GalNAc (Ac
3
) were analyzed in relation to these processes. Cellular 
binding of the HS binding growth factors VEGF and FGF-2 to SKOV3 cells was determined 
by flow cytometry. In addition, to determine ternary complex formation, binding of (solu-
ble) FGF-receptor 1 (FGFR1) to cells pre-incubated with FGF-2 was analyzed. Treatment with 
6F-GalNAc (Ac
3
) reduced the amount of bound VEGF and FGFR1 (Fig. 4a and c), whereas the 
amount of bound FGF-2 remained largely unchanged (Fig. 4b). 6F-GalNAc (Ac
3
) reduced signal 
transduction in primary endothelial cells (HUVECs) stimulated with either FGF-2 or VEGF, as 
probed by analysis of phospho ERK1/2 (Fig. 4d). Furthermore, 6F-GalNAc (Ac
3
) inhibited FGF-2 
stimulated HUVEC proliferation in a dose-dependent way (Fig. 4e). To test for inhibition of 
the formation of new blood vessels in vivo, the chicken chorioallantoic membrane (CAM) as-
say was used. Daily treatment with 50 µl of 5 or 10 mM 6F-GalNAc (Ac
3
) significantly reduced 
vessel-density by ~30%, whereas the parent sugar GalNAc (Ac
4
) had no significant effect 
(Fig. 4f). 
We recently reported on the in vitro and in vivo effects of peracetylated 4-deoxy-Glc-
NAc (11), and overall the effects were similar as observed here. Unlike previously used ana-
logs as peracetylated 4-deoxy and 4F-GlcNAc, the 6F analog used here was unlikely to func-
tion as a chain stopper given the α1,4 and β1,4 linkages in HS and β1,4 and β1,3 linkages 
in CS. In conclusion, this study, together with literature data (11,17-20), fuels the thought 
that a general mechanism underlies the observed effects: peracetylated deoxy, fluoro or thio 
modified sugar analogs are taken up by cells, transformed to their activated glycosyl donors 
thereby largely depleting natural activated sugar pools, resulting in inhibition of glycan syn-
thesis (also see model in Fig 1b).
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Supplementary data
Supplementary Results
Effect of 6F-GalNAc (Ac
3
) on cell viability 
To determine the effect of 6F-GalNAc (Ac
3
) on cell viability, SKOV3 cells were cultured for three 
days in the presence of various amounts of GalNAc (Ac
4
) or 6F-GalNAc (Ac
3
) (Supplementary 
Fig. 1). The presence of 6F-GalNAc (Ac
3
) up to a concentration of 100 µM did not adversely 
affect cell viability, as determined by the WST-1 assay. Incubation with higher concentrations 
(200 and 400 µM) resulted in cellular toxicity. Addition of GalNAc (Ac
4
) at various concentra-
tions up to 400 µM had no adverse effect on cell viability.
Effect of 6F-GalNAc (Ac
3
) on GAG disaccharide composition 
To assess the effect of 6F-GalNAc (Ac
3
) on disaccharide composition of HS and CS/DS, SKOV3 
cells were cultured with or without 50 µM of GalNAc (Ac
4
) or 6F-GalNAc (Ac
3
) and specific HS 
and CS/DS disaccharides were analyzed by enzymatic digestion and HPLC-UV analysis. Cul-
turing in the presence of 50 µM 6F-GalNAc (Ac
3
) significantly reduced the amount of 6O-mo-
no-sulfated CS/DS disaccharides (Supplementary Fig. 5a). However, in case of HS, there was 
a significant increase in UA2S-GlcNS6S disaccharides (Supplementary Fig. 5b) and a trend 
towards  increased total 6O-sulfation (Supplementary Fig. 5c; control vs. 6F-GalNAc (Ac
3
) P = 
0.053; GalNAc (Ac
4
) vs 6F-GalNAc (Ac
3
) P = 0.045). This increase in HS 6O-sulfation was con-
firmed by LC/MS in an independent duplicate experiment (Supplementary Fig. 5d; control vs. 
6F-GalNAc (Ac
3
) P < 0.001; GalNAc (Ac
4
) vs 6F-GalNAc (Ac
3
) P < 0.001).
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Supplementary Table 1. LC/MS analysis for 6F containing disaccharides. Ion intensities (in arbitrary 
units) for HS and CS/DS disaccharides, and their possible 6F containing counterparts are shown. No 
6F containing disaccharides were found. A mass window of 1 amu was used, centered on the listed 
disaccharide mass.
HS analysis
m/z Intensity m/z Intensity
UA-GlcN 413 0.0 6F-UA-GlcN 415 0.0
UA2S-GlcN 493 0.0 6F-UA2S-GlcN 495 0.0
UA-GlcNAc 455 88.9 6F-UA-GlcNAc 457 0.0
UA-GlcNS 493 54.5 6F-UA-GlcNS 495 0.0
UA2S-GlcNAc 535 5.0 6F-UA2S-GlcNAc 537 0.0
UA2S-GlcNS 573 21.0 6F-UA2S-GlcNS 575 0.0
CS/DS analysis
m/z Intensity m/z Intensity
UA-GalNAc 455 83.7 6F-UA-GalNAc 457 0.0
Supplementary Figure 1. Effect of GalNAc (Ac4) and 6F-GalNAc (Ac3) on cell viability. SKOV3 cells were 
cultured for three days with or without various concentrations of GalNAc (Ac
4
) or 6F-GalNAc (Ac
3
), after 
which the amount of metabolic active cells was measured by the WST-1 assay. Representative data of 
one of two separate experiments is shown (n = 5 or 6). * P < 0.05 compared to control, using Student’s 
t-test.
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Supplementary Figure 2. Tandem mass spectrometry with constellation of daughter ions of sugar 
nucleotides. UDP-HexNAc from control (untreated) cells (a) and UDP-6F-HexNAc recovered from 6F-Gal-
NAc (Ac
3
) treated cells (b) were analyzed. Assignments are indicated by the molecular diagram to the 
right. Ions marked with a black dot above represent non-reducing end fragment ions that include 
carbon-6 which differs by 2 amu depending on whether the parent molecule is HexNAc or 6F-HexNAc. 
This experiment was conducted together with untreated cells of which the data was also previously 
shown (1).
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Supplementary Figure 3. Assessment of 6F-GalNAc incorporation. (a) Isolated GAGs from untreated 
or 50 µM 6F-GalNAc (Ac
3
) treated cells were hydrolyzed to monosaccharides by HCl and analyzed by 
mass spectrometry. Natural hexosamines (HexN; mass of 180.09) were present in treated and untreated 
samples. 6F-hexosamine (mass of 182.09) was not found. (b) As a control, 6F-GalNAc (Ac
3
) itself was 
hydrolyzed and analyzed by mass spectrometry.
Supplementary Figure 4. Agarose gel electrophoresis of isolated GAGs from SKOV3 cells cultured for 
three days with or without 50 µM GalNAc (Ac
4
) or 6F-GalNAc (Ac
3
). Note the decrease in HS staining, as 
well as CS staining, by incubation with 6F-GalNAc (Ac
3
).
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Supplementary Figure 5. Effect of 6F-GalNAc (Ac
3
) on GAG disaccharide composition. GAGs of SKOV3 
cells cultured with or without 50 µM GalNAc (Ac
4
) or 6F-GalNAc (Ac
3
) were depolymerized by chon-
droitinase ABC (a) or by a combination of heparinases I, II and III (b-d), and specific disaccharides were 
determined by HPLC (a-c) (n = 3) or LC/MS (n = 2) (d). (a, b) Distribution of the disaccharide components 
of CS/DS (a) and HS (b). UA2S-GalNAc4S and UA2S-GalNAc6S elute as one peak and is therefore calculated 
as one. . (c) The amount of total, N-, 2O- or 6O- sulfation per disaccharide was calculated from the HS 
analysis as shown in b. (d) The amount of total, N-, 2O- or 6O- sulfation per disaccharide was calculated 
from an independent HS analysis by LC/MS. *P < 0.05 compared to control or GalNAc (Ac
4
), using Stu-
dent’s t-test. #P < 0.05 compared to GalNAc (Ac
4
), using Student’s t-test.
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Supplementary Figure 6. 6F-GalNAc (Ac
3
) reduces expression of GAGs in RF24 endothelial and HeLa 
cervical cancer cells. Treatment of RF24 endothelial cells with 50 µM 6F-GalNAc (Ac
3
), but not GalNAc 
(Ac
4
), reduces CS (a, antibody IO3H10) and HS (b, antibody HS4C3) expression, as analyzed by flow cy-
tometry. For HeLa cervical cancer cells, 300 µM 6F-GalNAc (Ac
3
) was required to reduce CS (c, antibody 
IO3H10) and HS (d, antibody HS4C3) expression. 
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Abstract
Heparan sulfate (HS) is a long, linear polysaccharide, variably modified by epimerization and 
sulfation reactions, and is organized into different domains defined by the extent of modifi-
cation. To further elucidate HS structural organization, the relative position of different HS 
structures, identified by a set of phage display derived anti-HS antibodies, was established. 
Two strategies were employed: inhibition of HS biosynthesis using 4-deoxy-GlcNAc, followed 
by resynthesis, and limited degradation of HS using heparinases. Using both approaches, 
information about the position of antibody-defined HS structures could be identified. The HS 
structure recognized by the antibody NS4F5, rigorously identified as (GlcN6S-IdoA2S)
3
, was 
found towards the non-reducing end of the HS chain.
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Introduction
Heparan sulfate (HS) is a long, linear, negatively charged polysaccharide that is generally 
bound to a protein core, thereby forming a HS proteoglycan. It is part of a larger family of 
glycosaminoglycans, is present at the cell membrane and in the extracellular matrix, and 
fulfills multiple important roles in almost all major organ systems by its interaction with 
numerous proteins (1). The HS backbone consists of repeating disaccharide units of N-acetyl-
d-glucosamine (GlcNAc) and d-glucuronic acid (GlcA), and is variably modified by N-deacetyla-
tion/N-sulfation, epimerization of d-GlcA to l-iduronic acid (IdoA) and O-sulfations at various 
positions. These reactions occur in a coordinated fashion and result in a specific domain 
structure of unmodified, moderately and highly modified domains (2).
An extensive set of anti-HS antibodies has been developed using phage display tech-
nology, and using these tools a number of different HS epitopes have been localized in differ-
ent tissues (3-7). These antibodies recognize different HS structures, and a number of specific 
HS modifications that contribute or are inhibitory for binding have been identified (Table 1). 
To further understand HS structural organization, we probed the position of various anti-
body-defined HS structures with respect to each other and with respect to the reducing and 
non-reducing end (NRE) of HS chains. Two approaches were taken, one based on inhibition of 
HS synthesis followed by resynthesis, the other based on limited enzymatic digestion  of HS. 
In the first approach, cells were incubated with 4-deoxy-GlcNAc, a sugar analog which inhib-
its HS synthesis and reduces HS chain length (8-10). Next, cells were allowed to resynthesize 
Table 1. Heparan sulfate modifications involved in binding of scFv antibodies.
Antibody Modifications involved in bindinga Modifications which may reduce bindinga 
HS4C3 NS, 2OS, 3OS, 6OSb  
HS3A8 NS, C5-epimerization, 2OS, 6OS (likely)  
HS4E4 NA, NS, C5-epimerization 2OS, 6OS 
EV3C3 NS, C5-epimerization, 2OS High 6OS (possibly) 
LKIV69 NS, C5-epimerization, 2OS 6OS 
NS4F5 NS, C5-epimerization, 2OS (high), 6OS (high)  
AO4B08 NS, C5-epimerization, 2OS, 6OS (high)  
RB4EA12 NA, NS, 6OS  
aPreferred and inhibitory modifications are adapted with changes from (21). b NA = N-acetylation, NS = 
N-sulfation, 2OS = 2O-sulfation, 3OS = 3O-sulfation, 6OS = 6O-sulfation.
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HS, and the sequence of the reappearance of antibody-defined HS structures was established. 
In the second approach, cells and kidney sections were treated with the HS-degrading en-
zymes heparinase I and III, and the sequence of  loss of immunoreactivity for each antibody 
was determined. The epitope defined by antibody NS4F5, recently identified as a motif con-
taining (GlcNS6S-IdoA2S)
3
 (7), was consistently located towards the NRE of HS chains in MV3 
melanoma and SKOV3 ovarian carcinoma cells, and in kidney in situ.
Materials and methods
Antibodies, enzymes and deoxy-monosaccharides
Periplasmic fractions of bacteria transfected with the vector (pUC119-His-VSV) containing 
the DNA sequences encoding the different anti-HS antibodies were isolated as described (5). 
The anti-HS antibodies used in this study were LKIV69 (11), HS4C3 (3), AO4B08 (4), RB4EA12 
(4), EV3C3 (5), NS4F5(7), HS4E4 (6) and HS3A8 (12). Mouse mAb anti-HS stub (3G10; IgG2b) 
was from Seikagaku Corporation (Tokyo, Japan). Heparinase I and III from Flavobacterium 
heparinum were purchased from IBEX Pharmaceuticals Inc. (Montreal, Quebec, Canada). The 
synthesis of non-peracetylated and peracetylated 4-deoxy-GlcNAc was described in (9) and 
(10), respectively.
Cell culture
Human MV3 melanoma cells and human SKOV3 ovarian carcinoma cells were cultured as 
described (9,10).
Inhibition of HS synthesis by 4-deoxy-GlcNAc, followed by resynthesis
MV3 melanoma cells were cultured on glass coverslips in the presence of 5 mM 4-deoxy-Gl-
cNAc (non-peracetylated) for three days. Medium was then replaced by fresh medium, with-
out 4-deoxy-GlcNAc, to allow synthesis of new HS chains. The reappearance of HS structures 
defned by  the antibodies was studied by immunocytochemistry at various time points (0 
to 142 h) after change of the medium. Cells were first incubated with anti-HS antibodies, 
followed by 1% paraformaldehyde fixation and incubations with mouse anti-VSV IgG (1:10) 
and Alexa488 fluorochrome conjugated anti-mouse IgG (1:200; Invitrogen, Carlsbad, CA) as 
described (9). SKOV3 ovarian carcinoma cells were cultured for three days in the presence of 
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3 - 200 µM 4-deoxy-GlcNAc (Ac
3
). Staining for HS and analysis by flow cytometry was per-
formed as described (10). Mean fluorescence intensity (MFI) was plotted as a percentage of 
inhibition and IC
50 
values were calculated in GraphPad Prism (GraphPad, San Diego, CA, USA).
Heparinase digestions
Digestion of cells. MV3 and SKOV3 cells were detached by enzyme free cell dissociation solu-
tion (Millipore; Billerica, MA) and subsequently incubated with either a fixed (MV3: 10 mIU/
ml heparinase I, 20 mIU/ml heparinase III) or various concentrations (SKOV3: 0.04 - 20 mIU/
ml heparinase I, 0.16 - 20 mIU/ml heparinase III) of heparinase I or III in culture medium 
containing 1% fetal bovine serum at 4 °C for a fixed (SKOV3: 5 h) or various amounts of time 
(MV3: 1 – 150 min). Staining for HS and analysis by flow cytometry was performed as de-
scribed (10). MFI was plotted as a percentage of undigested controls. 
In situ digestion. To probe HS structural organization in tissues, rat kidney cryosec-
tions were incubated for various amounts of time (30 sec - 2 h) with 5 mIU heparinase III / ml 
of 100 mM NaAc containing 0.2 mM Ca(Ac)
2
 (pH 7.0). Immunohistochemistry was performed 
by subsequent incubations with an anti-HS antibody, rabbit IgG anti-VSV (1:500, Rockland, 
Gilbertsville, PA) and Alexa488 fluorochrome conjugated anti-rabbit IgG (1:200, Invitrogen). 
In addition, staining for the unsaturated hexuronate present at the non-reducing end of 
HS formed by action of heparinase III, was performed by incubation with the mouse IgG 
mAb ‘anti-stub’ 3G10 (1:200), followed by Alexa594 fluorochrome conjugated anti-mouse IgG 
(1:200, Invitrogen).
Results
HS ‘resynthesis’ after 4-deoxy-GlcNAc treatment results in a time dependent 
reappearance of antibody-defined HS structures
The first approach of HS ‘immunosequencing’ was based on inhibition of HS synthesis by 
the sugar analog 4-deoxy-GlcNAc. Culturing of MV3 melanoma cells with 4-deoxy-GlcNAc for 
three days was previously shown to nullify HS staining (9). We reasoned that replacement of 
the culture medium at that time by medium without 4-deoxy-GlcNAc would result in a slow 
cellular wash-out of the sugar analog, resulting in increased HS chain size with time. To test 
this approach, MV3 cells were incubated with 4-deoxy-GlcNAc for three days, culture medium 
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was replaced and HS staining by 8 anti-HS antibodies was assessed at several time points 
(Fig. 1, Table 2). First appearance of cell surface HS staining was found at markedly different 
times for the different antibodies. HS4C3 and AO4B08 were the first two antibodies to show 
return of staining, indicating the HS epitopes defined by these antibodies to be present to-
wards the reducing end of HS. HS structures recognized by EV3C3 and NS4F5 were the last to 
reappear, suggesting that these structures are more closely located towards the NRE of HS.
Dose-dependent HS inhibition by 4-deoxy-GlcNAc is different for the NS4F5 motif  
(GlcNS6S-IdoA2S)
3
We have shown previously that incubation of SKOV3 ovarian carcinoma cells with various 
concentrations (3 - 200 µM) 4-deoxy-GlcNAc, peracetylated in this case to increase cellular 
entrance, resulted in a dose-dependent inhibition of HS biosynthesis (10). By flow cytometry 
using antibody LKIV69 we found an IC
50
 value of 16 µM (10), i.e. at 16 µM 4-deoxy-GlcNAc 
staining was reduced to half of the staining observed without 4-deoxy-GlcNAc. Next, we de-
termined IC
50
 values for several other antibodies (Fig. 1). The IC
50
 value for antibody NS4F5, 
identifying the motif (GlcNS6S-IdoA2S)
3 
(7), was markedly lower compared to four other ex-
amined antibodies, suggesting this HS motif is located towards the NRE of HS. Together, 
these results suggest that the NS4F5 epitopes in HS from MV3 and SKOV3 cells, and the 
EV3C3 epitope in HS from MV3 cells, are located towards the NRE of the HS chain.
Enzymatic digestion of cellular HS with heparinase I and III indicates the NS4F5 motif to 
be located towards the NRE
The second approach of HS ‘immunosequencing’ was based on limited degradation of HS by 
heparinases, a strategy applied by others before for digestion of chondroitin sulfate (CS) and 
mapping of anti-CS antibodies (13). First, MV3 melanoma cells were incubated with either 
heparinase I or III for different amount of times, and antibody staining was subsequently 
evaluated by flow cytometry (Fig. 3). After a short time (1 min) of digestion with either of the 
two heparinases, staining for EV3C3 and NS4F5 was strongly inhibited in comparison to the 
other antibodies used. Second, SKOV3 cells were incubated with different concentrations of 
either heparinase I or III and antibody staining was again evaluated by flow cytometry (Fig. 
4). Antibody NS4F5 staining was reduced at lower concentrations of heparinase, compared 
to the other three  antibodies evaluated. Taken together, these results support the data ob-
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Figure 1. Time dependent reappearance of antibody-defined HS structures after 4-deoxy-GlcNAc 
treatment. MV3 cells were cultured for three days in the presence of 5 mM 4-deoxy-GlcNAc, after which 
the medium was replaced by medium without 4-deoxy-GlcNAc. Presence of cell surface staining was 
monitored at various time points by immunocytochemistry. Three representative antibodies are shown. 
See also table 2.
132
Chapter 5
Table 2. Time dependent reappearance of antibody-defined HS structures after inhibition of HS syn-
thesis by 4-deoxy-GlcNAc treatment (see also figure 1).
Antibody
Time of first appearance of cell surface staining after 4-deoxy-GlcNAc treatment (hours)
8 22 32 46 56 70 80 94 104 118 128 142
HS4C3 X
HS3A8 X
HS4E4 X
EV3C3 X
LKIV69 X
NS4F5 X
AO4B08 X
RB4EA12 X
Figure 2. Epitope specific IC
50
 value for inhibition of HS staining by peracetylated 4-deoxy-GlcNAc. 
SKOV3 cells were cultured for three days in the presence of 3 - 200 µM of peracetylated 4-deoxy-Glc-
NAc, after which HS staining was evaluated by flow cytometry. The IC
50
 value for inhibition of HS 
staining was calculated by GraphPad Prism. Data are presented as mean ± SD from three independent 
experiments. Note the low IC
50
 value for the epitope defined by antibody NS4F5. LKIV69 IC
50
 data were 
previously shown in (10).
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tained with 4-deoxy-GlcNAc, indicating that NS4F5 epitopes in HS from MV3 and SKOV3 cells, 
and the EV3C3 epitope in HS from MV3 cells, are located towards the NRE of HS.
Heparinase III digestion of kidney sections indicates that EV3C3 and NS4F5 epitopes are 
located towards the NRE in situ
To map the anti-HS antibodies in tissue, sections of rat kidney were treated for different times 
with heparinase III and subsequently stained for HS using the anti-HS antibodies or using 
the HS neo-epitope ‘anti-stub’ (3G10) antibody. The time of disappearance of staining in the 
cortical (Fig. 5) and medullar region (Fig. 6) was evaluated. For the cortical region, including 
tubules, glomerulus and Bowman’s capsule, staining of the antibodies HS4C3, HS3A8, HS4E4 
and LKIV69 disappeared virtually at the same time (10 min), whereas staining of EV3C3 dis-
appeared after 5 min of heparinase treatment (Fig. 5). NS4F5 does not react in the cortical re-
gion and was therefore evaluated in the medullar region only (Fig. 6). For this region, a more 
differential disappearance of staining by the evaluated antibodies was noted (Table 3). Stain-
ing for NS4F5, EV3C3 and HS4E4 was lost after 5 min, whereas staining of HS3A8 and HS4C3 
disappeared after 30 and 120 min, respectively. Interestingly, LKIV69 staining of a subset of 
tubules disappeared after 5 min, whereas the remainder was lost after 30 min. Combined, 
these data suggest that EV3C3 and NS4F5 epitopes are located towards the NRE of HS in rat 
kidney. This also accounts for HS4E4 in the medullar region, but not in the cortical region. 
Figure 3. Time dependent removal of HS epitopes by heparinases. Cultured MV3 melanoma cells were 
incubated with either 0.01 IU/ml heparinase I or 0.02 IU/ml heparinase III for 1- 150 min. Staining for 
HS epitopes was assessed by flow cytometry. One representative experiment out of three is shown.
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Discussion
The aim of the present study was to gain more insight into HS structure by mapping the 
relative position of antibody-defined HS structures, and their position towards the reducing/
non reducing end. All data taken together, we may conclude that the HS4C3 and HS3A8 
epitopes are likely located towards the reducing end of the chain, whereas EV3C3 (although 
not evident in SKOV3 cells) and especially NS4F5 are found towards the NRE. However, in 
the time-dependent reappearance of HS after 4-deoxy-GlcNAc treatment, one must consider 
the possible effects of modification by e.g. endosulfatases and/or heparanase. Furthermore, 
it is possible that epitopes of one antibody reside at multiple locations within a HS chain. 
Interesting in this regard is the phased disappearance of staining by LKIV69 in the cortical 
kidney region, in which staining of a subpart of tubules disappears faster than of other mor-
phological structures. This may indicate that in the faster disappearing structures a LKIV69 
epitope is more closely located towards the NRE. Whereas most HS epitope structures have 
not been clearly defined, the epitope recognized by antibody NS4F5 has, and corresponds 
to (GlcNS6S-IdoA2S)
3 
(7). Our observation that this motif is located towards the NRE nicely 
correlates with literature data addressing the composition of the NRE. For bovine kidney HS, 
the likely sequence of the NRE was determined as GlcA-GlcNS6S-UA±2S-GlcNS±6S-Ido2S-Gl-
cNS±6S (14). More recently, it was shown that highly modified domains reside at the NRE of 
HS from various mammalian sources (15). Furthermore, this study reported that these are, on 
average, longer and more highly sulfated than internal highly modified domains. In addition, 
the observation that NS4F5 has a quite restrictive tissue distribution (7) is in line with the 
notion that these highly modified domains not always occupy the NRE (15). Biologically, the 
NRE seems particularly important for growth factor signaling, as this may be the site where 
HS-fibroblast growth factor 2 (FGF2)-FGF-receptor 1 (FGFR1) ternary complexes assemble (16). 
NRE oligosaccharides were strongly enriched in high affinity FGF2 binding fractions com-
pared to low affinity FGF2 binding fractions. The high affinity fractions were able to promote 
FGFR1 mediated cell proliferation, whereas the low affinity fractions were not (17). Moreo-
ver, there is data indicating that the extracellular 6O-sulfate removing enzyme, Hsulf2, has 
increased activity towards the NRE compared to internal regions (18), which is interesting as 
6O-sulfation is critical for FGFR1 binding (19) and FGF-2 signaling (20). 
In conclusion, we provide further evidence of HS structural organization and show 
the presence of the (GlcNS6S-IdoA2S)
3
 motif, defined by antibody NS4F5, to be located to-
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wards the NRE of HS. Antibody NS4F5 may be instrumental in topologically identifying high-
ly sulfated NRE of HS in cells and tissues, e.g. during development and pathology.
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Figure 4. Concentration dependent removal of HS epitopes by heparinases.  Cultured SKOV3 cells 
were incubated with different concentrations of either heparinase I or heparinase III for 5 h, and loss of 
epitopes was assessed by flow cytometry. One representative experiment out of three is shown.
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Table 3. Time dependent disappearance of antibody staining in the renal cortical region after diges-
tion with heparinase III for different periods of time(also see figure 6).
Antibody
Time of complete epitope loss with heparinase III digestion (minutes)
1 5 10 30 120
HS4C3 X
HS3A8 X
HS4E4 X
EV3C3 X
LKIV69 X* X*
NS4F5 X
Figure 5. Time dependent removal of HS epitopes from cortical kidney sections by heparinase. Kid-
ney sections were incubated with heparinase III for 30 sec - 10 min, and loss of epitopes was assessed 
by immunohistochemistry. Note the presence of the different kidney structures: tubules, Bowman’s 
capsule and the glomerulus. Staining with three representative antibodies is shown, in addition to 
3G10 (‘anti-stub’) which was used to monitor heparinase digestion.
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Figure 6. Time dependent removal of HS epitopes from medullary kidney sections by heparinase. 
Kidney sections were incubated with heparinase III for 30 sec - 2 h, and loss of epitopes was assessed 
by immunohistochemistry. Staining with three representative antibodies is shown, in addition to 3G10 
(‘anti-stub’) which was used to monitor heparinase digestion.
See also table 3.
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Abstract
Glycosaminoglycans (GAGs) are long, anionic polysaccharides involved in many basic aspects 
of mammalian physiology and pathology. Here we describe a method to extract GAGs from 
formalin-fixed, paraffin-embedded (FFPE) tissues and found that they are structurally com-
parable to GAGs extracted from frozen tissues. We employed this method to structurally 
characterize GAGs in tissues, including laser-dissected layers of skin and pathological speci-
mens. This method enables the use of the archival paraffin-embedded  material for detailed 
(structural) analysis of GAGs.
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Introduction
Archiving of clinical tissue samples is generally done by formalin fixation and paraffin wax 
embedment. Formalin-fixed, paraffin-embedded (FFPE) tissues are valuable samples, typically 
generated from human specimens, and are used for (patho)histological examination. It has 
been estimated that worldwide over a billion samples have been stored (1). As this material 
is generally readily available, and patient related data of many years is usually known, the 
ability to use this archival material is of great advantage in clinical and molecular research. 
Much attention has been given to the extraction of  DNA and RNA from human FFPE tissues, 
and this has offered tremendous experimental opportunities, including microarray analysis 
(2). Little attention has been given to the extraction of (poly-)saccharides, let alone the highly 
heterogeneous, polyanionic glycosaminoglycans. It has been reported that N-linked protein 
glycosylation remains preserved in FFPE tissues (3). Here, we report a method to extract 
intact glycosaminoglycans (GAGs) from FFPE material. GAGs are long (up to 100-150 disac-
charides), linear and highly negatively charged polysaccharides, and are generally attached 
to a protein core, forming proteoglycans. They are located at the cell surface and in the 
extracellular matrix. Based on their disaccharide composition, different family members are 
distinguished, which include heparan sulfate (HS)/heparin and chondroitin/dermatan sulfate 
(CS/DS) (4). GAGs are highly variable molecules due to variable degrees of polymerization, 
epimerization, and sulfation at different positions (see Supplementary Fig 1). They are po-
tentially highly information-dense molecules and recent evidence suggests the presence of 
defined monosaccharide sequences (5). Domain structures within GAGs are crucial for their 
interaction with a large variety of proteins, including growth factors and regulatory mole-
cules, and these interactions facilitate specific activities in mammalian physiology (6). GAGs 
and proteoglycans have been implicated in various pathological processes, e.g. amyloid dis-
eases, inflammation and infection, and cancer biology (7). Both qualitative changes (different 
modification patterns) and quantitative changes have been described. 
Materials and methods
Biological materials
Liver and skin were derived from two-three month old Wistar rats and tissue was divided in 
pieces (liver range: 310-1198 mg wet weight, mean±sd: 720±259 mg; skin range: 118-454 
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mg wet weight, mean±sd: 268±105 mg), and either directly frozen in liquid nitrogen or 
fixed overnight in 4% paraformaldehyde (in 0.1M sodium phosphate buffer, pH 7.4) at 4°C 
and embedded in paraffin. For isolation of GAGs from mouse skin sections, skin was derived 
from two-three month old BALB/c nude mice, and embedded in paraffin as described above. 
Tissue sections of human (pathological) skin were obtained from the archives of the Institute 
of Pathology of the Radboud University Nijmegen Medical Centre. We used anonymized ar-
chival biopsy material left over from previous diagnostic procedures, in accordance with the 
Dutch code of conduct on the use of human tissue.
Procedure for extraction/isolation of glycosaminoglycans (GAGs)
Extraction/isolation from tissue blocks. For isolation of GAGs from rat tissues, FFPE tissue was 
cut into small pieces (~5-10 mm3), after removing the excess of paraffin. Pieces were put 
into 50 ml conical tubes. In case the tissue blocks were deparaffinated, surrounding paraffin 
was cut away, and the blocks were placed in a xylene bath (100 ml) at 60°C for 15 min. This 
was repeated twice with fresh xylene. Excess xylene was discarded and the tissue piece was 
washed with 100% ethanol (100 ml) followed by 96%, 70%, 50%, 30% ethanol for 3 min each. 
Subsequently, the tissue was gently rinsed in running tap water for 30s and kept in PBS (100 
ml) for 30 min for rehydration. After deparaffination, the wet tissue was cut into small pieces 
(~5-10 mm3) and put into a 50 ml conical tube. 
To both paraffinated and deparaffinated samples 20 ml of digestion buffer (50 mM 
sodium phosphate, 2 mM cysteine, 2 mM EDTA, pH 6.5) and 25U of the proteolytic enzyme 
papain from Papaya latex (P3125, Sigma-Aldrich, St Louis, MO) was added per gram of wet 
tissue weight. For isolation from frozen liver tissues, homogenization by a potter-Elvehjem 
homogenizer with intervening space of 0.35 mm (5-10 strokes) was performed in 20 ml of di-
gestion buffer (without papain)/gram tissue and the tissue homogenate was transferred into 
a 50 ml conical tube, and 25U papain/gram tissue was added. For isolation from frozen skin, a 
similar procedure could not be used as skin is too rigid. Instead, ~5-10 mm3 pieces were cut.
Papain digestion was performed in a 65°C water bath overnight, followed by cen-
trifugation at 5200g for 20 min at room temperature. In case FFPE tissues were not first de-
paraffinated, centrifugation was performed at 37°C. The resulting tissue pellet was digested 
with papain once more. To the supernatant, trichloroacetic acid (TCA) was added to a final 
concentration of 15% (w/v), put on ice for 30 min and centrifuged at 5200g for 30 min at 4°C. 
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The supernatant was diluted at least five times and loaded onto an anion exchange column 
composed of 1 ml diethylaminoethyl (DEAE) Sepharose (GE Healthcare, Chalfont St. Giles, UK) 
for further purification of GAGs. In case FFPE tissues were not first deparaffinated, the TCA 
pellet was not very solid and the supernatant was filtrated after five times dilution, result-
ing in a clear filtrate which was subjected to the column. An initial wash of the column was 
performed with 3 ml 0.2M NaCl in 10 mM Tris (pH 6.8). GAGs were eluted with 3 ml 2M NaCl 
in 10 mM Tris (pH 6.8) and allowed to precipitate overnight at -20°C by adding five volumes 
of methanol, followed by 1h centrifugation at 5200g at 4°C. Methanol was discarded quickly 
and the precipitated GAGs were air-dried, dissolved in Milli-Q and stored at 4°C (the amount 
of Milli-Q added (in µl) corresponds to the value of half of the wet weight (in mg) of the orig-
inal tissue material). 
Extraction/isolation from tissue sections. For isolation of GAGs from mouse and hu-
man FFPE skin, sections of 40 µm were made and collected in 2 ml eppendorf tubes. Depa-
raffination was performed as described above, using 2 ml eppendorf tubes, and volumes of 
1 ml. Centrifugation steps of 5 min at 14,000g were performed after each incubation. The 
isolation procedure was as described above with the following changes: the amount of diges-
tion buffer was 50 µl/section (with a minimum of 150 µl for 1 or 2 sections), anion exchange 
chromatography was performed using Vivapure QminiH spin columns (Sartorius-Stedim Bio-
tech, Aubagne, France) with a volume of 450 and 150 µl for washing and elution, respectively. 
After methanol precipitation, GAGs were dissolved in 10 µl Milli-Q. All centrifugation steps 
were performed at 14,000g. 
Quantification of glycosaminoglycans by dimethylmethylene blue 
To determine the concentration of sulfated GAGs isolated from tissues, a spectrophotometric 
assay developed by Farndale et al. (8) was used. In brief, 200 µl of reagent (3.04 g/l glycine, 
2.37 g/l NaCl, and 18 mg/l 1,9-dimethylmethylene blue dye, pH 3.0) was added to 10 µl of 
samples in microtiter plates, using 0-100 µg/ml CS-A and HS (from bovine trachea/kidney, 
respectively; Sigma-Aldrich) as the standards. Absorption was read at 525 nm. 
Agarose gel electrophoresis 
Separation of the major classes of sulfated GAGs was achieved by agarose gel electropho-
resis, as described before (9).  Briefly, 50 ng of isolated GAGs was separated using 1% (w/v) 
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agarose gels in 50 mM Ba(Ac)
2
 buffer (pH 5.0). After electrophoresis at 30 mA/gel in 50 mM 
Ba(Ac)
2
 for 50 min, the gel was fixed and stained with 0.1% (w/v) azure A (Sigma-Aldrich) for 
60 min, and destained in 10 mM NaAc buffer (pH 5.5) for 30 min. After 30 min washing  in 
Milli-Q, the gel was air-dried, followed by a silver-staining procedure to visualize GAGs. 
ELISA
A 96-well microtiter plate was coated overnight with GAGs (1 µg/ml in coating solution), 
followed by rinsing six times with PBS containing 0.1% (v/v) Tween-20 (PBST) and blocking 
with 3% (w/v) BSA in PBS containing 1% (v/v) Tween-20. Plates were incubated with a two-
fold serial dilution in blocking solution of different single chain variable fragment (scFv) an-
ti-GAG antibodies for 60 min. For epitope preferences of these antibodies, see (10-12). Bound 
scFv antibodies were detected by 60 min incubation with mouse anti-VSV monoclonal an-
tibody P5D4 followed by 45 min incubation with alkaline-phosphatase conjugated rabbit 
anti-mouse IgG (Dako, Glostrup, Denmark). Plates were washed six times with PBST after 
each incubation. Enzyme activity was detected using 1 mg p-nitrophenyl phosphate/ml as a 
substrate, dissolved in 1M diethanolamine with 0.5 mM MgCl
2 
(pH 9.8). The absorbance was 
measured at 405 nm.
Polyacrylamide gel electrophoresis (PAGE)
300 ng of isolated GAGs was loaded on a 16.5% acrylamide/bis-acrylamide gel and 1 µg of 
HS was used as a standard. Electrophoresis was performed in 30 mM Tris/22 mM MES buffer 
at 200V for ca. 2h. After electrophoresis, the gel was stained with 0.8% (w/v) Alcian Blue 
(Sigma-Aldrich, in 2% (v/v) acetic acid) for 30 min and then destained by 10% (v/v) acetic acid 
for two times 30 min, followed by 30 min neutralization in Milli-Q. To visualize GAGs, the gel 
was placed in 5% (w/v) Na
2
CO
3
 for 10 min, and a silver-staining procedure was employed, as 
was done for agarose gels.
HPLC disaccharide analysis
For CS/DS disaccharide analysis of rat skin samples, 200 mIU chondroitinase ABC (from Pro-
teus vulgaris, Sigma-Aldrich) was added overnight at 37°C to 10 µg of isolated GAGs in 100 
µl of digestion buffer (25 mM Tris and 2 mM MgAc
2
, pH 8.0). For HS disaccharide analysis 
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of rat liver samples, 7.5 mIU each of heparinase I, II and III (from Flavobacterium heparinum, 
IBEX Pharmaceuticals., Montreal, Canada) were added to 15 µg of isolated GAGs  in 100 µl of 
digestion buffer (100 mM NaAc/0.2 mM Ca(Ac)
2
, pH 7.2) for 2h at 37°C, after which 7.5 mIU 
of heparinases was added again and the reaction was allowed to take place overnight. The 
reaction was stopped by boiling the samples for 30s, and disaccharide separation was carried 
out by ion-pair reversed-phase chromatography with a gradient elution using a Supelcosil 
LC-18-T column (150x4.6 mm; 3 µm). Solvents A and B consisted of 5% and 50% aqueous ace-
tonitrile, respectively, both supplemented with 5 mM tetrabutylammonium phosphate and 
10 mM ammonium phosphate monobasic (pH 7.0). Elution was carried out using isocratic 
elution with 100% A for 2 min, linear gradient elution for 33 min to 100% B, followed by a 
5 min wash with 100% B and equilibration by 100% A for 10 min. The flow-rate was 1.2 ml/
min, column temperature was 25°C and detection took place at 232 nm. Identity of disaccha-
rides was determined by comparison to disaccharide standards (Iduron, Manchester, UK) and 
amount of specific disaccharides was calculated from peak surface area.
For disaccharide analysis of mouse and human skin sections, 15 mIU chondroiti-
nase ABC (for CS/DS analysis) or 0.66 mIU each of heparinase I, II and III (for HS analysis) 
was added to 2-4 µl of isolated GAGs for 2h at 37°C in a total of 10 µl in digestion buffer, as 
described above, after which the same amount of enzyme was added again and the reaction 
was allowed to take place overnight. Disaccharides were labeled with 2-aminoacridone and 
separated and detected by RP-HPLC as described (13). 
Laser-microdissection
Tissue sections (8-9µm) from FFPE skin samples were mounted on cross-linked PEN mem-
brane slides (Leica Microsystems, Wetzlar, Germany). Sections were deparaffinized using xy-
lene and ethanol and nuclear stained with Mayer’s hematoxylin (1 min) followed by rinsing 
in tap water. After drying for 30 min, the papillary and reticular dermis were separately 
dissected from fifty tissue sections. Dissection was performed using a Leica Laser Micro-
dissection System equipped with an UV laser (LMD 6000, Leica Microsystems), as described 
earlier (14).
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General histochemistry and immunohistochemistry
Hematoxylin and eosin staining was performed as described (15). For staining of CS and DS, 
4 µm sections were deparaffinated in xylene, hydrated with graded ethanol and blocked for 
endogenous peroxidase activity by 0.3% hydrogen peroxide in methanol for 20 min. After 
rinsing in PBS containing 0.01% Triton-X100 (PBS-T), sections were incubated in 0.1M citrate 
buffer (pH 5.8) for 30 min at room temperature, and blocked with 2% BSA in PBS-T. Next, 
sections were incubated successively with the VSV-tagged ScFv anti-DS antibody GD3A12 
(16) or anti-CS mouse antibody CS-56 (Sigma-Aldrich), mouse anti-VSV antibody P5D4 (in case 
of GD3A12), and biotinylated horse-anti-mouse IgG (Vector laboratories, Burlingame, CA). 
After incubation with ABC-reagents (Vectastain ABC anti-mouse-IgG kit, Vector laboratories), 
bound antibodies were visualized using with 3-amino-9-ethylcarbazole. The sections were 
counterstained with hematoxylin and mounted with Kaiser’s glycerol gelatin (Merck, Darm-
stadt,Germany).
Statistics
Data are presented as mean with standard deviation and analyzed using a two-tailed Stu-
dent’s t-test, with P<0.05 considered as significant. 
Results and discussion
To determine the feasibility of GAG extraction/isolation from FFPE tissues we used rat liver 
and skin, and divided the tissues into several pieces which were either formalin-fixed and 
paraffin-embedded, or directly frozen in liquid nitrogen. Optionally, paraffin-embedded tis-
sues were deparaffinated before the start of the procedure (Fig 1a). The procedure comprised 
papain digestion (at 650 C, a temperature at which paraffin melts), trichloroacetic acid pre-
cipitation, anion exchange chromatography and methanol precipitation. Paraffinated, dep-
araffinated and frozen tissues were compared. Applying agarose gel electrophoresis, which 
separates the GAGs into the main classes of chondroitin, dermatan, and heparan sulfate 
(CS/DS/HS), we found that different types of GAGs could indeed be extracted and isolated 
from FFPE tissues (Fig 1b). Skin contained an abundance of DS and a smaller amount of 
HS, whereas liver contained about equal amounts of both. This proportion was similar for 
samples from FFPE tissues compared to frozen tissues. As the size of the GAG chains could 
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Figure 1. Extraction, isolation and structural analysis of glycosaminoglycans (GAGs) from FFPE tis-
sues. (a) Schematic workflow. (b) Compositional analysis by agarose gel electrophoresis (50 ng of GAGs 
was applied). M: markers. (c) Size analysis of  GAG chains by polyacrylamide gel electrophoresis (300 
ng of GAGs was applied). Std: standard (HS from bovine kidney). (d) Domain analysis by ELISA using a 
set of anti-GAG antibodies with GAGs immobilized. (e,f) Compositional disaccharide analysis by HPLC. 
GAGs were enzymatically depolymerized and HS (e) and CS/DS (f) disaccharides were analyzed. Data is 
presented as mean±sd from three independent isolations. For disaccharide abbreviations see supple-
mentary data; HS/CS/DS: heparan/chondroitin/dermatan sulfate.
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be compromised, as is seen with RNA isolated from FFPE tissues (17), GAGs from frozen and 
FFPE samples were analyzed using PAGE (Fig 1c). The size of isolated GAGs from FFPE tissues 
was comparable to that of GAGs from frozen tissues, for liver as well as for skin. To evaluate 
if the GAG domain structure was compromised by FFPE treatment, reactivity with seven 
anti-GAG antibodies, each recognizing different epitopes, was determined using ELISA (Fig 
1d). Similar reactivities were observed for GAGs isolated from FFPE (with or without pre-de-
paraffination) or frozen tissues, for both skin and liver. Two notable differences between 
the GAG composition of liver and skin were the higher reactivity of skin with the anti-DS 
antibody LKN1 and with the anti-HS antibody NS4F5. This reflects the abundance of DS and 
the presence of mast cells in skin. Mast cells contain heparin, a highly sulfated form of HS, 
which is recognized by the antibody NS4F5. The structural composition of GAGs was further 
investigated on the disaccharide level by enzymatic depolymerization using heparinases for 
HS (Fig 1e) and chondroitinase ABC for CS/DS (Fig 1f). The major disaccharide constituents of 
liver HS were UA-GlcNAc, UA-GlcNS, UA2S-GlcNS and UA2S-GlcNS6S (see supplementary data 
for disaccharide abbreviations), in agreement with literature data (18), and their proportions 
were comparable between FFPE and frozen samples (Fig 1e). The major disaccharide (~90%) 
found in CS/DS from skin was UA-GalNAc4S, which is abundantly present in DS (Fig 1f). Again, 
composition was not altered by FFPE treatment. 
As the yield from FFPE tissues as compared to frozen tissues was previously report-
ed to be reduced for DNA (19) and N-linked glycoproteins (3), we determined the concen-
trations of isolated GAGs using the metachromatic dye dimethylmethylene blue. For skin 
266±55 µg GAG/gram wet tissue (mean±sd) was isolated from directly frozen tissue, which 
was not significantly different (P=0.09, n=3) from the amount isolated from deparaffinated 
FFPE skin tissues (387±77 µg GAG/gram wet tissue). However, without deparaffination the 
yield was significantly less compared to frozen tissue (101±33; P=0.01, n=3). For liver a 
direct comparison could not be made since frozen material was homogenized, whereas FFPE 
material was cut into pieces (for skin both frozen and FFPE material were cut into pieces). 
The amount of GAGs isolated from FFPE liver material was 20±6 and 24±3 µg GAG/gram 
wet tissue for tissue with/without pre-deparaffination respectively, and this was significant-
ly less compared to frozen and homogenized material (63.8±24.4; P=0.04, n=3, P=0.05, 
n=3 respectively). Combined, these results indicate that, in case of skin, deparaffination is 
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sufficient to quantitatively extract GAGs compared to frozen tissue, but further adaptation 
may be needed for other tissues. 
In general, FFPE tissues from pathological conditions are precious and extraction 
should ideally be done using minute amounts of material such as present in tissue sections, 
which has the additional advantage that (immuno)histochemistry can be performed on adja-
cent sections. Therefore, sections of (deparaffinated) FFPE mouse skin material were probed 
for GAG isolation. As little as a single 40 µm section of  ~10x4 mm was sufficient to isolate 
and characterize GAGs using agarose gel electrophoresis (Supplementary Fig 2a-c). Encour-
aged by these results, we applied this technique in two different ways. First, GAG com-
position of two specific layers of the human skin, the papillary and reticular dermis, was 
determined using laser-microdissected layers (Supplementary Fig 3). For both layers, DS was 
by far the predominant GAG (agarose gel electrophoresis) and its composition was deter-
mined by CS/DS disaccharide analysis (Fig 2a). It was found that these dermal layers have 
compositional differences, for instance with regard to UA2S-GalNAc4S and UA2S-GalNAc6S. 
Second, GAGs were isolated from tissue sections from two human skin pathologies: psoriasis 
and keloid, and compared to normal skin by agarose gel electrophoresis and by disaccharide 
analysis of CS/DS and HS (Fig 2b-d). As these sections were generally very small (~3x2 mm) 
(Supplementary Fig 4), ten 40 µm sections were used for isolation. Although the size of the 
sections differed, making it difficult to compare the total amount of GAGs, their relative 
distribution could be determined by agarose gel electrophoresis (Fig 2b). In three out of five 
keloid patients there was a clear increase in CS compared to normal skin, in agreement with 
literature (20). In skin from psoriasis patients an increased level of HS and CS was noted. 
Alterations in GAG content and composition have been reported in psoriasis (12). Immuno-
histochemical staining of adjacent sections confirmed the increase in CS in these skin pathol-
ogies (Supplementary Fig 5). In addition, HPLC analysis was performed to evaluate the CS/DS 
and HS disaccharide composition (Fig 2c-d). For CS/DS, the relative amount of UA2S-GalNAc4S 
decreased for both pathologies, whereas UA-GalNAc and UA-GalNAc6S were increased. This 
difference in composition may be explained by the relative increase in CS compared to DS. For 
HS differences were noted as well.  
To summarize, we present a method to extract/isolate high quality GAGs from FFPE 
tissues and show that GAGs are structurally and compositionally comparable to those ob-
tained from frozen tissues. GAGs can be analyzed from as little as one 40 µm tissue section 
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Figure 2. Analysis of glycosaminoglycans (GAGs) from FFPE tissue sections. (a) CS/DS disaccharide 
composition of GAGs from the papillary and reticular skin layer, obtained by laser-microdissection 
(mean ± sd from three different enzyme digestions). (b-d) Composition of GAGs from sections of skin 
from five normal (N1-N5), keloid (K1-K5) and psoriatic (K1-K5) individuals. (b) agarose gel electrophore-
sis (note alterations, indicated by arrows). (c-d) HPLC disaccharide analysis (c, CS/DS; d, HS). Mean±sd 
from 4 (HS) or 5 (CS) individuals per group. HS/CS/DS: heparan/chondroitin/dermatan sulfate. * P<0.05, 
** P<0.01, *** P<0.001.
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and laser-dissected structures can be evaluated as shown for different layers of human skin. 
Pathology associated differences in GAG classes and disaccharide composition were demon-
strated using sections of tissue blocks from diseased skin. The method described enables 
the use of archival FFPE material for the structural characterization of GAGs, and opens new 
avenues to analyze GAGs in pathologies, and correlate this to patient related data.
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Supplementary data
Supplementary Methods
Disaccharide abbreviations 
Heparan sulfate. UA-GlcNAc: Δuronic acid - N-acetylglucosamine; UA-GlcNS: Δuronic acid - 
N-sulfoglucosamine; UA-GlcN: Δuronic acid - glucosamine; UA2S-GlcNAc: 2-O-sulfo-Δuronic 
acid - N-acetylglucosamine; UA2S-GlcNS: 2-O-sulfo-Δuronic acid - N-sulfoglucosamine; UA2S-
GlcN: 2-O-sulfo-Δuronic acid - glucosamine; UA-GlcNAc6S: Δuronic acid - 6-O-sulfo, N-acetyl-
glucosamine; UA-GlcNS6S: Δuronic acid - 6-O-sulfo, N-sulfoglucosamine; UA-GlcN6S: Δuronic 
acid - 6-O-sulfo, glucosamine; UA2S-GlcNAc6S: 2-O-sulfo-Δuronic acid - 6-O-sulfo, N-acetyl-
glucosamine; UA2S-GlcNS6S: 2-O-sulfo-Δuronic acid - 6-O-sulfo, N-sulfoglucosamine; UA2S-
GlcN6S: 2-O-sulfo-Δuronic acid - 6-O-sulfo, glucosamine. Note that the identity of the uronic 
acid, either glucuronic or iduronic acid, cannot be determined because of a C4-C5 double 
bond created by the heparinases.
Chondroitin/dermatan sulfate. UA-GalNAc: Δuronic acid - N-acetylgalactosamine; 
UA-GalNAc4S: Δuronic acid - 4-O-sulfo, N-acetylgalactosamine; UA-GalNAc6S: Δuronic acid 
- 6-O-sulfo, N-acetylgalactosamine; UA-GalNAc4S6S: Δuronic acid - 4-O-sulfo, 6-O-sulfo, 
N-acetylgalactosamine; UA2S-GalNAc4S: 2-O-sulfo-Δuronic acid - 4-O-sulfo, N-acetylga-
lactosamine; UA2S-GalNAc6S: 2-O-sulfo-Δuronic acid - 6-O-sulfo, N-acetylgalactosamine; 
UA2S-GalNAc4S6S: 2-O-sulfo-Δuronic acid - 4-O-sulfo, 6-O-sulfo, N-acetylgalactosamine. Note 
that the identity of the uronic acid, either glucuronic or iduronic acid, cannot be determined 
because of a C4-C5 double bond created by the chondroitinases.
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Supplementary Figure 1. Disaccharide structure of the major classes of sulfated glycosaminoglycans 
(GAGs). The repeating disaccharide structure of heparan sulfate (HS) consists of glucosamine (GlcN) and 
glucuronic acid (GlcA), or its C5 epimer iduronic acid (IdoA) created by the epimerase enzyme. The 
repeating disaccharide structure of chondroitin sulfate (CS) consists of N-acetylgalactosamine (GalNAc) 
and GlcA. Dermatan sulfate (DS) is structurally related to CS, but contains primarily IdoA instead of 
GlcA. GAGs can be variably modified by sulfation by different enzymes at indicated positions.
Supplementary Figure 2. Glycosaminoglycan (GAG) extraction/isolation from one 40 µm section of 
FFPE mouse skin. (a) Agarose gel of 0.5 µl (out of 10 µl total) of GAGs isolated from a single 40 um 
section. The marker (M) contains 10 ng HS, 5 ng CS and 5 ng DS. (b) Macroscopical view of the  paraffin 
block used for sectioning, indicating the size of the section in cm. (c) Adjacent hematoxylin and eosin 
stained section, showing the epidermis (1), dermis (2), subcutaneous fat (3) and muscle layer (4). Scale 
bar = 100 µm. HS/CS/DS: heparan/chondroitin/dermatan sulfate. 
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Supplementary Figure 3. Laser-dissected areas in section of human skin. Deparaffinized human skin 
sections were stained with Mayer’s hematoxylin and the papillary (red line) and reticular (yellow line) 
dermis were separately dissected using a laser-microdissection system.
Supplementary Figure 4. Macroscopical picture of hematoxylin-eosin stained sections adjacent to 
sections used for isolation of glycosaminoglycans (GAGs), indicating the size of the section. Note 
that the order of the different patients (top to down) corresponds to the order on the agarose gel, 
shown in Fig 2b (left to right). Also note that in several cases multiple sections were stained. Scale bar 
= 1 cm.
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Supplementary Figure 5. Sections adjacent to sections used for glycosaminoglycan (GAG) extraction/
isolation and stained with hematoxylin and eosin (HE), and for chondroitin sulfate (CS) and der-
matan sulfate (DS) using specific antibodies. Note the increased CS staining in keloid and -to a lesser 
extent- in psoriasis. Scale bar = 100 µm.
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Abstract
Autotaxin (ATX) is a secreted lysophospholipase D that generates the lipid mediator lyso-
phosphatidic acid (LPA), playing a key role in diverse physiological and pathological process-
es. ATX exists in distinct splice variants, but isoform-specific functions remain elusive. Here 
we characterize the ATXα isoform, which differs from the canonical form (ATXβ) in having 
a 52-residue polybasic insertion of unknown function in the catalytic domain. We find that 
the ATXα insertion is susceptible to cleavage by extracellular furin-like endoproteases, but 
cleaved ATXα remains structurally and functionally intact due to strong interactions within 
the catalytic domain. Through ELISA and surface plasmon resonance assays, we show that 
ATXα binds specifically to heparin with high affinity (K
d 
~10-8 M), whereas ATXβ does not; 
furthermore, heparin moderately enhanced the lysophospholipase D activity of ATXα. We 
further show that ATXα, but not ATXβ, binds abundantly to SKOV3 carcinoma cells. ATXα 
binding was abolished after treating the cells with heparinase III, but not after chondroiti-
nase treatment. Thus, the ATXα insertion constitutes a cleavable heparin-binding domain 
that mediates interaction with heparan sulfate proteoglycans, thereby targeting LPA produc-
tion to the plasma membrane.
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Introduction
Autotaxin (ATX or NPP2 ) is a secreted ectonucleotide pyrophosphatase/phosphodiesterase 
(NPP) that functions as a lysophospholipase D (lysoPLD), converting lysophosphatidylcholine 
(LPC) into the lipid mediator lysophosphatidic acid (LPA) (1-3). LPA, a major serum constitu-
ent, signals through specific G protein-coupled receptors to influence numerous cellular pro-
cesses including cell migration, proliferation and differentiation (3,4). ATX and LPA signaling 
play a vital role in embryonic development (5-7) and are implicated in a wide variety of phys-
iological and pathological processes, as diverse as lymphocyte homing (8,9), neurogenesis 
(10,11), tumor progression (12-14) and fibrosis (15).
Full-length ATX is synthesized as a pre-proenzyme. Upon removal of its N-terminal 
signal peptide followed by N-glycosylation, ATX is further processed by proprotein conver-
tases and secreted via the classical secretory pathway as an active glycoprotein of 110-120 
kDa (16,17). Mature ATX consists of a central phosphodiesterase domain (PDE) flanked by two 
N-terminal somatomedin B-like (SMB) domains and a C-terminal nuclease-like (NUC) domain. 
Structural studies have revealed that the PDE domain contains a deep lipid-binding pocket 
at the active site and a nearby open tunnel that might function as a product release channel 
(18,19). The NUC domain serves to maintain the rigidity of the PDE domain, while the N-ter-
minal SMB domains mediate binding of ATX to activated integrins (18,20). Integrin binding 
localizes ATX to the plasma membrane, thus providing a mechanism to generate LPA in the 
vicinity of its cognate receptors (20,21). Whether ATX uses additional or alternative mecha-
nisms for spatially and temporally restricted LPA production is unknown. 
The intricacy of the ATX-LPA receptor system is further enhanced by alternative 
splicing of ATX mRNA, giving rise to distinct isoforms (3,22,23). However, isoform-specific 
functions of ATX are still largely uncharacterized. The canonical isoform, termed ATXβ, was 
originally cloned from teratocarcinoma cells (3,24) and later found to be identical to plasma 
lysoPLD, accounting for LPA production in the circulation (1,2). Virtually all our current un-
derstanding of ATX is derived from studies on ATXβ. A longer isoform, ATXα, was originally 
isolated as an ‘autocrine motility factor’ from melanoma cells (25) and is characterized by 
a unique 52-residue polybasic insertion of unknown function in the catalytic domain (3,26). 
Conceivably, the ATXα insertion could confer different catalytic activity, cellular localization, 
processing or binding partner preference. On the other hand, it was reported that the inser-
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tion renders ATXα intrinsically unstable and prone to proteolyic degradation, which would 
be a mechanism to rapidly terminate ATXα activity in vivo (22,23).
In the present study, we explore the unique properties of ATXα compared to those 
of ATXβ, guided by the polybasic nature of the ATXα insertion and by the crystal structure of 
ATXβ. We show that the ATXα insertion constitutes a heparin-binding domain that mediates 
specific interaction with cell-surface heparan sulfate (HS) proteoglycans. As such, the inser-
tion functions to direct ATXα to the plasma membrane thereby ensuring localized LPA pro-
duction and signaling. We also show that the insertion is susceptible to processing by (an) 
extracellular furin-like proprotein convertase(s), which might serve to fine-tune the binding 
of ATXα to cell-surface HS proteoglycans. 
Experimental procedures
Cells and Materials
HEK293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% 
(v/v) fetal calf serum. SKOV3 ovarian carcinoma cells were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA) and cultured in McCoy’s 5A medium containing Glu-
taMax (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal calf serum and 1 mM so-
dium pyruvate. The furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone (Dec-RVKR-
CMK) was obtained from Biomol International, recombinant furin from New England Biolabs, 
LPC(18:1) and LPA(18:1) from Avanti Polar Lipids Inc. (Alabaster, AL), and heparin (from por-
cine intestinal mucosa; sodium salt) from Sigma-Aldrich (cat. no. H4784). Heparinase III from 
Flavobacterium heparinum was purchased from IBEX Pharmaceuticals Inc. (Montreal, Quebec, 
Canada). Chondroitinase ABC from Proteus vulgaris (C3667) was obtained from Sigma-Aldrich 
(St Louis, MO). Antibodies used: anti-Myc (9E10, custom made); polyclonal anti-ATX against 
the C-terminal part of ATX (aa 573-588) (Cayman Chemical, Ann Arbor, USA); goat anti-ATX 
IgG  (R&D systems, Minneapolis, USA); monoclonal anti-ATX, 4F1, raised against an N-ter-
minal polypeptide of ATX (aa 58-182) (ref. (27); kindly provided by Dr. Junken Aoki, Tohoku 
University, Sendai, Japan).
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ATX Constructs and Recombinant Protein
For ATX overexpression studies, human ATXβ was ligated in the pcDNA3 vector with a 3’ 
Myc tag, as previously described (28). Human ATXα, ligated in pcDNA3 containing a 3’ Myc/
His tag was a generous gift from Dr. Andree Blaukat (Merck-Serono, Darmstadt, Germany). 
Mutant ATXα(R340A) was generated using the Stratagene site-directed mutagenesis kit, 
with the following primers: p686-forward: GGCTAAGAGACCTAAGGCGAAAGTTGCCCC, and 
p687-reverse: GGGGCAACTTTCGCCTTAGGTCTCTTAGCC). For production of recombinant pro-
tein, ATXα and ATXβ were ligated in pcDNA5-FRT (Invitrogen) with a C-terminal Myc-tag and 
a 6xHis-tag. HEK293 cells stably expressing ATXα or ATXβ were generated using the FLPin 
system (Invitrogen). Recombinant His-tagged ATX was purified from conditioned HEK293 
medium using POROS-20 MC columns pre-loaded with Ni2+, as previously described (29). The 
column was washed with eight to ten column volumes of buffer A (20 mM Tris-HCl pH 8.0, 
150 mM NaCl and 20 mM imidazole). ATX protein was eluted with a linear gradient of buffer 
A containing 750 mM imidazole.
Expression Analysis 
Cells were grown to confluency and total RNA was extracted using the RNeasy mini kit and 
column DNase treatment (Qiagen). First strand cDNA synthesis was performed using 2 ug 
total RNA, 0.5 ug oligo-dT primers (Promega), 500 nM dNTPs (Roche), 40 units RNAsin (Prome-
ga), 10 mM DTT (Invitrogen) and 200 units Superscript II RT. Quantitative ATX expression 
was measured using the TaqMan gene expression probe Hs00196470_m1 in an ABI 7500 Fast 
Sequence Detection System (Applied Biosystems). Cycling parameters were: 10 min. at 95°C 
followed by 40 cycles of 15 sec. at 95°C and 1 min. at 60°C. The relative product levels were 
quantified using the ddCt method and were normalized to GAPDH expression. Expression 
of the ATXα and ATX β isoforms was measured by RT-PCR using primers (forward 5’-AT-
TACAGCCACCAAGCAAGG-3’ and reverse 5’-TCCCTCAGAGGATTTGTCAT-‘3) located around the 
ATXα-specific insertion, resulting in a 209 bp fragment for ATXα and a 366 bp fragment for 
ATX β. Human plasmid DNA was used to confirm the specificity of the primers, which were 
species-independent.
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Transfection and Western Blotting
HEK293 cells were transfected with ATX constructs using the calcium phosphate method. At 
24 hrs after transfection, cells were incubated in serum-free DMEM for 48 hrs. Conditioned 
medium was centrifuged (5000 rpm for 30 min.) to remove cell debris. Samples were analyz-
ed by gel electrophoresis using NuPAGE 4-12% Bis-Tris gels (Invitrogen) under either reducing 
or non-reducing conditions. For Western blot analysis, nitrocellulose filters were blocked 
using 5% non-fat powdered milk and probed with primary antibodies, followed by HRP-con-
jugated secondary antibodies (Dako, Glostrup, Denmark) and proteins were visualized using 
ECL detection (Amersham, Arlington Heights, IL).
Cell Migration
Chemotactic migration of human A2058 melanoma cells was measured in 48-wells Boyden 
chambers (Neuroprobe) as described previously (30). Filters (8 µm pores) were coated with 
gelatin and cells were serum starved overnight, trypsinized and seeded in the upper cham-
ber. ATX (2 ng/ml) was added to the bottom chamber in the presence of 2 mM LPC(18:1) and 1 
mg/ml fatty acid- free BSA. After 4 hrs, cells at the top side were removed and migrated cells 
at the bottom side of the filter were fixed, stained and quantified.
Immunofluorescence
HEK293 cells were transfected with C-terminally Myc-tagged ATXα or ATXβ. At 24 hrs after 
transfection, cells were fixed with ice-cold ethanol and ATX was visualized by confocal mi-
croscopy using anti-Myc antibody (9E10) and anti-mouse Alexa488. 
ATX Activity Assays
To measure lysoPLD activity, LPC(18:1) was used as substrate in 50 mM Tris (pH 7.4), 0.01% 
Triton X-100, 25 mM CaCl
2
, containing 2.5 mM homovanillic acid, 2 units ml-1 horseradish 
peroxidase, 2 units/ml choline oxidase, essentially as described (31). After addition of re-
combinant ATX, the increase in fluorescence was monitored at 37°C (excitation/emission: 
355/460 nm) as described (28,31). Nucleotide phosphodiesterase activity was measured us-
ing pNP-TMP (Sigma-Aldrich) as substrate in 50 mM Tris (pH 7.8), 140 mM NaCl, 5 mM KCl, 1 
mM CaCl
2
, 1 mM MgCl
2
, 1 mg ml-1 fatty-acid free BSA. After addition of recombinant ATX, the 
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amount of liberated para-nitrophenolate (pNP) was determined by the absorbance at 405 nm, 
as described (28). Michaelis-Menten kinetic parameters were determined using GraphPad 
Prism software.
ELISA
Binding of ATX (α or β) to heparin was evaluated by ELISA in two ways: first, application of 
ATX to heparin-coated wells of microtiter plates; and second, competition assays in which 
ATX was first incubated with heparin and then transferred to a heparin-coated plate. A 96-
well flat-bottom plate was incubated for 16 h with 100 µl of 10 µg ml-1 heparin in coating 
buffer. As a control, wells were coated for 16 h with 1 µg ml-1 ATX in 0.05 M carbonate- bi-
carbonate buffer (Sigma-Aldrich). After blocking with PBS containing 2% BSA (w/v) for 1 h, 
1 µg ml-1 ATX (in PBS containing 2% BSA) was added and incubated for 2 hrs. Plates were 
washed six times with PBS and bound ATX was detected using goat anti-ATX IgG  (1:200; R&D 
systems), followed by incubation with alkaline phosphatase-conjugated rabbit anti-goat IgG 
(1:2000; Sigma-Aldrich), both for 1 hr. Plates were washed six times with PBS, and enzyme ac-
tivity was detected using 100 µl of a p-nitrophenyl phosphate solution (1 mg ml-1) containing 
1 M diethanolamine and 0.5 mM MgCl
2
 (pH 9.8). Absorbance was measured at 405 nm. For 
the competition assay, 0.1 µg ml-1 ATX was incubated with an increasing content of heparin 
(0-1 mg ml-1) for 1 h in 100 µl and transferred to a 96-well plate previously coated with hepa-
rin. Plates were washed six times with PBS before measuring bound ATX, as described above.
Surface Plasmon Resonance assays
ATX binding to heparin was measured by surface plasmon resonance spectroscopy using a 
Biacore T100 machine (Biacore, GE Healthcare). Recombinant ATXα and ATXβ were covalent-
ly coupled to separate flow cells of a CM5 sensor chip at pH 4.0 at roughly equal amounts 
(about 10,000 response units). Increasing concentration of unfractionated heparin in running 
buffer (150 mM NaCl, 20 mM Hepes pH 7.6) were injected across the chip at flow rate of 50 µl/
min. Injection of 1 M NaCl was used to regenerate the chip surface at the end of each cycle. 
The response units (RUs) for the binding of heparin were evaluated after subtraction of the 
signal in a flow cell of the same sensor chip which has been left uncoated. To determine the 
apparent dissociation constant (), the background-subtracted data were fit using a model in 
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which the total binding results from specific binding plus a linear nonspecific component 
and a concentration-independent background according to the equation:
where c is the protein concentration, the observed response for that specific concentration, 
the estimated maximal response,  the slope of the linear nonspecific components and the 
estimated background. The values for non-specific binding and the background ( and  ) were 
kept the same for both ATXα and ATXβ binding, and only the  value was fit individually for 
each protein. The model used was judged to be 99.9% more probable than a model assuming 
only specific binding, according to the Akaike information criterion (AIC). Analysis was per-
formed with GraphPad software, using an average MW value for heparin of 15 kDa.
Flow Cytometry
For flow cytometry assays, SKOV3 cells were detached by enzyme-free cell dissociation solu-
tion (Millipore; Billerica, MA) and kept on ice for the remaining of the procedure. To establish 
ATX (α or β) binding capacity, cells were incubated with 3 µg ATX ml-1. Bound ATX was de-
tected by a goat anti-ATX IgG antibody (1:50; R&D systems) and an Alexa488 fluorochrome 
conjugated anti-goat IgG antibody (1:100; Invitrogen). To determine heparan sulfate or chon-
droitin/dermatan sulfate dependency, cells were predigested with 20 mIU heparinase III  or 
100 mIU chondroitinase ABC, respectively,  ml-1 basal culture medium containing 1% FCS for 2 
h at 4°C. Omission of the first antibody was used as a negative control. Flow cytometry anal-
yses were performed using a Beckton Dickinson FACSscan or FACScalibur. Viable cells were 
gated using forward and side scatter, and the fluorescence of this population was measured. 
Results and discussion 
ATXα: Structure and Expression 
The mammalian ATX gene is organized in 27 exons. The three best known splice variants of 
ATX, termed α, β and γ, differ by the presence or absence of sequences encoded by exons 12 
and 21 (Fig. 1A). ATXα contains an exon 12-encoded region of 52 residues in the PDE domain. 
The canonical ATXβ isoform lacks exons 12 and 21, while the ‘brain-specific’ ATXγ isoform 
(formerly PD-1a) contains a 25-aa insertion encoded by exon 21 in the NUC domain (32,33). A 
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Figure 1. ATX α, β and γ isoforms: domain architecture and structure. (A) The α, β and γ isoforms 
of ATX differ by the absence or presence of exon 12 or 21. All isoforms share the same domain archi-
tecture of two N-terminal somatomedin B-like domains (SMB-1 and SMB-2), a central phosphodiester 
domain (PDE) with the catalytic residue T210, a C-terminal nuclease-like domain (NUC) and a ‘lasso’ 
loop connecting the PDE and NUC domains. ATXβ is the canonical isoform. ATXα contains a 52-residue 
insertionion (aa 325-376) in the catalytic domain containing a proteolytic site at R340 (see Fig. 1B). 
ATXγ contains a 25-residue insertionion (aa 594-618), encoded by exon 21, in the NUC domain. Tran-
script ID: ENST00000259486 (ATXα), ENST00000075322 (ATXβ), ENST00000522826 (ATXγ). (B) Amino 
acid sequence of the ATXα insertion. Basic residues are indicated in blue. A consensus furin cleavage 
site (R-x-K/R-R) is located between residues R340 and K341 (arrow). (C) The crystal structure of ATXβ 
(18) with the ATXα-specific insertion shown as a flexible loop protruding out of the PDE domain. Do-
main colors are the same as in Fig. 1A. LPA (blue-green), the phosphate (orange), the zinc ions (yellow 
spheres) bound to the active site, and the EF hand-bound calcium ion (blue sphere) are shown in stick-
and-sphere representation. The figure was prepared using Pymol (www.pymol.org).
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recently identified fourth isoform, termed ATXδ, is identical to ATXβ except for a four-residue 
deletion in the region that links the NUC and PDE domain (23). 
Here we explore the properties of ATXα relative to those of ATXβ. The 52-aa in-
sertion in ATXα is highly basic with a calculated pI~11.5. Sequence inspection revealed a 
consensus cleavage site for furin and furin-like endoproteases (target sequence R-x-K/R-R; ref. 
(34)) between residues R340 and K341 (Fig. 1B). Cleavage of ATXα at R340 by (an) unidentified 
protease(s) was observed in a previous study (22). Furthermore, we noticed that the insertion 
contains putative heparin-binding motifs, which are commonly characterized by clusters of 
basic residues (Fig. 1B, indicated in blue). The crystal structure of ATXβ (refs. (18,19)) allowed 
us to understand the localization of the insertion in ATXα. The insertion is predicted to be 
unstructured and solvent exposed, starting right before an a-helix in the PDE domain (a-helix 
no. 10; ref. (18)). In Fig. 1C, it is depicted as a flexible, hydrophilic loop that protrudes out 
of the PDE domain, pointing away from the catalytic site and the substrate binding pocket. 
However, we cannot rule out the possibility that the insertion adopts a more ordered confor-
mation and might interact with the ATX surface. Given its location and hydrophilic nature, 
the insertion loop is unlikely to affect the tertiary structure of the ATXα catalytic domain.
We examined ATX expression in various tissues and cell lines. In agreement with 
previous studies (3,8,22) and publicly available expression data (35), highest ATX mRNA ex-
pression (all isoforms) was found in brain, kidney, spleen and lung, and somewhat lower 
expression in liver, skin and adipose tissue (Fig. 2A). ATXα mRNA has been detected in kidney 
and liver (22) as well as in melanoma (25) and non-small-cell lung cancer cells (36), but oth-
erwise ATXα is much less widely expressed than ATXβ. We detected ATXα mRNA in human 
skin fibroblasts (HF cells) and glioblastoma cells (SNB-78 and U-138) as well as in mouse skin 
(Fig. 2B), presumably reflecting expression in dermal fibroblasts since skin-derived keratino-
cytes lacked detectable ATXα (data not shown). ATXα-specific antibodies raised against se-
quences in the insertion recognized overexpressed ATXα in HEK293 cells, but unfortunately 
they failed to detect endogenous ATXα in selected cell lines (LvM, unpublished results).
It is of note that ATXα was consistently found co-expressed with ATXβ in the cell 
lines and tissues examined (Fig. 2B). We therefore examined whether both isoforms might 
interact, but co-immunoprecipitation studies using transfected HEK293 cells did not support 
this possibility (data not shown). In transfected cells, ATXα and ATXβ showed a similar local-
171
The polybasic insertion in autotaxin-a confers specific binding 
to heparin and cell-surface heparan sulfate proteoglycans
Figure 2. ATX expression. (A) Quantitative PCR analysis of total ATX mRNA (all isoforms) relative to 
GAPDH expression in various mouse tissues. (B) RT-PCR analysis of ATXα and ATXβ expression in hu-
man cell lines and mouse tissues. Plasmid DNA analysis (upper left panel) confirms specificity of the 
primers. Cell lines used: SNB78 and U-138, glioblastoma; MDA-MB-435, melanoma; HF, foreskin fibro-
blasts. PCR primers were designed based on sequences around the ATXα-specific insertion, resulting 
in an isoform-discriminative PCR. (C) Subcellular localization of  ATXα and ATXβ (C-terminally Myc-
tagged) in transfected HEK293 cells.
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ization pattern in intracellular vesicles, consistent with both isoforms following the classical 
trafficking route prior to secretion (Fig. 2C).
Furin-Mediated Cleavage of the Insertion at R340
It was previously reported that the insertion renders ATXα unstable and prone to proteolyic 
degradation in vivo (22,23). We examined the expression of both ATXα and ATXβ in HEK293 
cells under reducing and non-reducing conditions. When analyzed by reducing SDS-PAGE, 
secreted ATXα was consistently detected not only as a ~120 kDa protein but also as two 
cleavage fragments of ~70 kDa and ~40 kDa, as shown by using antibodies against the 
C- and N-terminal parts, respectively (Fig. 3A). In contrast, ATXβ was always detected as the 
full-length protein (Fig. 3A). This result is consistent with secreted ATXα being cleaved at the 
furin consensus site (R340). Indeed, mutant ATXα(R340A) was resistant to proteolysis while 
treatment of ATXα-expressing cells with a specific inhibitor of furin and furin-like endopro-
teases (decanoyl-Arg-Val-Lys-Arg-chloromethylketone (37)) prevented proteolysis. Further-
more, addition of recombinant furin caused a nearly complete cleavage of full-length ATXα, 
but left ATXα(R340A) and ATXβ intact (Fig. 3A). Importantly, ATXα cleavage was detected 
only in the medium but not in cell lysates (Fig. 3A), indicating that proteolytic processing 
occurs extracellularly rather than along the intracellular trafficking route. Although furin 
and furin-like proprotein convertases predominantly reside in the trans-Golgi network, they 
can also traffic to the cell surface and be shed or secreted into the extracellular milieu (38,39). 
In particular, furin and its relatives PC5 and PACE4 are known to be secreted and to process 
diverse extracellular substrates, including growth factors, receptors and metalloproteinases 
(38-41). Which of the secreted furin family members may preferentially attack the ATXα in-
sertion remains to be determined. 
As shown in Fig. 3B, ATXα fragmentation was not observed under non-reducing 
conditions (Fig. 3B). Thus, furin-mediated cleavage at R340 leaves ATXα fully intact. As can 
be inferred from the structure (Fig. 3C), cleavage at R340 leaves the N- and C-terminal parts 
tightly together due to an extended interaction surface area between both parts (10,980 Ǻ2; 
as calculated by PISA (42)). The stability of the interface is primarily due to van der Waals 
interactions (-76 kcal mol-1) and numerous hydrogen bonds (-69 kcal mol-1), as revealed by 
FoldX analysis (43). Stability is further reinforced by ionic interactions (-12 kcal mol-1) and a 
disulfide linkage between Cys157and Cys403 (-3 kcal mol-1) (Fig. 3C). It thus appear that the 
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Figure 3. Cleavage of the ATXα insertion by furin. (A) Western blot analysis of conditioned media from 
HEK293 cells expressing ATXb (lane 1), ATXα (lanes 2, 4, 6) or mutant ATXα(R340A) (lanes 3, 5, 7). Cleaved 
ATXα was detected in the medium (upper two panels), but not in cell lysates (lower panel). Cells were 
treated with the furin inhibitor Dec-RVKR-CMK overnight (10 mM) (lanes 4 and 5). Conditioned medium 
was treated with recombinant furin for 1 hr at 37°C (lanes 6 and 7). Antibodies used: anti-ATX C-term 
(polyclonal; Cayman) ) and anti-ATX N-term (monoclonal 4F1). The residual faint bands observed in 
lanes 3, 4, 5 and 7 may be attributable to ATXα cleavage at non-optimal cleavage sites present in the 
insertion. (B) Detection of HEK293 cell-conditioned media containing ATXα or ATXβ under reducing 
and non-reducing SDS-PAGE conditions. ATXα cleavage is not observed under non-reducing conditions. 
Antibody: polyclonal anti-ATX C-term (Cayman). (C) The crystal structure of ATXβ with the ATXα inser-
tion superimposed. The N-terminal cleavage fragment is depicted in light grey, the C-terminal fragment 
in dark grey. The lipid binding pocket is composed by residues in both halves. LPA is depicted in the 
binding pocket. The disulfide bridge Cys157-Cys403 connects the two fragments. The model was tilted 
90°C on the x-axis compared to Fig. 1B to emphasize the extended interface between the two cleavage 
fragments. The polybasic insertion of ATXα protrudes into the direction of the viewing plane, depicted 
by its first and last amino acid (aa 325 and 376, respectively).  
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N- an C-terminal parts of cleaved ATXα form a very stable structure (calculated free energy 
of dissociation >100 kcal mol-1) that can only be separated under reducing SDS-PAGE condi-
tions. These results refute previous notions that the ATXα isoform is unstable and rapidly 
degraded in vivo (22,23).
ATX Catalysis
We examined the kinetic parameters of ATXα versus ATXβ, using LPA(18:1) and the nucle-
otide derivative p-nitrophenyl thymidine 5’-monophosphate (pNP-TMP) as substrates. As 
shown in Fig. 4A, the catalytic efficiency (V
max
/K
m
) of ATXα towards LPC was about 70% of 
that of ATXβ, due to a lower V
max
 value (Fig. 4A). Treatment of ATXα with recombinant furin 
Figure 4. LysoPLD activity of ATXα relative to ATXβ. (A) LysoPLD activity of ATXα (red) and ATXβ (blue) 
at increasing concentrations of LPC(18:1). (B) LysoPLD activity of ATXα before and after treatment with 
recombinant furin. Data in (A) and (B) are expressed as means ± SD of three replicates and are repre-
sentative of two independent experiments. (C) Chemotactic activity of ATXα and ATXβ as measured by 
the transwell migration of A2058 melanoma cells (during 4 hrs) using 2 nM recombinant ATX in the 
presence of 2 mM LPC. LPA (1 mM) was used as a positive control and LPC (1 mM) as a negative control
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(to fully cleave the insertion) did not affect lysoPLD activity (Fig. 4B). Moreover, ATXα and 
ATXβ (at 2 nM) were equally effective in stimulating the transwell migration of A2058 mel-
anoma cells in the presence of 2 mM LPC during a 4-hrs time period (Fig. 4C). From these 
results, we conclude that ATXα and ATXβ show roughly similar LPC-hydrolyzing efficiency, 
regardless of the cleavage state of ATXα.
However, the catalytic efficiency of ATXα towards pNP-TMP was about 5-fold  lower 
than that of ATXβ due to a much lower V
max
 (Fig. 5A). We have currently no structural data 
that can explain this observation. LPA inhibited pNP-TMP hydrolysis by ATXα and ATXβ with 
K
i
 values of 50 nM and 110 nM, respectively, suggesting that the insertion may exert a moder-
ately positive effect on LPA binding affinity (Fig. 5B; see also (28)). Finally, both isoforms were 
equally sensitive to the ATX inhibitor HA130 (ref. (31); data not shown). 
ATXα Binds Specifically to Heparin
The positively charged Lys/Arg clusters in the ATXα insertion (Fig. 1B) could confer binding 
to heparin, possibly in a cooperative manner (44,45). Heparin is structurally very similar to 
heparan sulfate (HS), which is ubiquitously expressed as proteoglycans on cell surfaces and 
in extracellular matrices, where it recruits growth factors, chemokines and other molecules 
Figure 5.  Nucleotide phosphodiesterase activity of ATXα relative to ATXβ. (A) Posphodiesterase 
activity of ATXα and ATXβ at increasing concentrations of pNP-TMP. (B) LPA-induced inhibition of ATX 
activity towards 1 mM pNP-TMP. Based on the indicated IC
50
 values, the Ki values were calculated as 50 
nM and 110 nM for ATXα and ATXβ, respectively. Data are the means ± SD  of three replicates and are 
representative of two independent experiments.
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to fine-tune signaling events under both physiological and pathophysiological conditions 
(46-48). High-affinity binding of ATX to heparin in vitro could point to an HS-mediated mech-
anism for localized LPA production in vivo.
We first determined the binding of ATXα and ATXβ to unfractionated heparin (from 
intestinal mucosa) using ELISA, in which recombinant ATX was added to heparin-coated 
wells. We found that ATXα binds strongly to immobilized heparin, whereas ATXβ hardly did 
(Fig. 6A). As a control for specificity, both isoforms were immobilized directly to the wells 
(without prior heparin coating), which gave similar readings for both isoforms (Fig. 6A). 
In addition, we used a competition ELISA, in which ATX was pre-incubated with various 
amounts of soluble heparin prior to addition to heparin-coated wells. We observed a dose-de-
pendent inhibition of ATXα binding to immobilized heparin (IC
50 
~4.5 mg/ml or 300 nM), 
confirming that the observed ATXα-heparin interaction is specific (Fig. 6B).
We next examined ATX-heparin binding using surface plasmon resonance, in which 
recombinant ATX was immobilized and heparin was used as the analyte. Again, we found 
that ATXα  binds heparin much stronger than does ATXβ (Fig. 7A-C). As shown in Fig. 7A, 
Figure 6. ATX binding to immobilized heparin measured by ELISA. (A) ATXα and ATXβ were applied 
to heparin-coated wells as detailed under Exp. Procedures. Left panel: ATXα binds strongly to heparin, 
whereas ATXβ does not. Right panel: control experiments in which ATXα and β were directly immo-
bilized to the wells (without heparin), which gave similar readings for both isoforms. (B) Competition 
ELISA. ATXα and ATXβ were pre-incubated with various amounts of heparin prior to application to hep-
arin-coated wells. Binding of ATXα to immobilized heparin was inhibited by pre-incubation with hep-
arin in a dose-dependent manner (IC
50 
~ 300 nM, based on a MW of unfractionated heparin of 15 kDa).
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heparin binds to ATXα rapidly and dissociates slowly, consistent with specific binding. In 
contrast, ATXβ showed very fast heparin binding and dissociation kinetics (Fig. 7B), sug-
gestive of non-specific binding dominated by electrostatic interactions. On the basis of an 
average MW of heparin of 15 kDa, we determined the apparent K
d
 of ATXα for heparin to 
be approx. 10 nM. The K
d
 of ATXβ could not reliably be determined since heparin binding 
did not reach a plateau; however, it is at least 10-fold lower than that of ATXα (Fig. 7C). We 
conclude that the insertion of ATXα confers saturable, high-affinity binding to heparin with 
a slow dissociation rate.
Figure 7. ATX binding to soluble heparin measured by surface plasmon resonance. (A), (B). Surface 
plasmon resonance analysis of ATX binding to heparin. Sensorgrams of heparin binding to immobilized 
ATXα and ATXβ, respectively. Heparin concentrations are based on a MW of unfractionated heparin of 
15 kDa. (C) Heparin saturation binding plot of ATXα (red) and ATXβ (blue). The inset shows the expo-
nential, saturable heparin-binding curve (red) and a linear component (blue; non-specific binding). The 
data were fit as described in Exp. Procedures. Error bars correspond to the SD for a duplicate experi-
ment. (D) Surface representation of ATXα indicating the electrostatic potential (-65 to +65 kT; positive 
charges in blue, negative charges in red). The polybasic insertion of ATXα may cover a negative patch 
and might even extend the long positive patch running vertically over the protein. The figure was pre-
pared using Pymol (www.pymol.org).
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An electrostatic surface charge representation of ATX sheds some light on how and 
where heparin may bind (Fig. 7D). The model shows several positively charged patches com-
mon to both isoforms. It is seen that the basic insertion of ATXα is located close to one 
of those patches in the catalytic domain (Fig. 7D), suggesting that the insertion and the 
positively charged surface patch might act in a cooperative manner to enhance binding to 
heparin/HS. Co-crystallization studies using defined heparin/HS fragments should help to 
test this scenario and, furthermore, uncover to what extent proteolytic cleavage at R340 may 
affect heparin binding.
We also tested whether heparin may affect the catalytic activity ATXα. As illustrat-
ed in Fig. 8, heparin enhanced the lysoPLD activity of ATXα towards LPC(18:1) up to two-fold 
in a concentration-dependent manner (EC
50 
~100 nM). In contrast, heparin had little or no 
effect on the lysoPLD activity of ATXβ. 
ATXα Binds to Cell-Surface HS Proteoglycans
The observed high-affinity binding of ATXα to heparin strongly suggests that this isoform 
preferentially interacts with HS proteoglycans, as a means to target LPA production to the 
cell surface. Although heparin and HS are structurally similar, HS is less negatively charged 
and shows more structural hetereogeneity compared to heparin. We measured the binding 
of both ATXα and ATXβ to SKOV3 ovarian carcinoma cells, which have a well-characterized 
Figure 8. Effect of heparin on ATX lysoPLD activity. LysoPLD activity of ATXα (red) and ATXβ (blue) 
using LPC (150 mM; albumin-bound) as a substrate and increasing concentrations of heparin. Half-max-
imal effect was observed at ~100 nM (based on a MW of heparin of 15 kDa). Data are means ± SD of 
three independent experiments.
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glycosaminoglycan expression pattern (49-51). Flow cytometry analysis shows that ATXα 
binds abundantly to the cell surface of SKOV3 cells, whereas ATXβ does not (Fig. 9A,B). Cell 
binding was strictly dependent on HS, since pretreatment of the cells with the HS-degrading 
enzyme heparinase III almost completely abolished ATXα binding. Binding was HS-specific in 
that digestion of cell-associated chondroitin/dermatan sulfate, another class of highly sulfat-
ed glycosaminoglycans, did not affect ATXα binding (Fig. 9). Since heparin stimulates ATXα 
activity in vitro (Fig. 8), binding of ATXα to HS proteoglycans may serve not only to target 
LPA production to the plasma membrane, but also to locally increase the catalytic efficiency 
of this particular isoform.
In conclusion, our study is the first to define an isoform-specific function for ATX. 
The polybasic insertion of ATXα constitutes a heparin-binding region that targets ATX ac-
tivity to the plasma membrane via binding to cell-surface HS proteoglycans. Previous stud-
ies have established that ATX binds to activated integrins via its N-terminal SMB domains, 
which provides one mechanism for localized production of LPA close to its cognate receptors 
(18,20). Binding of ATXα to cell-surface HS proteoglycans via its unique polybasic insertion 
represents an additional, isoform-specific mechanism for spatially and temporally restricted 
LPA production (21). Future studies should explore to what extent furin-mediated cleavage 
of the insertion may modulate its heparin/HS-binding properties, either positively or nega-
tively, and assess whether ATXα, HS and a furin-like protease can be detected in a ternary 
complex at the cell surface.
Figure 9. ATX binding to human carcinoma cells. ATXα binds abundantly to SKOV3 ovarian carcino-
ma cells (A), whereas ATXβ  does not (B), as measured by flow cytometry. ATXα binding was strongly 
reduced by predigestion of cell-associated heparan sulfates using heparinase III (Hep3), but not after 
digestion of chondroitin/dermatan sulfates using chondroitinase ABC (ChABC). For technical details see 
Exp. Procedures. 
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Summary
An overview of the current literature concerning the role of heparan sulfate (HS) in angiogen-
esis, and the aims and outline of thesis were given in chapter 1. The interaction of HS with 
pro-angiogenic factors as FGF-2 and VEGF, and its consequent role in angiogenesis, renders 
HS an excellent target for anti-angiogenic therapy, e.g. in cancer. This provided a framework 
for the following chapters, in which sugar analogs were tested for their ability to inhibit 
and/or modify HS biosynthesis and angiogenesis. In addition, the chemical biology of HS 
was further explored by the development of new tools, and the identification of a novel HS 
binding partner.
Chapter 2 described the synthesis and use of a 4-deoxy sugar analog, 4-deoxy-Gl-
cNAc. This analog was chosen as possible incorporation into HS blocks chain elongation due 
to the lack of the OH-group required for glycosidic bond formation. 4-deoxy-GlcNAc inhibited 
HS expression of multiple cell lines, reduced binding of the HS dependent growth factors 
FGF-2 and VEGF, and diminished FGF-2 induced sprouting of endothelial cells.
This work provided the basis for the research described in Chapter 3. 4-deoxy-Gl-
cNAc was peracetylated to enhance cellular entry. An IC
50
 value of 16 µM for inhibiting HS 
expression in SKOV3 ovarian carcinoma cells, and a 93% decrease at 50 µM, was described. 
Surprisingly, although 4-deoxy-GlcNAc was transformed in cells into its activated nucleotide 
sugar, UDP-4-deoxy-GlcNAc, it was not incorporated into HS. Rather, it decreased cellular 
levels of UDP-GlcNAc. The effect of 4-deoxy-GlcNAc on cellular processes, as determined by 
microarray analysis, showed that expression of genes regulated by HS binding growth fac-
tors as FGF-2 and VEGF was inhibited. This warranted a further examination of inhibition 
of HS biosynthesis and angiogenesis by 4-deoxy-GlcNAc in vivo. Micro-injection in zebrafish 
embryos strongly reduced HS biosynthesis, and treatment with 4-deoxy-GlcNAc reduced an-
giogenesis in models of the zebrafish and chicken embryo.
Chapter 4 described the effect of another sugar analog, 6F-GalNAc, aimed at inhibi-
tion of 6O-sulfation of glycosaminoglycans (GAGs), an important modification for pro-angi-
ogenic signaling. Analogous to 4-deoxy-GlcNAc, 6F-GalNAc was transformed in cells into its 
activated nucleotide sugar, but was not incorporated into GAGs. Although this sugar analog 
was not aimed to inhibit glycosidic bond formation, we observed a reduction in GAG expres-
sion, probably due to reduced cellular levels of UDP-GlcNAc and UDP-GalNAc. We concluded 
that overall the effects of 6F-GalNAc were very similar to those observed for 4-deoxy-GlcNAc 
187
Summary and future directions | Nederlandse samenvatting en toekomstvisie
and other sugar analogs described in literature, indicating a possible general mechanism of 
action of sugar analogs. 
Chapter 5 described how re-synthesis of HS after inhibition by 4-deoxy-GlcNAc, and 
limited HS degradation by heparinases, together with a set of anti-HS antibodies, were used 
as a tool to ‘immunosequence’ HS. Antibody NS4F5, which recognizes highly sulfated HS, 
was found closest to the non-reducing end of HS, a region important for FGF-2 signaling.  
Chapter 6 described the development of a procedure to extract GAGs from forma-
lin-fixed, paraffin-embedded (FFPE) tissues. GAGs extracted from FFPE tissues were struc-
turally similar to GAGs extracted from frozen tissues. This allowed the use of FFPE samples 
stored abundantly in hospitals worldwide for structural GAG analysis. This chapter described 
two examples: the analysis of different human skin layers, separated by laser microdissec-
tion, and the analysis of human pathological skin, keloid and psoriasis. 
Chapter 7 focused on the relation of HS and the long isoform of autotaxin (ATXα), an 
enzyme generating a lipid mediator (LPA) important in a range of cellular processes, includ-
ing migration and proliferation. This longer splice variant contains a polybasic insertion of 
which the function was previously unknown. In this chapter, binding of this longer isoform 
to heparin and HS was described. Binding to HS might represent a new isoform specific 
mechanism for localized LPA production close to its cognate receptors.
General conclusions and future directions
GlcNAc/GalNAc sugar analogs were shown in this thesis to inhibit GAG biosynthesis, and an-
giogenesis in developmental models. Future studies should focus on the feasibility of these 
sugar analogs for inhibition of pathological angiogenesis, e.g. tumor angiogenesis. Consid-
ering the role of GAGs in physiology, care should be taken when applying therapies based on 
GAG biosynthesis inhibition. However, our observation that zebrafish embryos displaying 
a ~87% reduction of cell surface HS appeared to be grossly morphological normal might 
indicate that modulation of GAG biosynthesis to a certain extent is feasible. GlcNAc/GalNAc 
sugar analogs by itself are little celltype-specific and future studies should investigate target-
ed delivery to (tumor) endothelial cells, e.g. by liposomes, to enhance biological effects and 
reduce possible toxicity. In addition, this could increase plasma half-life (a half-life of ~2.3 
hours in mouse plasma was reported for peracetylated 4F-GlcNAc (1)). Besides angiogenesis, 
inhibition of HS biosynthesis by sugar analogs might prove useful in other HS related diseas-
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es. For example, in mucopolysaccharidosis, a group of lysosomal storage disorders caused by 
dysfunctional lysosomal degradation of GAGs, sugar analogs could be used as a novel way of 
substrate reduction therapy.
Although 6F-GalNAc was not incorporated into GAGs, GAG 6O-sulfation is still an 
attractive target for inhibition of angiogenesis and should be explored by the development of 
specific HS 6O-sulfotransferase inhibitors. This may be done by screening large small-mole-
cule libraries. The non-reducing end of HS might be another attractive target as is it proposed 
to be involved in FGF-2 signaling. Therefore further studies could also address whether anti-
body NS4F5 competes for HS binding with growth factors as FGF-2, and whether NS4F5 could 
specifically block ternary complex (FGF-2, FGFR1, HS) formation. 
Exactly how sugar analogs function to reduce glycan biosynthesis has been, and 
still is, debated in literature. Earlier work reported glycoprotein incorporation of radiolabeled 
peracetylated 4F-GlcNAc (2), but incorporation was not found by mass spectrometry analysis 
in later studies (3,4). Incorporation was also not observed for 4-deoxy-GlcNAc and 6F-GalNAc 
in this thesis. In addition, our and other studies (3-6) indicate that treatment with sugar 
analogs reduces levels of natural nucleotide activated sugars. It has been proposed that this 
is due to the analog acting as a ‘decoy’ substrate diverting synthesis from the natural sugar 
(3), or by the inhibition of de novo synthesis of natural nucleotide activated sugars by a feed-
back mechanism induced by activated analog accumulation (5). Whether reduction of natural 
nucleotide activated sugars fully accounts for reduced glycan expression has been debated 
(6,7) and activated analogs can inhibit glysoyltransferase activity as well (5). Therefore, the 
exact mechanism how 4-deoxy-GlcNAc and 6F-GalNAc reduce levels of natural UDP-GlcNAc/
UDP-GalNAc, whether glycosyltransferase activity is inhibited by the activated analogs, and 
the exact contribution of these mechanisms on the formation of different glycans should 
be the focus of future work. This will further enhance the understanding of sugar analog 
functioning within cells, and could clarify common and analog specific inhibition of glycan 
expression. In addition, effects of 4-deoxy-GlcNAc and 6F-GalNAc on processes other than 
angiogenesis, either GAG-mediated, e.g. lipoprotein uptake, or non-GAG mediated, O-GlcNAc 
protein modification, might be further explored. Also processing and trafficking of some HS 
proteoglycans could be disturbed as a result of HS biosynthesis inhibition, as we found vesi-
cle-like staining for the HS proteoglycans perlecan and agrin in 4-deoxy-GlcNAc treated, but 
not in GlcNAc treated cells (unpublished observation). 
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Future research using new tools developed in this thesis should be directed towards 
the role of structural HS composition in physiology and pathology. The developed procedure 
for extraction of GAGs from paraffin embedded material allows for the use of abundantly 
stored human pathological samples. Ideally, different parts of pathological tissue sections 
will be identified using general staining procedures and separated by laser microdissection, 
in order that GAGs can be separately isolated and analyzed. The described procedure for 
‘immunosequencing’ of HS could be used to explore whether the structural organization 
of antibody-defined HS structures differs in physiology, e.g. in different organs, organisms 
or developmental stages, and pathology, either by limited heparinase digestions on tissue 
sections, or by isolation of primary cells and re-synthesis of HS after 4-deoxy-GlcNAc treat-
ment. Ultimately, mass spectrometry methods might become available to precisely sequence 
complicated GAGs as HS. 
In respect to the relation of HS and the long isoform of autotaxin, future studies 
should focus on the functional consequences of HS binding on LPA production and signaling, 
preferred HS modifications for ATXα binding, whether binding of ATXα to HS is tissue specif-
ic, and possible modulation of HS binding by furin cleavage of ATXα. In addition, a possible 
role of ATXα binding to HS in pathology, e.g. tumor angiogenesis, might be explored.
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Heparaansulfaat (HS) is een glycosaminoglycaan (GAG): een lang polymeer van suikermolecu-
len, sterk negatief geladen door de aanwezigheid van sulfaat- en carboxylgroepen. HS bevin-
dt zich op de celoppervlakte en in de extracellulaire matrix. HS is belangrijk in de biologie 
omdat het een grote variëteit van eiwitten kan binden en de locatie en activiteit van deze 
eiwitten kan reguleren. Op deze manier is HS betrokken bij een groot aantal fysiologishe 
processen, zoals celsignalering, basaalmembraan organisatie, lipolyse en inflammatie. HS 
is echter ook vaak betrokken in ziekteprocessen, bijvoorbeeld amyloïdose, inflammatoire 
ziektebeelden, infectie en kanker. 
Onderwerp van dit proefschrift is remming van de HS biosynthese in angiogenese, 
het proces van  vorming van nieuwe bloedvaten uit bestaande capillairen. Dit is een fysiol-
ogisch proces betrokken bij o.a. de menstruatiecyclus en wondgenezing. Angiogenese kan 
echter ook pathologisch zijn, bijvoorbeeld in de groei en metastasering van solide tumoren. 
Deze tumoren produceren vaak factoren die angiogenese induceren, zoals de fibroblastaire 
groeifactor 2 (FGF-2) en de vasculaire endotheliale groeifactor (VEGF). Deze factoren binden 
vervolgens aan receptoren die zich bevinden op endotheelcellen, de cellen die binnenkant 
van de bloedvaten bedekken, en zetten deze cellen aan tot proliferatie en migratie. HS is een 
co-receptor voor FGF-2 en VEGF en kan de activiteit van deze pro-angiogene groeifactoren 
sterk bevorderen. Bovendien kan HS deze factoren beschermen en op de juiste locatie pre-
senteren. In verschillende (muis)modellen is aangetoond dat HS een belangrijke rol speelt bij 
de angiogenese.
De doel van dit proefschrift was om met verschillende suikeranalogen de biosynthese van 
HS te remmen of te moduleren, op een zodanige manier dat angiogenese geremd wordt. 
Bovendien is er aandacht besteed aan de ontwikkeling van nieuwe methoden en aan de 
identificatie van een nieuw HS bindend eiwit. 
In hoofdstuk 1 wordt de recente literatuur met betrekking tot de rol van HS bij 
angiogenese besproken, samen met de doelstellingen en een overzicht van dit proefschrift.
Hoofstuk 2 beschrijft de synthese en de toepassing van een 4-deoxy suikeranaloog, 
4-deoxy-GlcNAc. Deze analoog was gekozen omdat mogeljke inbouwing in HS ervoor zorgt 
dat er geen ketenverlenging kan plaatsvinden. 4-deoxy-GlcNAc mist namelijk de benodigde 
OH-groep voor de vorming van glycosidische verbindingen. 4-deoxy-GlcNAc remde de ex-
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pressie van HS in verschillende cellijnen, verminderde binding van de HS afhankelijke factor-
en FGF-2 en VEGF, en remde FGF-2 geïnduceerde ontspruiting van endotheelcellen. 
Dit werk vormde de basis voor het onderzoek beschreven in hoofdstuk 3. 4-de-
oxy-GlcNAc werd geperacetyleerd om de cellulaire opname te bevorden. Een IC
50
 waarde van 
16 µM voor de inhibitie van HS expressie, en een reductie van 93% bij 50 µM, werd waarge-
nomen. 4-deoxy-GlcNAc werd in cellen geactiveerd tot UDP-4-deoxy-GlcNAc, maar werd vrij 
onverwachts niet ingebouwd in HS. In plaats daarvan verminderde behandeling met 4-de-
oxy-GlcNAc de cellulaire hoeveelheid van de geactiveerde natuurlijke suiker, UDP-GlcNAc. Het 
effect van 4-deoxy-GlcNAc op cellulaire processen, bepaald met microarray analyse, toonde 
aan dat de expressie van genen gereguleerd door HS bindende groeifactoren zoals FGF-2 en 
VEGF geremd was. Hierna zijn de effecten van 4-deoxy-GlcNAc op HS biosynthese en angi-
ogenese ook in vivo getest. Micro-injectie in zebravis embryos reduceerde HS biosynthese 
sterk, en behandeling met 4-deoxy-GlcNAc remde angiogenese in embryonale modellen van 
de zebravis en de kip. 
Hoofstuk 4 beschrijft het effect van een andere suikeranaloog, 6F-GalNAc, welke 
beoogd was om 6O-sulfatering van GAGs te remmen, een belangrijke modificatie in angio-
genese inducerende signalering. 6F-GalNAc werd in cellen geactiveerd, maar niet ingebouwd 
in GAGs, vergelijkbaar met 4-deoxy-GlcNAc. Hoewel deze suiker niet beoogd was om vorming 
van glycosidische verbindingen te remmen, observeerden we een reductie in GAG expresie, 
waarschijnlijk door een reductie in de cellulaire hoeveelheid van UDP-GlcNAc en UDP-GalNAc. 
We concludeerden dat in het algemeen de effecten van 6F-GalNAc zeer vergelijkbaar waren 
met de effecten van 4-deoxy-GlcNAc en andere suikeranalogen beschreven in de literatuur. 
Dit geeft aan dat suikeranalogen mogelijk via een algemeen mechanisme effectief zijn.
Hoofdstuk 5 beschrijft een methode om door middel van HS resynthese na rem-
ming met 4-deoxy-GlcNAc, en door partiële HS degradatie door heparinases, samen met een 
set van anti-HS antilichamen, de ‘immunosequentie’ van HS te bepalen. Antilichaam NS4F5, 
welke hoog gesulfateerd HS herkent, bond een HS structuur welke zich aan de kant van het 
niet-reducerende einde van HS bevond, een regio belangrijk in signalering van FGF-2.
Hoofdstuk 6 beschrijft de ontwikkeling van een procedure om GAGs te extraheren 
uit formaline gefixeerde en paraffine ingebed (FFPE) weefsels. GAGs geëxtraheerd uit FFPE 
weefsels waren structureel vergelijkbaar met GAGs geëxtraheerd uit bevroren weefsels. Dit 
maakt het gebruik van FFPE monsters, welke veelvuldig zijn opgeslagen in ziekenhuizen 
192
Chapter 8
wereldwijd, voor GAG extractie mogelijk. Twee voorbeelden werden beschreven: de analyse 
van verschillende lagen humane huid, welke gescheiden waren door laser-microdissectie en 
de analyse van humane pathologische huid ( keloïd en psoriasis).
In hoofdstuk 7 ligt de focus op de verhouding tussen HS en de lange isovorm van 
autotaxine (ATXα), een enzym welke een lipide (LPA) genereert die belangrijk is in een aantal 
cellulaire processen, zoals migratie en proliferatie. De lange splicevariant bevat een basische 
insertie, van welke de functie tot voorheen onbekend was. In dit hoofdstuk is de binding van 
deze lange isovorm aan heparine en HS beschreven. Binding aan HS zou een nieuw isovorm 
specifiek mechanisme kunnen zijn voor gelocaliseerde LPA productie dichtbij de verwante 
receptoren.
Algemene conclusies en toekomstvisie
In dit proefschrift is aangetoond dat GlcNAc/GalNAc suikeranalogen de biosynthese van 
GAGs en angiogenese in ontwikkelingsmodellen remmen. Toekomstig onderzoek zou zich 
moeten richten op de haalbaarheid van deze suikeranalogen om pathologische angiogenese, 
bijvoorbeeld tumor angiogenese, te remmen. Gezien de rol van GAGs in de fysiologie is het 
verstandig om voorzichtig om te gaan met therapieën die de biosynthese van GAGs remmen. 
Echter, de observatie beschreven in dit proefschrift dat zebravis embryos met een reductie 
van ~87% in celoppervlakte HS grofweg morphologisch normaal zijn, zou kunnen aangeven 
dat modulatie van GAG biosynthese tot op zekere hoogte haalbaar is. GlcNAc/GalNAc suiker-
analogen zijn nauwelijks celtype specifiek en toekomstig onderzoek zou zich moeten richten 
op doelgerichte afgifte aan (tumor) endotheelcellen, bijvoorbeeld door liposomen, om het 
biologische effect te vergroten en mogelijke toxiciteit te verminderen. Bovendien zou dit de 
plasmahalfwaardetijd kunnen verlengen (een halfwaarde tijd van ~2,3 uur in muizenplasma 
is beschreven voor geperacetyleerd 4F-GlcNAc (1)). Naast angiogenese zou inhibitie van HS 
biosynthese door suikeranalogen ook van waarde kunnen zijn in andere HS gerelateerde ziek-
tebeelden. In mucopolysaccharidose bijvoorbeeld, een groep van lysosomale stapelingsziek-
ten veroorzaakt door disfunctionele afbraak van GAGs in lysosomen, zouden suikeranalogen 
gebruikt kunnen worden als een nieuwe vorm van substraatreductietherapie.
Hoewel 6F-GalNAc niet ingebouwd werd in GAGs is specifieke remming van GAG 
6O-sulfatering nog steeds een aantrekkelijke manier om angiogenese te remmen. Dit zou 
onderzocht moeten worden door de ontwikkeling van specifieke HS 6O-sulfotransferaser-
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emmers, welke door het screenen van grote verzamelingen van stoffen ontdekt kunnen 
worden. Het niet-reducerende einde van HS zou ook van therapeutische waarde kunnen zijn, 
aangezien deze regio belangrijk is in de signalering van FGF-2. Vervolgonderzoek zou zich 
daarom kunnen richten op de vraag of antlichaam NS4F5 competeert voor HS binding met 
HS bindende groeifactoren zoals FGF-2 en of NS4F5 specifiek de vorming van een drievoudig 
signaleringscomplex FGF-2-FGFR1-HS kan remmen.
Hoe suikeranalogen de biosynthese van glycanen precies remmen is, en wordt nog 
steeds, bediscussieerd in de literatuur. Eerder onderzoek liet inbouwing van radioactief gep-
eracetyleerd 4F-GlcNAc in glycoproteïnen zien (2), maar inbouwing werd in later onderzoek 
met behulp van massaspectrometrie niet gedetecteerd (3,4). Inbouwing werd ook niet ge-
detecteerd voor 4-deoxy-GlcNAc en 6F-GalNAc in dit proefschrift. Bovendien, ons en ander 
onderzoek (3-6) geeft aan dat behandeling met suikeranalogen de hoeveelheid geactiveerde 
natuurlijke suikers reduceert. In de literatuur is het voorgesteld dat dit veroorzaakt wordt 
doordat de suikeranalogen werken als ‘afleidings’-substraten welke de synthese ‘omleiden’ 
van natuurlijke suikers (3), of doordat een accumulatie van geactiveerde suikeranalogen 
een feedback mechanimse induceert welke de novo synthesis van geactiveerde natuurlijke 
suikers remt (5). Of vermindering van geactiveerde natuurlijke suikers volledig verantwoor-
delijk is voor een reductie in de expressie van glycanen is onderwep van discussie (6,7). 
Geactiveerde analogen kunnen namelijk ook de activiteit van glycosyltransferases remmen 
(5). Het exacte mechanisme hoe 4-deoxy-GlcNAc en 6F-GalNAc de hoeveelheid natuurlijke 
UDP-GlcNAc/UDP-GalNAc reduceren, de vraag of de activiteit van glycosyltransferases wordt 
beïnvloed door UDP-4-deoxy-GlcNAc en UDP-6F-GalNAc, en de bijdrage van beide mecha-
nismen op de vorming van verschillende glycanen zou daarom het onderwerp moeten zijn 
van vervolgonderzoek. Bovendien kunnen de effecten van 4-deoxy-GlcNAc en 6F-GalNAc op 
andere door GAG gemedieerde processen zoals de opname van lipoproteïnen, of op niet door 
GAGs gemedieerde processen zoals O-GlcNAc proteïnenmodificatie, verder verkend worden. 
Eveneens kan het zo zijn dat de intracellulaire verwerking van sommige HS proteoglycanen 
verstoord is als een gevolg van HS biosynthese remming, aangezien een ‘blaasjes’-achtige 
kleuring voor de HS proteoglycanen perlecan en agrine werd waargenomen in 4-deoxy-Gl-
cNAc behandelde cellen (ongepubliceerde waarneming).
Toekomstig onderzoek dat gebruik maakt van de nieuwe methoden ontwikkeld in 
dit proefschrift zou gericht moeten zijn op de rol van de structurele HS samenstelling onder 
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normale omstandigheden en bij pathologische condities. De ontwikkelde procedure voor 
extractie van GAGs uit paraffine-ingebed materiaal maakt het gebruik van opgeslagen hu-
mane pathologische monsters mogelijk. Idealiter worden verschillende delen van patholo-
gische weefselsecties gescheiden door laser microdissectie, zodat GAGs afzonderlijk kunnen 
worden geïsoleerd en geanalyseerd. De beschreven procedure voor ‘immunosequencing’ van 
HS kan worden gebruikt om te onderzoeken of de structurele organisatie van antilichaam-ge-
definieerde HS structuren wisselend is, bijvoorbeeld in verschillende organen, organismen 
of ontwikkelingsstadia, en onder pathologische condities. Dit kan onderzocht worden door 
beperkte digestie met heparinase op weefselcoupes of door isolatie van primaire cellen en 
resynthese van HS na 4-deoxy-GlcNAc behandeling. Uiteindelijk zou een methode gebaseerd 
op massaspectrometrie beschikbaar kunnen komen om de sequentie van ingewikkelde GAGs 
als HS  exact te analyseren.
Met betrekking tot de relatie van HS en de lange isovorm van autotaxine moet-
en toekomstige studies zich richten op de functionele gevolgen van HS binding voor LPA 
productie en signalering, op de HS modificaties die betrokken zijn bij ATXα binding, op de 
weefselspecificiteit van binding van ATXα, en op de mogelijke modulatie van HS binding 
door furinesplitsing van ATXα. Bovendien zou een mogelijke rol van ATXα binding aan HS in 
pathologie, bijvoorbeeld tumor angiogenese, onderzocht kunnen worden.
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